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ABSTRACT 
Prostate cancer is the most frequent cancer and the second most common cause of 
cancer death among men in Europe. Since prostate cancer is a common disease and 
tumours usually grow slowly, multiple agents have been researched for 
chemoprevention of prostate cancer. Digoxin has been suggested to be a promising 
chemopreventive agent since in vitro studies have provided encouraging results. We 
used information from Finnish national health care registries and the Finnish 
Randomized Study of Screening for Prostate Cancer (FinRSPC) to evaluate potential 
associations between digoxin or other antiarrhythmic drug use and prostate cancer 
risk, prostate cancer -specific survival and overall cancer mortality. 
Two large study populations were used. The case-control study included all new 
prostate cancers diagnosed in Finland during 1995-2002. Controls individually 
matched by age and area of residence at the time of the diagnosis were identified 
from the Population Register Center of Finland. Finally, a total of 24,657 case‐
control pairs were included in the study. The other study population contained 
80,458 men participating in the FinRSPC, in which, 31,866 men were invited to 
prostate-specific antigen (PSA) screening. The rest of the study population formed 
the control arm and received no intervention. We obtained information on 
reimbursed antiarrhythmic medication purchases from the national prescription 
database of the Social Insurance Institution of Finland (SII). 
Compared to non-users of antiarrhythmic drugs, digoxin users had a similar risk 
of prostate cancer and advanced prostate cancer both in the case-control study and 
the cohort study. We observed, however, a decreasing trend in the risk of Gleason 
7-10 prostate cancer by duration of digoxin use in the cohort study, suggesting that 
long-term use of digoxin might decrease the risk. Other antiarrhythmic drug use was 
not associated with prostate cancer risk, with the exception of a diminished risk of 
advanced prostate cancer in the case-control study. However, sotalol use was 
associated with neither overall prostate cancer risk nor advanced prostate cancer risk 
in the cohort study. In the analysis of prostate cancer survival, digoxin use was not 
associated with the risk of prostate cancer death. Similar results were found for 
sotalol use and any antiarrhythmic drug use. In the cancer mortality study, digoxin 
users had increased overall risk of cancer death compared to non-users. Similarly, 
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sotalol use and any antiarrhythmic drug use was associated with increased cancer 
mortality. However, background co-morbidities modified the risk associations and 
long-term use of antiarrhythmic medication was not associated with an increased 
cancer mortality. Therefore, the association between antiarrhythmic drug use and 
cancer death is likely non-causal. 
In conclusion, we found that use of digoxin and other antiarrhythmic drugs does 
not increase prostate cancer risk, reduce prostate cancer survival or increase cancer 
mortality. Our results and previous studies suggest that long-term use of digoxin 
might reduce prostate cancer risk, but such an effect is probably weak, since it has 
not been observed among our large study populations.  
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TIIVISTELMÄ 
Eturauhassyöpä on länsimaiden yleisin syöpä ja toiseksi yleisin syöpäkuoleman 
aiheuttaja miehillä. Koska eturauhassyöpä on yleinen tauti ja kasvain kasvaa yleensä 
hitaasti, useita mahdollisesti syövän kehittymistä inhiboivia lääkeaineita on tutkittu. 
Digoksiinin on ehdotettu olevan varteenotettava eturauhassyövä kasvua ehkäisevä 
lääkeaine, sillä in vitro -tutkimukset ovat olleet lupaavia. Selvitimme kansallisten 
rekisterien ja suomalaisen eturauhassyövän seulontatutkimuksen (FinRSPC) 
aineiston avulla digoksiinin ja muiden rytmihäiriölääkkeiden käytön yhteyttä 
eturauhassyövän riskiin, ennusteeseen sekä yleiseen syöpäkuolleisuuteen. 
Tutkimuksessa käytettiin kahta suurta aineistoa. Tapaus-verrokkitutkimuksessa 
aineiston muodostivat kaikki Suomessa diagnosoidut uudet eturauhassyöpätapaukset 
vuosina 1995-2002 sekä näille iän ja asuinalueen perusteella väestörekisteristä valitut 
verrokit. Lopullisen tutkimusaineston muodostivat 24,657 yksittäin valittua tapaus-
verrokki -paria. Toisen tutkimusaineston muodostivat 80,458 FinRSPC:hen 
osallistunutta miestä. Seulontatutkimuksessa 31,866 miestä kutsuttiin 
prostataspesifisen antigeenin (PSA) mittaukseen. Loput aineistosta kuuluivat 
kontrolliryhmään, eikä heihin kohdistettu interventioita. Tieto 
rytmihäiriölääkeostoista poimittiin Kansaneläkelaitoksen reseptitietokannasta. 
Digoksiinin käyttö ei ollut yhteydessä eturauhassyövän tai levinneen 
eturauhassyövän riskiin, kun vertasimme digoksiinin käyttäjiä miehiin, jotka eivät 
käyttäneet rytmihäiriölääkkeitä. Tulokset olivat samankaltaiset sekä tapaus-
verrokkitutkimuksessa että kohorttitutkimuksessa. Kohorttitutkimuksessa havaittiin 
kuitenkin Gleason 7-10 eturauhassyövän riskissä laskeva trendi suhteessa digoksiinin 
käyttöaikaan, mikä viittaa siihen, että pitkäaikainen digoksiinin käyttö saattaa 
pienentää aggressiivisen eturauhassyövän riskiä. Muiden rytmihäiriölääkkeiden 
käyttö ei ollut yhteydessä eturauhassyöpäriskiin lukuun ottamatta sotalolia, jonka 
käyttäjillä oli matalampi levinneen eturauhassyövän riski tapaus-
verrokkitutkimuksessa. Sotalolin käyttäjien eturauhassyöpäriski tai levinneen 
eturauhassyövän riski eivät kuitenkaan poikenneet ei-käyttäjien riskeistä 
kohorttitutkimuksessa. Digoksiinin käyttö ei ollut yhteydessä 
eturauhassyöpäpotilaan elossaoloaikaan. Vastaavat tulokset havaittiin myös sotalolin 
käytölle ja rytmihäiriölääkkeiden käytölle kaiken kaikkiaan. Viimeisessä osatyössä 
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havaittiin, että digoksiinin käyttäjillä oli korkeampi syöpäkuolleisuus kuin ei-
käyttäjillä. Myös sotalolin käyttäjillä sekä rytmihäiriölääkkeiden käyttäjillä kaiken 
kaikkiaan oli korkeampi syöpäkuoleman riski kuin ei-käyttäjillä. Liitännäissairaudet 
muovasivat havaittua yhteyttä ja pitkäaikainen rytmihäiriölääkkeiden käyttö ei ollut 
yhteydessä suurentuneeseen syöpäkuolleisuuteen. Näin ollen rytmihäiriölääkkeiden 
ja suurentuneen syöpäkuolleisuuden välillä ei todennäköisesti ole syy-
seuraussuhdetta. 
Digoksiinin tai muiden rytmihäiriölääkkeiden käyttö ei suurenna 
eturauhassyöpäriskiä tai syöpäkuolleisuutta, ja on näin ollen turvallista. Tuloksemme 
yhdessä muiden tutkimusten kanssa viittaa siihen, että pitkäaikainen digoksiinin 
käyttö saattaa alentaa eturauhassyöpäriskiä, mutta vaikutus on todennäköisesti 
vähäinen, sillä se ei tule esiin suurissakaan aineistoissamme. 
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1 INTRODUCTION 
Prostate cancer is the most common cancer among men in the Western World 
including in Finland and the second most frequent cancer after lung cancer among 
men worldwide (Ferlay et al. 2015). Prostate cancer usually has a good prognosis. 5-
year survival rate for prostate cancers diagnosed between 2010-2014 was at least 90% 
in 25 countries and 80-89% in 17 countries (Allemani et al. 2018). However, globally 
approximately 307,000 men died due to prostate cancer in 2012 (Ferlay et al. 2015; 
Noone et al. 2017). The etiology of prostate cancer is incompletely understood but 
probably prostate cancer is generated from damaged prostate epithelium and 
progresses along decades (Rosenberg et al. 2010). 
Due to long disease progression, several agents have been researched for prostate 
cancer chemoprevention. It has been observed that 5-alpha- reductase inhibitors (5-
ARI) reduce prostate cancer risk (Andriole et al. 2010; I. M. Thompson et al. 2003). 
In addition, statins have been found to potentially have antineoplastic properties and 
decrease risk of prostate cancer (Jespersen et al. 2014; Kantor et al. 2015; Murtola et 
al. 2010). 
Digoxin seems to be a promising antineoplastic agent. Even though in vitro 
experiments have been encouraging, results of observational studies have been 
conflicting (Flahavan et al. 2014; Kao et al. 2018; Platz et al. 2011; Zhang et al. 2008). 
We studied prostate cancer risk among users of digoxin and other antiarrhythmic 
drugs in two large study population: the first included all new prostate cancer cases 
in Finland during 1995-2002 and matched controls. The other consisted of men 
included in the Finnish Randomized Study of Screening for Prostate Cancer 
(FinRSPC). Furthermore, we evaluated the prostate cancer-specific survival and 
overall cancer mortality among antiarrhythmic drugs users participating in the 
FinRSPC trial. 
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2 REVIEW OF THE LITERATURE 
2.1 Prostate cancer definition and diagnosis 
Prostate is an exocrine gland of the male reproductive system and it consists of 
glandular cells, myoepithelial cells and subepithelial interstitial cells. In most cases, 
prostate cancer originates from glandular cells in the peripheral zone of the prostate 
and can therefore be classified as an adenocarcinoma. Rarely, prostate cancer can 
arise from epithelial origin. Carcinogenesis is a complex process including activation 
of several oncogenes and deactivation of tumor suppression genes. Some of these 
mutations are known, TMPRSS2:ERG gene fusion and Phosphatase and Tensin 
homolog (PTEN) deletion, for example (Jamaspishvili et al. 2018; Z. Wang et al. 
2017). The development from carcinoma in situ to clinically detectable cancer lasts 
usually at least several years. If the tumor is aggressive, it is likely to spread first to 
the pelvic lymph nodes and afterwards to the skeleton, most typically vertebrae, ribs 
and pelvis (Bubendorf et al. 2000).  
2.1.1 Detection 
Early prostate cancer is nearly invariably asymptomatic. Classic clinical symptoms of 
prostate cancer are due to urinary obstruction and resemble those of benign prostate 
hyperplasia (BPH). The most common symptoms are frequent urination, difficulties 
in maintaining adequate urine flow, urinary obstruction, nocturia, dysuria and 
hematuria. Advanced prostate cancer can give systemic symptoms, such as 
unintentional weight loss, fever, anemia, fatigue and bone pain (typically in spine) or 
fractures (Taari et al. 2013). 
The first clinical exam is the digital rectal examination (DRE). Typical findings in 
prostate cancer include abnormally hard or irregular prostate. It is important to 
consider that early-stage tumor might not be palpable and therefore to detect early-
stage cancers further examination is required (Duodecim 2014).  
PSA concentration helps clinicians to decide which patients might benefit from 
additional urological examination. Patients with evidently high PSA levels should be 
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referred to a urologist, but often PSA level is only marginally over the reference levels 
(Taari et al. 2013). If total PSA is 2.5 - 10 ug/l, it is useful to determine the proportion 
of free PSA. Low free PSA concentration indicates an increased prostate cancer risk 
and 15 % is considered as a cut-point to decide whether a patient needs further 
examination (Duodecim 2014). Probability of prostate cancer at certain levels of PSA 
and free PSA percentages are presented in Table 1. It is essential to comprehend that 
poor sensitivity is the most relevant disadvantage of PSA testing. There is a lot of 
variation in sensitivity and specificity of PSA depending on a study population and 
a method used to confirm the prostate cancer diagnosis. The American Cancer 
Society concluded that baseline PSA of 4.0 ug/l or more has a sensitivity of 21% and 
specificity of 91% (Wolf et al. 2010). 
In suspicious but unclear cases it is important to monitor PSA concentration 
since with prostate cancer PSA level usually rises over time. PSA velocity over 0.75 
ug per year is an indication for further examination. In addition, if 5-ARI has been 
prescribed for the patient, PSA level should decrease 50% during the treatment and 
if this does not occur, the possibility of prostate cancer should be excluded. 
Urologist’s basic exams to patient with suspected prostate cancer are transrectal 
ultrasound (TRUS) and prostate biopsy. TRUS is useful to evaluate the size and 
consistency of the prostate, but malignancy cannot be excluded by TRUS. Prostate 
biopsy is conveniently taken after ultrasound. It is recommended to take 12 tissue 
samples at different parts of the prostate. Negative biopsy results do not definitively 
exclude a prostate cancer, so examination should be repeated if malignancy is 
clinically probable. (Duodecim 2014). 
Magnetic resonance imaging (MRI) provides additional information besides 
classic diagnostic methods. The primary indication for MRI is a situation, in which 
prostate biopsy is negative but PSA increases during a follow-up. If a suspicious area 
is found, MRI-targeted prostate biopsies are taken. The cancer detection percentage 
among men with previous negative biopsies was found to be higher with MRI-
targeted biopsy compared to TRUS-guided biopsy (46% vs. 23%, p<0.05) and 
cancers diagnosed with MRI-targeted biopsy showed more features of clinical 
significance (biopsy Gleason pattern ≥ 4 or tertiary pattern 5, serum PSA >10 ug/l 
and PSA density >0.15 ug/l/cm3) (Kaufmann et al. 2015). In the PRECISION trial, 
among the MRI-targeted biopsy group Gleason score 3+4 or greater cancer was 
detected in 95 men (38%) whereas among men in the standard-biopsy group 
clinically significant cancer was detected in 64 men (26%) (p = 0.005) 
(Kasivisvanathan et al. 2018). However, conflicting results have been published 
(Arsov et al. 2015). In the future, it might be possible to perform MRI and take 
 18 
 
targeted biopsies before or instead random prostate biopsies. Studies have observed 
that the method mentioned above reduces the detection of low-grade prostate 
cancers and the number of biopsies whereas the detection of clinically significant 
prostate cancer is improved (Delongchamps et al. 2013; Garcia Bennett et al. 2017; 
Pokorny et al. 2014). 
Due to poor sensitivity of PSA, several new prostate cancer detectors are being 
researched. A four-kalligrein panel called 4Kscore includes total PSA, free PSA, 
intact PSA and kallikrein-related peptidase 2. Combining markers mentioned above 
can reduce unnecessary prostate biopsies. Data from ERSPC shows that four-
kallikrein panel had better predictive accuracy compared to PSA and age alone (the 
area under the curve (AUC) of 0.711 vs 0.585, p<0.001) (Vickers et al. 2010). The 
Stockholm 3 model is a combination of plasma protein biomarkers (PSA, free PSA, 
intact PSA, hK2, MSMB, MIC1), gene polymorphisms (232 Single nucleotide 
polymorphisms (SNPs)), and clinical variables (age, family history, previous prostate 
biopsy). When the Stockholm 3 model was compared to PSA testing only, the 
Stockholm 3 was significantly better for detection of prostate cancers with a Gleason 
score 7 or more (the AUC 0.74, 95% CI 0.72-0.75 vs 0.56, 95% CI 0.55-0.60, 
p<0.0001) (Scott et al. 2017). 
The Prostate Health Index (phi) is a combination of three different isoforms of 
PSA: total PSA, free PSA, and [−2]proPSA. An Italian study of 268 men with PSA 
levels of 2-10 ng/ml and negative DRE evaluated phi. Men were referred to 
extended prostate biopsy with the primary objective to compare phi with commonly 
used tests, total PSA, free PSA percentage and PSA density. Diagnosed prostate 
cancer cases (39.9%) had a higher phi (median 44.3 compared to 33.1, p < 0.001). 
Phi had superior sensitivity (42.9%) than free PSA percentage (20.0%) or PSA 
density (26.5%) and predictive accuracy (AUC 0.76 for phi) than PSA density (AUC 
0.61), free PSA percentage (AUC 0.58) or total PSA (AUC 0.53) (Guazzoni et al. 
2011). A similar observation was made in a US study (Catalona et al. 2011).  
In addition, biomarkers can be used to distinguish prostate cancer from BPH 
even though they are not commonly used. The Prolaris cell cycle progression (CCP) 
test is a gene test evaluating how quickly neoplastic cells proliferate. It has been 
suggested to be potentially used to advance the accuracy of individual risk evaluation. 
However, a review evaluating two before-after studies observed that even though 
CCP test may change the treatment for some low- and intermediate-risk patients it 
would result in a major increase in cost to the health care budget (Health Quality 
Ontario 2017). 
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Table 1.  Likelihood of prostate cancer at certain PSA (prostate specific antigen) concentrations 
(Jousimaa et al. 2017). 
Total PSA Probability of prostate cancer 
0-2 ug/l 1% 
2-4 ug/l 15% 
4-10 ug/l 25% 
>10 ug/l >50% 
Free PSA percentage when total PSA 
between 4-10 ug/l 
 
0-10% 56% 
10-15% 28% 
15-20% 20% 
20-25% 16% 
>25% 8% 
2.1.2 Screening 
 Two large screening trials commenced in the 1990s to evaluate whether PSA 
screening can reduce prostate cancer mortality; the European Randomized Study of 
Screening for Prostate Cancer (ERSPC) (Schröder et al. 2014) and the Prostate, 
Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial by the U.S. National 
Cancer Institute (NCI) (Pinsky et al. 2017). 
The main results differed slightly. PSA screening reduced prostate cancer-specific 
mortality (RR (Rate ratio) 0.80, 95% CI (Confidence interval) 0.72-0.89) at 16 years 
of follow-up in the ERSPC (Hugosson et al. ). However, there was no difference 
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between the screening arm and the control arm (RR 1.04, 95% CI 0.87-1.24) in the 
PLCO Cancer Screening Trial (Pinsky et al. 2017). The difference in results between 
these two large trials might be explained by more common PSA testing prior to 
randomization and contamination testing in the PLCO control arm during the trial 
since the PLCO study population consisted of American citizens and a random PSA 
testing was more common in America than in Europe during that era. Furthermore, 
biopsy compliance was only 25% approximately in the PLCO study (Schröder and 
Roobol 2010). When differences (enrollment and attendance patterns, screening 
intervals, PSA thresholds, biopsy receipt, control arm contamination, and primary 
treatment) in the ERSPC and the PLCO studies were taken into account, the PLCO 
study provides consistent evidence that PSA screening might decrease prostate 
cancer mortality (de Koning et al. 2018; Tsodikov et al. 2017).  
PSA screening has multiple adverse effects. Overdiagnosis is probably the most 
severe hindrance and it concerns especially clinically insignificant low-grade cancers. 
A second problem is lead time, which means time that screening advances cancer 
diagnosis. Draisma et al. 2003 evaluated effects of lead time and overdetection 
among the ERSPC study population. Authors concluded that mean lead times and 
overdetection rate depended on age of patients at screening. Mean lead time was 
calculated to be 12.3 years and the overdetection rate was 27% for a single screening 
test at age 55. However, mean lead time was 6.0 years and the overdetection rate 
56% at age 75 (Draisma et al. 2003). Prostate cancer incidence was higher in the 
screening arm compared to the control arm in both studies (RR 1.57, 95% CI 1.51-
1.62 in the ERSPC and RR 1.27, 95% CI 1.20-1.35 in the PLCO). In the ERSPC, 
one prostate cancer death was avoided per 781 screening invitation and per 27 
additional prostate cancer diagnoses. A prostate biopsy is an invasive operation and 
approximately 1% of men undergoing it ended up with a severe adverse effect, 
infection for example (Chou et al. 2011). Minor complications are common; a study 
evaluating 5957 prostate biopsies reported that hematospermia occurred after 36.3% 
of biopsies, hematuria after 14.5% and rectal bleeding persisting for up to 2 days 
after 2.3% (Berger et al. 2004). 
Overdiagnosis leads to overtreatment and prostate cancer treatment options have 
difficult adverse effects. Radical prostatectomy was associated with erectile 
dysfunction (14.6% vs 5.4%) and incontinence (17.3% vs 4.4%) compared to the 
control group (Wilt et al. 2017). Men receiving external-beam radiation therapy had 
comparable adverse effects with men with radical prostatectomy after 15 years 
follow-up (Resnick et al. 2013). 
 21 
 
In Finland, prostate cancer incidence has increased strongly alongside generalized 
PSA testing. However, prostate cancer prognosis has improved concurrently. Age-
adjusted 5-year survival was 41.96% among prostate cancer cases diagnosed during 
1969-1971 whereas for prostate cancer cases diagnosed between 2011-2013 5-year 
survival was 91.98% (Finnish Cancer Registry a). 
One of the future goals is to find men benefiting the most from PSA screening. 
Epidemiological studies have shown that men with PSA concentration below 
median have minimal risk of advanced prostate cancer during the next 15 years 
(0.28%, 95% CI 0.11-0.66) (Vickers et al. 2013). Therefore, PSA screening should be 
focused on men with high PSA concentration at the baseline. Further screening for 
men with PSA ≥ 1.0 ug/l at age of 40 years and ≥ 2.0 ug/l at age of 60 years might 
be reasonable (Carlsson et al. 2014; Vickers et al. 2013).  
New prostate cancer screening methods are currently being researched. The 
ProScreen trial started in 2018 and it involves new procedures to detect clinically 
relevant prostate cancers. Study population will consist of 67,000 men aged between 
50-63 years at the start of the follow-up. A quarter of the study population will be 
allocated to the screening arm and the rest will form the control arm, which will 
receive no intervention. The screening arm participants will be invited to a PSA test 
and men with PSA of 3 ug/l or higher will receive a further multi-kallikrein panel. 
Multiparametric magnetic resonance imaging (MpMRI) will be performed to patients 
with a risk of clinically significant prostate cancer >7.5% and finally, men with a 
suspect finding in MRI are directed to targeted biopsies. The objective is to reduce 
overdiagnosis without losing mortality benefit (Auvinen et al. 2017). 
2.1.3 The Gleason grading system 
The Gleason grading system is an important part of evaluation of prostate cancer 
prognosis (Gleason and Mellinger 1974). A pathologist evaluates tissue samples and 
gives a Gleason grade based on its glandular architecture. A grade can vary between 
1 to 5, a lower score representing less aggressive pattern. Two grades are given – the 
first one is based upon the predominant pattern and a second grade on the second 
most common pattern. The sum of the two grades gives the Gleason score. Figure 
1 demonstrates Gleason grading system (N. Chen and Zhou 2016). 
When 305 men with prostate cancer were followed, the disease-specific survival 
for Gleason score 4-5 was 20 years, for Gleason score 6 survival was 16 years, for 
score 7 10 years and for score 8-10 5 years (p < 0.001) (Egevad et al. 2002).  When 
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biochemical recurrence-free survival among men with different Gleason scores were 
studied, clear trend was observed. Five-year survivals were 94.6% for men with 
Gleason score ≤ 6, 82.7% for score 3 + 4, 65.1% for score 4 + 3, 63.1% for score 8 
and 34.5% for score 9 – 10 (Pierorazio et al. 2013). 
The International Society of Urological Pathology (ISUP) published a consensus 
in 2005 proposing a new modification of the Gleason score called Grade Grouping 
(GG). If Gleason score is Gleason ≤ 6, GG is 1, Gleason score 3+4 means GG 2, 
Gleason score 4+3 forms GG 3, Gleason score 8 (4+4, 3+5, 5+3) means GG 4 and 
Gleason score 9-10 (4+5, 5+4, 5+5) form GG 5. GG 1 cancer is a low-risk disease, 
GG 2-3 are intermediate-risk cancers and GG 4-5 are high-risk cancers (Epstein et 
al. 2016).  
However, the Gleason grading system has some limitations. Gleason score 
depends on location of a prostate tissue sample since there might be a lot of 
histological heterogeneity within a tumor, and it is always a subjective estimate of a 
pathologist. 
 
Figure 1.   Gleason grading system and typical Gleason patterns. Reused with permission from AME 
Publishing Company (N. Chen and Zhou 2016). 
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2.1.4 TNM classification and staging 
The TNM classification of Malignant Tumors is commonly used system for staging 
cancer (O'Sullivan et al. 2015). It consists of three individual parts. T describes size 
or local extension of the primary tumor. N describes invasion to regional lymph 
nodes and M describes extent of metastases. TNM classification can be divided in 
two separate systems: clinical and pathological TNMs. cTNM is determined clinically 
based on DRE, prostate biopsy and further imagining such as prostate MRI and 
bone scan. pTNM is microscopically determined by pathologist after surgery, such 
as radical prostatectomy. N-stage is possible to determine reliably only after 
lymphadenectomy. TNM classification for prostate cancer is described in Table 2 
(Cheng et al. 2012). TNM classification can be used to classify prostate cancer on 
different stages and stage grouping is described in Table 3 (Cheng et al. 2012). Stage 
grouping can be further used to classify cancer to local, locally advanced or advanced 
disease. Local disease includes stages I and II, locally advanced disease means stages 
III and IV (excluding M1 disease) and M1 forms advanced disease. 
TNM classification influences treatment decision. This is further discussed in the 
Treatment-chapter. 
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Table 2.  TNM staging for prostate cancer (Cheng et al. 2012) 
 
 
 
Stage Properties 
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
T1 Clinically inapparent tumor neither palpable nor visible by 
imaging 
T1a Tumor incidental histological finding in ≤5% of tissue 
resected 
T1b Tumor incidental histological finding in >5% of tissue 
resected 
T1c Tumor identified by needle biopsy 
T2 Tumor confined within prostate 
T2a Tumor involves ≤one-half of one lobe 
T2b Tumor involves >one-half of one lobe but not both lobes 
T2c Tumor involves both lobes 
T3 Tumor extends through the prostate capsule 
T3a Extracapsular extension (unilateral or bilateral) 
T3b Tumor invades seminal vesicle(s) 
T4 Tumor is fixed or invades adjacent structures other than 
seminal vesicles such as external sphincter, rectum, bladder, 
levator muscles, and/or pelvic wall 
NX Regional lymph nodes were not assessed 
N0 No regional lymph node metastasis 
N1 Metastases in regional lymph node(s) 
M0 No distant metastasis 
M1 Distant metastasis 
M1a Non-regional lymph node(s) 
M1b Bone(s) 
M1c Other site(s) with or without bone disease 
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Table 3.  Stage grouping of prostate cancer by American Joint Committee on Cancer (Cheng et al. 
2012). 
 
PSA = Prostate-specific antigen  
Stage T N M PSA (ug/l) Gleason Score 
I T1a-c N0 M0 <10 ≤6 
T2a N0 M0 <10 ≤6 
T1-2a N0 M0 X X 
IIA T1a-c N0 M0 <20 7 
T1a-c N0 M0 ≥10 and <20 ≤6 
T2a N0 M0 <20 7 
T2b N0 M0 <20 ≤7 
T2b N0 M0 X X 
IIB T2c N0 M0 Any PSA Any Gleason 
T1-2 N0 M0 ≥20 Any Gleason 
T1-2 N0 M0 Any PSA ≥8 
III T3a-b N0 M0 Any PSA Any Gleason 
IV T4 N0 M0 Any PSA Any Gleason 
Any T N1 M0 Any PSA Any Gleason 
Any T Any N M1 Any PSA Any Gleason 
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2.2 Prostate cancer occurrence 
2.2.1 Incidence and prevalence 
Prostate cancer is the second most commonly diagnosed cancer among men globally. 
It has been estimated that there were 1,276,100 new prostate cancer cases in 2018. 
The cumulative risk of prostate cancer to age 75 was 3.73% and age standardized 
rate was 29.3/100,000 person-years worldwide (Ferlay et al. 2019). Incidence of 
prostate cancer is higher in more developed regions (758,700 new cancer cases in 
2012, 12.5 % of all cancer cases) than less developed regions (353,000 new cancer 
cases in 2012, 4.4 % of all cancer cases). Age-standardized rates of prostate cancer 
incidence were 69.5/100,000 person years and 14.5/100,000 person years in more 
and less developed countries, respectively. (Ferlay et al. 2015) 
In Finland, the Finnish Cancer Registry compiles statistics of all Finnish cancer 
cases. A total of 5,162 new prostate cancer cases were diagnosed in 2016 (Finnish 
Cancer Registry b) and the age standardized incidence rate (global standard 
population) was 82.5/100,000 person-years (Finnish Cancer Registry c). At the 
beginning of 2015, 36,357 prostate cancer patients (prostate cancer diagnosis within 
less than 10 years) were alive in Finland (Finnish Cancer Registry d) and the 
prevalence was 1,340/100,000 (Finnish Cancer Registry e). 
Autopsy studies have suggested that prostate cancer is a common incidental 
finding. Among men aged between 70-79 years, the prevalence of prostate cancer 
was 50.5% in U.S. blacks, 35.7% in U.S. whites and Europeans, and 21.2% in Asians 
and prevalence of prostate cancer increased with every decade of age (OR 1.7, 95% 
CI 1.6-1.8) (Bell et al. 2015; Jahn, Giovannucci, Stampfer 2015).  
2.2.2 Mortality and prognosis 
Prostate cancer is a major cause of death worldwide but especially in North America, 
Europe and Oceania. Approximately 307,500 men died from prostate cancer 
worldwide in 2012. Age-standardized prostate cancer mortality was 10.0/100,000 
person-years in more developed countries, notably higher compared to 6.6/100,000 
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person-years in less developed countries. (Ferlay et al. 2015). Ten-year relative 
survival has increased radically over the decades: it was 53.2% for prostate cancers 
diagnosed in 1975-1979 whereas in 2005 the rate was 99.2% in the U.S. (Howlader 
et al. 2016). 
In 2016, there were 900 prostate cancer deaths in Finland. Age-standardized 
mortality rate (global standard population) was 11.38/100,000 person-years (Finnish 
Cancer Registry a). Five year age-standardized survival among men aged 15–99 years 
diagnosed with prostate cancer during 2010-2014 was 93.2% in Finland, 90.7% in 
Sweden, 97.4% in U.S., 94.5% in Australia, 79.3% in Russian Federation, 69.2% in 
China and 58.7% in Nigeria (Allemani et al. 2018). 
Prostate cancer prognosis has improved over the past decades, as shown in Table 
4, due to more developed cancer treatments and earlier detection (Howlader et al. 
2016). Before the PSA era majority of prostate cancer patients died due to the 
disease. Alongside with early detection, prognosis have improved radically. However, 
prognosis depends considerably on stage and grade of the disease (Mottet et al. 
2017). Despite improved treatment, prognosis for advanced prostate cancer remains 
low. Five-year survival percent by stage at diagnosis is presented in Table 5 (Finnish 
Cancer Registry b). 
The European Association of Urology has composed prognostic risk groups by 
PSA, TNM stage and Gleason score. Tumor is defined as a low-risk disease if PSA 
is <10 ug/l, Gleason score is <7 and T-stage is T1-2a. Intermediate-risk disease 
exists if PSA is between 10-20 ug/l, Gleason score is 7 or T-stage is 2b. If PSA is 
over 20 ug/l, Gleason score is more than 7 or T-stage is T2c there is a high-risk local 
disease (Mottet et al. 2017).  
 
Table 4.  5-year relative survival 2007-2013 by stage at diagnosis. Data from U.S. National Cancer 
Institute (Howlader et al. 2016). 
Stage at diagnosis Survival percent 
All stages 98.6 
Localized 100.0 
Locally advanced 100.0 
Advanced 29.8 
Unstaged 81.2 
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Table 5.  5-year relative survival by year of diagnosis. Data from Finnish Cancer Registry (Finnish 
Cancer Registry e). 
 
2.3 Prostate cancer etiology 
2.3.1 Age  
Age is the most important risk factor for developing prostate cancer. Even though 
prostate cancer is the most frequent cancer among men in the western world, its 
prevalence among men younger than 50 years is diminutive. Figure 2 demonstrates 
distribution of prostate cancer by age in Finland. The prostate gland requires 
androgens (testosterone, dehydroepiandrosterone and dihydrotestosterone) and 
especially dihydrotestosterone has been linked with prostate cancer progression. 
(Lonergan and Tindall 2011). Accumulated androgen burden might be one possible 
explanation for activation of oncogenes in the prostate.   
 
Year of diagnosis Survival percent 
1975-1977 55.0 
1978-1980 55.0 
1981-1983 59.9 
1984-1986 55.8 
1987-1989 62.8 
1990-1992 61.8 
1993-1995 65.6 
1996-1998 73.3 
1999-2001 81.1 
2002-2004 86.5 
2005-2007 91.8 
2008-2010 93.2 
2011-2013 92.5 
2014-2016 93.1 
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Figure 2.  Number of new prostate cancer cases diagnosed among different age groups in Finland in 
2012-2016 (Finnish Cancer Registry b). 
2.3.2 Geography 
The prostate cancer incidence varies considerably worldwide. The world age-
standardized incidence rates are highest in Australia and New Zealand (86.4/100,000 
person-years), whereas in South Central Asia the incidence rate is only 5.0/100,000 
person-years. In semi-industrial world, the incidence rates are between these two 
extremes, for example, 60.4/100,000 and 42.2/100,000 person-years in South 
America and in Eastern Europe, respectively (Bray et al. 2018). 
The substantially higher incidence rates in the industrial world likely reflect in part 
more active PSA screening and subsequent biopsies. Another explanation is a 
difference in burden of chronic diseases between high- and low-income countries. 
Chronic diseases might lead to underdiagnosis of almost asymptomatic prostate 
cancer. 
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Nevertheless, it has been reported that there is divergence by race in the prostate 
cancer incidence rate in the USA (Brawley 2012; Krieger et al. 1999; Siegel, Miller, 
Jemal 2016). The incidence rate is notably higher among black males (Incidence rates 
208.7/100,000 person years) than among the Asians (67.8/100.000 person years) in 
the USA (Siegel et al. 2016). Various explanations have been provided for the racial 
disparities. Socioeconomic and behavioral factors might account  but physiological, 
constitutional and genetic factors have an important role as well (Bhardwaj et al. 
2017). 
2.3.3 Genetic factors 
Family history is a well-known risk factor for prostate cancer, and it has been studied 
extensively. Prostate cancer demonstrates Mendelian inheritance model and there is 
a rare high penetrant hereditary form (Carter et al. 1992; Pilie, Giri, Cooney 2016). 
Findings from Nordic twin registries have suggested that heritable factors have a 
greater effect for prostate cancer than any other cancers (Hjelmborg et al. 2014; 
Mucci et al. 2016). A review of 13 case-control and cohort studies estimated that the 
risk of prostate cancer is 2.5 times higher for men with first-degree relatives 
diagnosed with prostate cancer compared to the men without prostate cancer in the 
family. If there was more than one affected first-degree relative, the risk ratio 
increased to 3.5. The risk ratio was even higher (4.3 95% CI 2.9-6.3) for men with 
first-degree relatives diagnosed with prostate cancer before age of 60. (Johns and 
Houlston 2003). 
Mutations in BRCA1/2 genes have been reported to have an association with 
increased prostate cancer risk (Ostrander and Udler 2008; D. Thompson, Easton, 
Breast Cancer Linkage Consortium 2002). However, several studies have shown that 
BRCA1/2 mutations have only minor influence on familiar prostate cancer risk since 
they are relatively rare (Agalliu et al. 2007; Ikonen et al. 2003; Sinclair et al. 2000). 
Nevertheless, a mutation named G84E in HOXB13 gene seems to have an 
association with hereditary prostate cancer (Ewing et al. 2012; Huang and Cai 2014; 
Laitinen et al. 2013). 
Approximately 160 single nucleotide polymorphisms (SNPs) have been linked 
with increased prostate cancer risk. It has been estimated that the identified SNPs 
explain a third of the familial risk among European population. The RR for 
developing prostate cancer was 2.69 (95% CI 2.55-2.82) times higher among the top 
10% of the men in the highest risk group and 5.71 (95% CI 5.04-6.48) times higher 
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among the top 1% of men in the highest risk group compared to the population 
average (Schumacher et al. 2018). The SNPs are concentrated at 12 regions and 
majority of the signals are related to known biological mechanisms including AR, 
ERG and FOXA1 (Dadaev et al. 2018). 
In the PLCO trial, the study population was divided into groups by genetic risk 
score (GRS) and there was an association between GRS and prostate cancer 
detection rate (43.2%, 47.8%, 58.8% and 69.4% in the first, second, third and fourth 
quartiles, respectively, p < 0.001) (Liss et al. 2015). A similar observation was made 
with the population from the FinRSPC. The overdiagnosis percentage was 58% 
(95% CI 54–65) of the prostate cancers detected by PSA screening among men with 
the lower polygenic risk whereas men with higher polygenic risk had the 
overdiagnosis percentage of 37% (95% CI 31–47). 74% of all prostate cancers were 
diagnosed from men with polygenic risk over population median (Pashayan et al. 
2015). 
2.3.4 Behavioral risk factors 
 
Besides many other cancers, smoking has been connected with fatal prostate 
cancer. Meta-analysis of 51 studies showed that smokers had significantly increased 
risk of prostate cancer death (RR 1.24, 95% CI 1.18-1.31). Surprisingly, current 
smoking was associated with decreased prostate cancer incidence (RR 0.90 95% CI 
0.85-0.96) but this is probably explained by smoking promoting more aggressive 
cancers instead of prostate cancer. (Islami et al. 2014). Similar findings were obtained 
in two smaller reviews also (Huncharek et al. 2010; Zu and Giovannucci 2009). 
A meta-analysis summarizing 22 randomized controlled trials (RCTs) assessed 
the association between testosterone replacement therapy (TRT) and prostate 
cancer. Neither short-term (< 12 months) nor long term (12-36 months) use of TRT 
increased risk of prostate cancer: odds ratio (OR) 0.39 (95% CI 0.06-2.45) for short-
term and OR 2.09 (95% CI 0.18-24.73) for long-term use of testosterone injection 
treatment. Transdermal administration of TRT: OR was 1.10 (95% CI 0.26-4.65) for 
short-term use and 3.06 (95% CI 0.12-76.70) for long-term use. Current literature 
suggests that TRT does not increase risk of prostate cancer (Cui et al. 2014). 
Two previous meta-analyses suggest that obesity is associated with both increased 
aggressive prostate cancer risk and decreased localized cancer risk (Discacciati, 
Orsini, Wolk 2012; Discacciati and Wolk 2014). The explanation for these opposite 
relationships between obesity and risk of localized and advanced prostate cancer 
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might be different concentrations of free testosterone in serum. Obese men tend to 
have lower testosterone concentration (Lima et al. 2000), which is a risk factor for 
aggressive prostate cancer (Platz et al. 2005b; Severi et al. 2006). Physical activity was 
associated with slightly reduced overall prostate cancer risk (RR 0.90, 95% CI 0.84-
0.95) in a large meta-analysis when comparing men with the highest to men with the 
lowest level of activity (Y. Liu et al. 2011). 
A large number of studies considering dietary factors and prostate cancer have 
been published. There is no solid association between reduced prostate cancer risk 
and any specific nutrient, but the most promising dietary factors for decreasing 
prostate cancer risk are the Mediterranean diet, soy protein, lycopene, vitamin E and 
green tea. 
Adherence to the Mediterranean diet was associated with prolonged prostate 
cancer survival (HR for death 0.78, 95% CI 0.67-0.90) in the Health Professional 
Follow-up Study compared to low adherence (Kenfield et al. 2014) and a meta-
analysis reported that men with the highest adherence to Mediterranean diet had 
slightly decreased prostate cancer risk compared to men with low adherence (RR 
0.96, 95% CI 0.92-0.99) (Schwingshackl and Hoffmann 2014). There was 
significantly reduced prostate cancer risk among men consuming more soy food (p < 
0.001), genistein (p = 0.008), daidzein (p = 0.018) and unfermented soy food (p < 
0.001) in a previous review (Applegate et al. 2018). Both dietary consumption and 
circulating concentration of lycopene were associated with decreased prostate cancer 
risk (RR 0.88, 95% CI 0.78-0.98 and RR 0.88, 95% CI 0.79-0.98, respectively) in a 
large meta-analysis including 42 studies (Rowles et al. 2017). In the Finnish Alpha-
Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study, vitamin E 
supplement use was connected with significantly decreased prostate cancer risk (RR 
0.68, 95% CI 0.53-0.88) (Heinonen et al. 1998), but supplement use was directly 
associated with prostate cancer risk (RR 1.17, 95% CI 1.00-1.36) in the Selenium and 
Vitamin E Cancer Prevention Trial (Klein et al. 2011). A meta-analysis containing 
38 studies observed decreased risk of prostate cancer among men with high selenium 
intake or plasma level compared to men with less (RR 0.86, 95% CI 0.78-0.94) 
(Sayehmiri et al. 2018). Men with the highest coffee intake had decreased risk of 
prostate cancer compared to men with the lowest intake (RR 0.90, 95% CI 0.85-
0.95) in a meta-analysis of 13 cohort studies (H. Liu et al. 2015). Consumption of 
green tea reduced prostate cancer in a Chinese case-control study (OR 0.28, 95% CI 
0.17-0.47) (Jian et al. 2004) and a similar finding was obtained in a Japanese 
prospective study (OR 0.52, 95% CI 0.28-0.96) (Kurahashi et al. 2007). Hackshaw-
McGeagh et al. (2015) identified 44 RCTs of behavioral interventions with prostate 
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cancer progression or mortality outcomes. Only 10 of the trials were assessed as 
having good methodological quality and low risk of bias. Beneficial effects were 
observed in a trial of a nutritional supplement of pomegranate seed, green tea, 
broccoli, and turmeric, in a trial comparing flaxseed, low-fat diet, flaxseed, and low-
fat diet versus usual diet and in a trial supplementing soy, lycopene, selenium, and 
coenzyme Q10 (Hackshaw-McGeagh et al. 2015). 
Ejaculation frequency has been suggested to be associated with risk of prostate 
cancer. Men with increased sexual activity might have a reduced prostate cancer risk 
compared to men with less sexual activity. The Health Professionals’ Follow-up 
Study observed that men with more than 20 ejaculation per month at ages 20–29 
and 40–49 years had a decreased prostate cancer risk compared to men with average 
of 4–7 ejaculations per month (HR 0.81, 95% CI 0.72–0.92 and HR 0.78, 95% CI 
0.69–0.89, respectively) (Rider et al. 2016).
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2.4 Prostate cancer treatment 
2.4.1 Active surveillance 
Active surveillance is a reasonable alternative for first treatment of localized low-risk 
prostate cancer. It involves regular urologist appointments (at least annually), PSA 
tests (every 6 months) and repeated prostate biopsies (within the first year and then 
once every 3 to 5 years) according to European Association of Urology (EAU) 
guidelines. Since there are no prospective clinical trials comparing active surveillance 
to immediate surgical or radiotherapy treatment, selection criteria for active 
surveillance varies globally. In Finland, active surveillance is an option for men with 
Gleason score 6 or less, PSA less than 10 ug/l, T-stage less than T3 and 2 or less 
cores with cancer involvement in prostate biopsy (Duodecim 2014). If disease 
progresses during surveillance, switching to active treatment is indicated. Strongest 
indicators to start active treatment are Gleason score 7 or more, more than 2 cancer 
positive cores in prostate cancer biopsy or T-stage progression. PSA increase is less 
specific indicator compared to the previous ones (Dall'Era et al. 2012). 
A Canadian prospective cohort study followed 993 men with low- or 
intermediate-risk prostate cancer. Overall and prostate cancer-specific survival rates 
after 15 years of follow-up were 62% and 94.8%, respectively. At 15 years, 55% of 
men were not treated but still on surveillance (Klotz et al. 2015). 
The Prostate Testing for Cancer and Treatment study compared active 
surveillance (PSA test every three months for the first year and 1-2 times per year 
thereafter), radical prostatectomy and external-beam radiotherapy on 1643 men with 
localized prostate cancer. 17 prostate cancer-specific deaths occurred during the 
median follow-up of 10 years. 8 of them belong to the active surveillance group, 5 
of them to the radical prostatectomy group and 4 of them to the radiotherapy group 
(p=0.48, for overall comparison) suggesting that treatment option does not have 
impact on the 10-year cancer-specific survival. 291 men (53%) among the active 
surveillance group received a radical treatment by the end of the follow-up. 
However, incidence of disease progression, including metastasis, was increased in 
the active surveillance group compared to the radical prostatectomy and 
radiotherapy groups. 112 men in the active surveillance group had disease 
progression, whereas 46 and 46 men had disease progression in the prostatectomy 
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and in the radiotherapy group, respectively (p<0.001, for the overall comparison). 
Since there was no difference in survival, it can be deduced that radical treatment 
after disease progression in active surveillance is safe (Hamdy et al. 2016). 
2.4.2 Radical prostatectomy 
Radical prostatectomy is a classic treatment option for localized prostate cancer. 
Surgically removing malignant prostate tissue improves survival compared to 
watchful waiting. Radical prostatectomy reduced both overall and cancer-specific 
mortality among men with localized prostate cancer in the SPCG-4 study (Bill-
Axelson et al. 2011). There was no statistically significant difference between radical 
prostatectomy and watchful waiting in all-cause or cancer-specific mortality in the 
PIVOT trial. However, among men with PSA over 10 ug/l or with intermediate- or 
high-risk tumor all-cause mortality was increased in the control arm (Wilt et al. 2012). 
The SPCG-4 study started before common PSA testing era at 1989 so the study 
included a lot of advanced cancer cases. On the other hand, the PIVOT trial has 
been conducted during the PSA era and it includes early stage tumors. This 
divergence in study populations probably explains the difference in the outcomes. 
The most common side-effects of radical prostatectomy are incontinence and 
sexual dysfunction. Long-term urine incontinence and sexual dysfunction rates after 
radical prostatectomy have been reported to be 8.9% – 18.3% and 72% – 81%, 
respectively (Prabhu et al. 2013). Surgical techniques have developed, first after 
laparoscopic innovations, and later with robotic-assisted laparoscopic prostatectomy 
(RALP). RALP was associated with improved recovery of erectile function (RR 1.51, 
95% CI 1.19-1.92) and continence (RR 1.14, 95% CI 1.04-1.24) compared to 
laparoscopic operation (Allan and Ilic 2016).  
2.4.3 Radiation therapy 
Indications for radiation therapy are rather identical with those for radical 
prostatectomy: curative care due to localized or locally advanced cancer (T1-4, N0-
1, M0). There are multiple RCTs comparing radiation therapy dozes and dose 
increase improved biochemical progression-free survival but there was no impact on 
overall survival (Dearnaley et al. 2014; Heemsbergen et al. 2014). A propensity-
matched retrospective analysis showed dose escalation having an overall survival 
benefit for men with intermediate or high-risk prostate cancer. Patients with low-
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risk prostate cancer did not have an advantage of increased radiation dose (Kalbasi 
et al. 2015). A Finnish guideline recommends 3D conformal radiation therapy with 
total dose of 72- 74 Gray (Duodecim 2014). 
There is a strong evidence suggesting treating high-risk patients with adjuvant 
androgen-deprivation therapy (ADT) alongside with radiation therapy. The 
European Organization for Research and Treatment of Cancer (EORTC) trial 
randomized patients to receive radiation therapy alone or with 3-year ADT. 10-year 
clinical disease-free survival was 22.7% in the radiation therapy alone group and 
47.7% in the combined treatment group (p<0.001). Similar risk decrease was seen 
for 10-year overall survival (39.8% vs 58.1%, p=0.0004) without major adverse 
effects (Bolla et al. 2010). The radiation therapy combined with ADT is the primary 
treatment option for locally advanced prostate cancer according to EAU guidelines 
(Mottet et al. 2017). 
Most common adverse effects include bowel and urinary symptoms. Acute 
rectum irritation causes diarrhea, hemorrhage and rectal discharge. Radiation cystitis 
results in overactive bladder, dysuria, nocturia and hemorrhage. Acute adverse 
effects often relieve within 2 – 3 months after radiation therapy. Long-term adverse 
effects occur usually within 3 years and involve rather similar gastrointestinal and 
genitourinary symptoms as acute ones. Prevalence of acute and late symptoms was 
49% and 21%, respectively, in a retrospective data comparison. Severe late side-
effects were rare (prevalence of genitourinary symptoms 4% and gastrointestinal 
symptoms 2%) (Mohammed et al. 2012). 
Brachytherapy is a form of radiation therapy in which a radioactive source is 
placed into a prostate. There are two types of brachytherapy; low-dose rate and high-
dose rate. Low-dose rate therapy involves the insertion of permanent radioactive 
seeds into the prostate whereas temporary needles are inserted into the prostate for 
a short period of time at high-dose rate therapy. There are no randomized trials 
comparing low-dose rate therapy to other curative treatment options but population-
based studies suggest that low-dose rate therapy is safe and effective treatment 
option for localized low-risk or intermediate-risk prostate cancer (Grimm et al. 2012; 
Sylvester et al. 2011; Taira et al. 2010).  
High-dose rate brachytherapy is newer treatment option than low-dose rate 
therapy and therefore knowledge of its safety and effectiveness is still limited. A 
randomized trial comparing radiation therapy to radiation therapy combined with 
high-dose rate brachytherapy showed that the combination had statistically 
significantly improved the clinical relapse-free survival (10-year estimate of 
biochemical control of 46% vs 39%, p=0.04) but differences in overall survival were 
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not statistically significant (Hoskin et al. 2012). There are no trials considering high-
dose rate brachytherapy as monotherapy but registry studies have observed that 
high-dose rate therapy seem to be a safe and effective monotherapy treatment option 
for men with low- and intermediate-risk prostate cancer (Hauswald et al. 2016; 
Zamboglou et al. 2013). 
2.4.4 Androgen-deprivation therapy 
Dihydrotestosterone is the main androgen in the prostate and an important factor 
for prostate cancer progression. Therefore, inhibiting the expression of 
dihydrotestosterone and other androgens is an efficient method of reducing the 
progress of prostate cancer and it is the primary treatment for metastatic prostate 
cancer and additionally it is used as neoadjuvant treatment for radiation therapy.  
There are two possibilities to achieve androgen suppression: elimination of 
testicular androgen secretion (castration) or androgen receptor blockade 
(antiandrogens). Castration can be achieved by bilateral subcapsular orchiectomy. 
Other option is to use gonadotropin-releasing hormone (GnRH) agonist or 
antagonist (chemical castration). The castrate testosterone level has been defined to 
be less than 1.73 nmol/l. However, there were inferior 5-year biochemical 
recurrence-free survival in men with testosterone level at 1.1-1.7 nmol/l compared 
to men with the level less than 1.1 nmol/l (Pickles et al. 2012). 
Surgical and chemical castrations are equally efficient and safe (Seidenfeld et al. 
2000). Often surgical treatment is offered to elder men since it is a quicker method 
to achieve castration level than the chemical one (Loblaw et al. 2004). GnRH-
agonists are usually delivered as depot-injections and it is recommended to treat the 
patient with antiandrogens after the first GnRH-agonist injection due to flare 
phenomenon (transient increase in testosterone level), especially if there are 
widespread bone metastases (Kuhn et al. 1989). GnRH-antagonist provide quick 
castration level without flare-up reaction but the disadvantage is monthly injection 
rate. Side-effects are similar among all castration options: hot waves, sweating, 
muscle atrophy, osteoporosis, sexual dysfunction, anemia and increased risk of 
metabolic syndrome. 
Antiandrogen treatment is a considerable alternative to castration, especially for 
sexually active younger patients without widespread bone metastases. Monotherapy 
with bicalutamide has been shown to be as effective as castration in men with non-
metastatic locally advanced prostate cancer. In addition, there were statistically 
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significant decrease in side-effects (sexual interest and physical capacity) (Iversen et 
al. 2000). Classic adverse effect of bicalutamide is breast tenderness due to 
testosterones increased aromatization to estrogen. Therefore, prophylactic 
irradiation of breasts is provided before initiation of antiandrogen monotherapy. In 
Finland, another non-steroidal antiandrogen in clinical use is flutamide. Combining 
castration with antiandrogen treatment provides slight improve in 5-year survival 
(HR 0.87, 95% CI 0.81-0.94) but there were more withdrawals from treatment 
among men receiving combined medication (Samson et al. 2002).  
Intermittent alternative has been developed to reduce the adverse effects of 
continuous ADT. A meta-analysis including 15 trials and 6856 patients reported that 
there was no statistically significant difference between continuous and intermittent 
ADT for overall survival (HR 1.02, 95% CI 0.93-1.11) or prostate cancer-specific 
survival (HR 1.02, 95% CI 0.87-1.19). However, men in intermittent therapy had less 
adverse effects, for example hot flashes (RR 0.76, 95% CI 0.57-1.00) and 
cardiovascular death (RR 0.86, 95% CI 0.73-1.02) compared to men in continuous 
therapy (Magnan et al. 2015). 
2.4.5 Treatment of castration resistant prostate cancer 
2.4.5.1 Chemotherapy 
Chemotherapy is indicated treatment if there is an active metastatic disease despite 
castration. Docetaxel-based chemotherapy given every three weeks was associated 
with improved survival (p=0.009) compared to men receiving mitoxantrone. Median 
survivals were 18.9 and 16.5 months, respectively (Tannock et al. 2004). Men with 
long progression-free period after first-line docetaxel benefit from subsequent 
treatment with docetaxel (Loriot et al. 2010). The most common adverse effects 
include neutropenia, nausea, hand-foot syndrome and mucosal atrophy. 
Cabazitaxel has advantageous effect on docetaxel-resistant cancers. Median 
survivals were 15.1 and 12.7 months (p < 0.0001) among men with cabazitaxel and 
mitoxantrone, respectively (de Bono et al. 2010). Adverse effects are similar with 
docetaxel. 
2.4.5.2 Androgen targeted therapy 
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Second generation antiandrogen enzalutamide has been shown to be efficacious in 
treatment for castrate resistant prostate cancer both as first-line treatment and after 
docetaxel (Beer et al. 2014; Scher et al. 2012). Similar findings have been made for 
another androgen biosynthesis inhibitor abiraterone. The intervention group 
without previous docetaxel treatment had median overall survival of 34.7 months 
whereas the placebo group had median survival of 30.3 months (p = 0.0033) (Ryan 
et al. 2015). In addition, abiraterone was beneficial after docetaxel treatment if there 
was cancer progression. Median overall survival was 15.8 months for the abiraterone 
group and 11.2 for the placebo group (p < 0.0001) (Fizazi et al. 2012). The most 
usual adverse effects include fatigue, hypertension, dizziness and lower back pain for 
enzalutamide and cardiac disorders, hypokalemia and elevated liver enzyme levels. 
2.4.5.3 Alpha-emitted therapy 
Radium-223 (Alfarad) has been shown to be effective for patients with bone 
metastasis. It binds to tissues with increased bone metabolism and hence has high 
affinity for bone metastasis but not for visceral metastasis. Men receiving six radium-
223 injections had statistically significant improvement in overall survival (HR 0.70, 
95% CI 0.58-0.83) compared to the placebo group (Parker et al. 2013). However, 
high price restricts radium-223 use. Another serious adverse effect is myelotoxicity. 
2.4.5.4 Bone targeted agents 
Zoledronic acid (bisphosphonate) has been used to prevent bone fractures. The 
intervention group (4 mg zoledronic acid every 3 weeks) had less skeletal-related 
events than the placebo group (33.2% vs 44.2%, p=0.021) in a randomized study 
but there was no differences in quality-of-life scores or disease progression (Saad et 
al. 2002). 
However, a modern receptor activator of nuclear factor-kB ligand (RANKL) 
inhibitor denosumab has been showed to be superior when compared to zoledronic 
acid. Median time to first skeletal-related effect was 20.7 months among denosumab 
group and 17.1 months among zoledronic acid group (p = 0.008) (Fizazi et al. 2011). 
The most serious but rare adverse effect is osteonecrosis of the jaw. 
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2.5 Prostate cancer and pharmacoepidemiology 
A summary of medications with a possible association with prostate cancer is 
presented in Table 6. Associations between use of digoxin and beta-blockers and 
cancer are discussed in greater detail in chapters 2.6.3 and 2.7.2.1. 
2.5.1 5-alpha-reductase inhibitors (5-ARIs) 
5-ARIs inhibit testosterone conversion to dihydrotestosterone, which is the primary 
androgen in the prostate. The primary indication for 5-ARI use is the treatment of 
BPH and the two 5-ARIs sold in Finland are finasteride and dutasteride (Kela and 
Fimea 2017).  The Prostate Cancer Prevention Trial (PCPT) randomized 18,882 
previously healthy men, aged 55 years or older, to receive finasteride or placebo. 
After 7 years of follow-up, cumulative incidence of prostate cancer was 18.4% in the 
finasteride group and 24.4% in the control group (p < 0.001). However, there was a 
higher percentage of high-grade tumors in the finasteride arm. Cumulative incidence 
was relatively high mainly due to biopsy protocol of the trial; PSA concentration was 
measured annually, and because use of finasteride lowers PSA level, the PSA values 
among finasteride arm were first doubled. However, at the start of the participants’ 
fourth year in the study, the factor was changed to 2.3 aiming to an equal percentage 
of biopsies in both groups. Men with a PSA value higher than 4.0 ug/l were referred 
to prostate biopsy  (I. M. Thompson et al. 2003). A randomized trial comparing 
dutasteride to placebo showed similar results. In the RCT of 8,231 men aged 
between 50-75 years, dutasteride use was associated with decreased prostate cancer 
risk (RR 0.77, 95% CI 0.70-0.85), but there were more high-grade cancers over the 
4-year study period (Andriole et al. 2010). 5-ARI use was not associated with prostate 
cancer survival (HR 0.94, 95% CI 0.72-1.24 and HR 0.98, 95% CI 0.69-1.41 for usage 
before and after the diagnosis, respectively) among men with prostate cancer in the 
FinRSPC (Murtola et al. 2016). 
2.5.2 Statins 
Statins are used to lower low-density lipoprotein (LDL) concentration and thus to 
reduce the risk of cardiovascular diseases. Statins sold in Finland are simvastatin, 
atorvastatin, fluvastatin, rosuvastatin, lovastatin and pravastatin. Use of statins is 
common and for example 42% of study population in the FinRSPC  had used statins 
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during the 16 year study period (Kaapu et al. 2016). Statin use was associated with 
slightly reduced prostate cancer risk in a Danish case-control study of 254,880 men; 
adjusted OR 0.94, 95% CI 0.91-0.97 for statin use compared with non-use. Risk 
reduction was larger for risk of advanced prostate cancer, adjusted OR 0.90, 95% CI 
0.85-0.96 and with statin use of 10 years or more, adjusted OR 0.78, 95% CI 0.65-
0.95 (Jespersen et al. 2014). Similar results were obtained in the FinRSPC cohort. 
Overall prostate cancer risk was lower among statin users (HR 0.75, 95% CI 0.63-
0.89) when compared with non-users of statins. The association was in the same 
direction between long-term use (6 years or more) and prostate cancer risk but not 
statistically significant (HR 0.70, 95% CI 0.45-1.08) (Murtola et al. 2010). Consistent 
but statistically non-significant results were observed in an American cohort study 
of 32,091 men aged between 40-79 at baseline. Compared to non-use, there was no 
statistically significant association between statin use and overall risk of prostate 
cancer (HR 0.86, 95% CI 0.63-1.18) The association was stronger, but nevertheless 
non-significant, for high-grade cancer (HR 0.62, 95% CI 0.30-1.28) (Kantor et al. 
2015). The REDUCE study differed from the studies mentioned above; statin use 
did not modify prostate cancer risk (Freedland et al. 2013). There are no published 
reviews concerning statin use and risk of prostate cancer. 
A meta-analysis of 34 cohort studies showed statin use was associated with a 
reduction in both risk of all-cause mortality and prostate cancer-specific mortality 
(HR 0.76, 95% CI 0.63-0.91 and HR 0.76, 95% CI 0.64-0.89, respectively). Statin use 
was associated with decreased risk of biochemical recurrence among men treated 
with radiation therapy (HR 0.79, 95% CI 0.65-0.95) but not with radical 
prostatectomy (HR 0.94, 95% CI 0.81-1.09) (Raval et al. 2016). Randomized trials 
are required to achieve further information about statins and prostate cancer. 
2.5.3 Metformin and other anti-diabetic drugs 
Metformin is the first-line medication for the treatment of type 2 diabetes mellitus. 
The association between metformin use and prostate cancer is widely studied, and 
the results are inconsistent. Compared to non-users, metformin users had a reduced 
prostate cancer risk in a Danish case-control study (Preston et al. 2014) and in a 
Finnish cohort study (Haring et al. 2017), whereas there was no association between 
use of metformin and prostate cancer risk in the REDUCE study (T. Feng et al. 
2015) and a Canadian cohort study (Margel et al. 2013). A meta-analysis of 18 cohort 
or case-control studies with 52,328 cases concluded that metformin use was not 
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statistically significantly associated with prostate cancer risk (RR 0.97, 95% CI 0.80-
1.16) (Z. Feng et al. 2019). Similar conclusion was made in another meta-analysis, 
which included 18 cohort studies and 6 case-control studies with 2,009,504 men. 
There was no association between prostate cancer risk and use of metformin (HR 
0.97, 95% CI 0.84-1.12 in case-control studies and HR 0.94, 95% CI 0.79-1.12 in 
cohort) (Y. Wang et al. 2019).   
Metformin users had borderline significant reduction in the biochemical 
recurrence risk (HR 0.82, 95% CI 0.76-1.01) in a systematic review. Metformin use 
was associated neither with prostate cancer-specific mortality (HR 0.76, 95% CI 
0.46-1.33) nor all-cause mortality (HR 0.86, 95% CI 0.67-1.10) (Raval et al. 2015). In 
a separate review, prostate cancer patients with diabetes not using metformin were 
at higher prostate cancer recurrence risk (HR 1.20, 95% CI 1.00-1.44) (Hwang et al. 
2015). 
A meta-analysis of 10 cohort studies and one case–control study evaluated 
prostate cancer risk among men receiving insulin therapy. A total number of 205,523 
men with 7,053 prostate cancer cases were included. Prostate cancer risk among 
insulin users did not differ from men using other glucose-lowering agents (RR 0.89, 
95% CI 0.72-1.09) (Y. Chen et al. 2013).  
2.5.4 Other suggested agents besides antiarrhythmic drugs 
Aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) have been suggested to 
be associated with a reduced prostate cancer risk. Several population-based studies 
have found an association between aspirin/NSAID use and decreased prostate 
cancer incidence (Doat et al. 2017; Platz et al. 2005a; Vidal et al. 2015). However, 
conflicting results have been published and further studies are required (Veitonmaki 
et al. 2014). NSAID users had a decreased risk of prostate cancer (RR 0.89, 95% CI 
0.81-0.98) in a meta-analysis of 43 studies. In addition, use of aspirin was associated 
with a decreased prostate cancer risk (RR 0.93, 95% CI 0.89-0.96) (Shang et al. 2018). 
Antiepileptic drugs, especially valproate, have been suggested to have 
antineoplastic properties due to histone deacetylase inhibitory features (Batta et al. 
2007). Salminen et al. found diminished prostate cancer risk among 
valproate, phenobarbital and carbamazepine users (Salminen et al. 2016). 
Nonetheless, contradictory results have been observed and again, additional studies 
are necessary (Kang et al. 2014). 
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In addition, association between antihypertensive drugs and prostate cancer risk 
has been researched. A meta-analysis of 12 cohort and 9 case-control studies showed 
that use of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor 
blocker (ATRB) or diuretics had no influence on prostate cancer risk. Calcium 
channel blocker (CCB) use increased prostate cancer incidence (RR 1.08, 95% CI 
1.00-1.16) (Cao et al. 2018a).
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2.6 Digoxin 
2.6.1 Mechanism of action and traditional indications 
Cardiac glycosides, of which digoxin is the most commonly used, are inotropic 
agents. They increase stroke volume, and thus enlarges cardiac output. Additionally, 
cardiac glycosides decrease heart rate. Above-mentioned properties make digoxin 
and other cardiac glycosides, such as digitoxin, optimal drug for congestive heart 
failure, especially, if patient has an atrial fibrillation or flutter, and therefore, 
indications for digoxin use are decreasing heart rate in atrial fibrillation or improving 
cardiac output in chronic heart failure (Ruskoaho et al. 2014). 
Digoxin binds to alpha unit of an enzyme called sodium-potassium adenosine 
triphosphatase (Na+/K+ -ATPase). The Na+/K+ -ATPase transports sodium out of 
the cell and exchanges it to potassium. Digoxin decreases activity of the Na+/K+ -
ATPase resulting in increased intracellular sodium concentration. This inhibits the 
sodium-calcium exchanger, which substitutes intracellular calcium with extracellular 
sodium. The cascade leads to increased intracellular calcium concentration, which 
intensifies the force of contraction of the heart. Furthermore, increased calcium 
concentration slows the heart rate via lengthening the cardiac action potential 
(Ruskoaho et al. 2014). 
Digoxin has systemic effects also. It increases sensitivity to vagal stimulation and 
activates vagal centers in the central nervous system, and therefore intensifies 
parasympathetic nervous system activation (Ruskoaho et al. 2014).   
2.6.2 Potential antineoplastic mechanisms of digoxin 
2.6.2.1 Na+/K+ -ATPase 
Inhibition of Na+/K+ -ATPase increases intracellular Ca2+-concentration as 
discussed above. Calcium has a vital role in activating programmed cell death 
(apoptosis) (McConkey and Orrenius 1997). Na+/K+ -ATPase is also expressed at 
tumor cells (Repke 1988). A previous study has shown that injecting thapsigargin 
(inhibitor of Ca2+-APTase) to prostate cancer cell increases Ca2+-concentration, 
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likewise digoxin, and activates apoptosis (Furuya et al. 1994). An in vitro study 
observed digoxin injections inducing apoptosis in androgen-independent human 
prostate cancer cell lines and concluded that increased intracellular Ca2+-
concentration was the most important trigger for apoptosis (McConkey et al. 2000). 
Furthermore, digoxin decreases intracellular K+-concentration via inhibiting 
Na+/K+ -ATPase and decreased K+-concentration is another apoptosis trigger 
(Hughes et al. 1997). 
2.6.2.2 HIF-1alpha 
Hypoxia-inducible factor 1-alpha (HIF-1alpha) is a subunit of transcription factor 
HIF-1, which is an essential gene activator for tumor invasion, angiogenesis and cell 
survival (Harris 2002). Intratumoral hypoxia and oncogene mutations induce 
overexpression of HIF-1alpha in human cancers, which has also been identified as a 
risk factor for treatment failure (Semenza 2003). Digoxin and other cardiac 
glycosides do not inhibit the expression of HIF-1alpha mRNA, but the translation 
of mRNA into protein (Zhang et al. 2008). Reduced HIF-1alpha expression and 
xenograft tumor growth were observed both in vitro and in vivo after digoxin 
injections (Zhang et al. 2008).  
2.6.2.3 Estrogenic effects 
There are two estrogen receptors (ER) in the human prostate, ER-alpha and -beta. 
Activation of the beta receptor restricts cell proliferation in prostate cancer and 
therefore it might be possible to inhibit disease progression to the castration-resistant 
form via ER-beta (Bonkhoff 2018; Carruba 2007; Thelen, Wuttke, Seidlová-Wuttke 
2014). Since the chemical structure of digoxin is rather similar to estradiol, it has 
affinity for estrogen receptors too (Rifka, Pita, Loriaux 1976; Rifka et al. 1978). 
Phyto-estrogenic effect might have impact on risk of estrogen-sensitive cancers, for 
example breast cancer. A review considering 18 studies found that women 
consuming high doses of phytoestrogens might have a reduced breast cancer risk 
(Peeters et al. 2003). A meta-analysis containing 23 studies and a total of 11,346 cases 
and 140,177 controls showed that there was an association between use of daidzein 
(OR 0.85, 95% CI 0.75-0.96), genistein (OR 0.87, 95% CI 0.78-0.98) and glycitein 
(OR 0.89, 95% CI 0.81-0.98) and decreased prostate cancer risk. However, use of 
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total isoflavones (OR 0.93, 95% CI 0.84-1.04) and several other separate isoflavones 
lacked the association (Q. Zhang et al. 2017). 
2.6.3 Digoxin use and cancer 
2.6.3.1 Digoxin use and overall cancer risk 
Even though there are only few studies on digoxin use and overall cancer risk, there 
are numerous studies on individual cancer types and digoxin. A Norwegian case-
control study reported an increased overall cancer incidence among digitoxin users 
among study population consisting of both men and women (OR 1.21, 95% CI 1.15-
1.28) (Haux et al. 2001a). 
The most widely studied cancer is breast cancer; two rather identical meta-
analyses have been published on the breast cancer risk and cardiac glycoside use. 
Both included 9 studies, of these 8 were the same in both reviews. Results are very 
similar: cardiac glycoside use was associated with an increased risk of breast cancer 
(RR 1.33, 95% CI 1.25-1.42 and RR 1.34, 95% CI 1.25-1.44) with no significant 
heterogeneity between studies. Digoxin users have especially high risk for ER-
positive breast cancer compared to non-users (Karasneh, Murray, Cardwell 2017; 
Osman et al. 2017). 
A meta-analysis on the risk of colorectal cancer and cardiac glycoside use included 
four studies but only one of them considered digoxin, while the others studied 
digitalis or digitoxin. The conclusion was that cardiac glycoside users had an 
increased risk of colorectal cancer (RR 1.38, 95% CI 1.20-1.58) (Osman et al. 2017). 
A large Swedish cohort study, published after the meta-analysis, had coherent results. 
After adjustment for age, sex, residence and comorbidities, digoxin users had an 
increased colorectal cancer incidence (HR 1.24, 95% CI 1.18-1.30). However, the 
risk increase was associated with short-time use of digoxin and disappeared in long-
term use (Xie et al. 2017). 
Digoxin use was associated with an increased lung cancer risk in a meta-analysis 
of three studies (RR 1.32, 95% CI 1.03-1.69) (Osman et al. 2017). Similar findings 
were obtained in a Taiwanese study: digoxin users had an increased lung cancer risk 
(HR 1.38, 95% CI 1.11-1.70) after an 8-year follow-up. Nonetheless, after adjustment 
for age, sex, region, income, urbanization and Charlson comorbidity index (CCI), 
the association was not statistically significant (HR 1.20, 95% CI 0.98-1.51) (Chung 
et al. 2017). 
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There are several cohort and case-control studies reporting of digoxin use and a 
risk of separate cancer types. The studies are listed in Table 7. 
2.6.3.2 Digoxin use and overall cancer prognosis 
There are no published prospective studies on digoxin use and overall cancer 
survival. However, some publications have addressed digoxin use and cancer 
survival in specific cancer types and even a meta-analysis has been published based 
on these studies (Osman et al. 2017). The meta-analysis contained six cohort studies: 
two on prostate cancer and one on colorectal cancer, breast cancer, epithelial ovarian 
cancer and glioblastoma each. All reported all-cause mortality and four of them also 
reported cancer-specific mortality. Digoxin users had a decreased overall survival 
(HR for death 1.35, 95% CI 1.25-1.46) but there was no association between digoxin 
use and a cancer-specific survival (HR 1.08, 95% CI 0.97-1.19) (Osman et al. 2017).  
The studies are listed in Table 8.  
 
  
 52 
 
 
Table 7.  Epidemiological studies on digoxin and cancer risk (prostate cancer, breast cancer, 
colorectal cancer and lung cancer excluded).  
Cancer type Study Study design 
Size of study 
sample 
RR (95% CI)   
Glioblastoma     
 Boursi et al Case-control 5329 0.80 (0.40-1.59) 
 Seliger et al Case-control 22,055 0.74 (0.36-1.55) 
Uterine     
 Biggar et al Cohort 2,116,029 1.48 (1.32-1.62) 
Ovarian     
 Biggar et al Cohort 2,116,029 1.06 (0.92-1.22) 
Cervical     
 Biggar et al Cohort 2,116,029 1.00 (0.79-1.25) 
Esophagus     
 Xie et al Cohort 708,285 1.22 (1.01-1.46) 
Stomach, cardia    
 Xie et al Cohort 708,285 1.04 (0.80-1.36) 
Stomach, non-cardia   
 Xie et al Cohort 708,285 0.90 (0.78-1.05) 
Small intestine    
 Xie et al Cohort 708,285 1.00 (0.76-1.33) 
  
 Xie et al Cohort 708,285 1.06 (0.88-1.29) 
Gallbladder     
 Xie et al Cohort 708,285 1.63 (1.19-2.25) 
Pancreas     
 Xie et al Cohort 708,285 1.08 (0.94-1.24) 
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Table 8.  Epidemiological studies on digoxin and cancer prognosis.  
 
Cancer type Study Size of study sample 
HR (95% CI), 
overall survival 
HR (95% CI), 
cancer-specific 
survival 
Prostate cancer    
 Flahavan et al 5,732 1.24 (1.07-1.43) 1.13 (0.91-1.42) 
 Karasneh et al 13,134 1.39 (1.23-1.56) 1.13 (0.93-1.37) 
Colorectal cancer    
 Karasneh et al 10,357 1.53 (1.34-1.73) 1.10 (0.91-1.34) 
Glioblastoma    
 Boursi et al 1,076 1.56 (0.80-3.04) - 
Epithelial ovarian cancer    
 Vogel et al 762 1.29 (0.81-2.06) - 
Breast cancer    
 Karasneh et al 17,842 1.24 (1.08-1.41) 0.91 (0.72-1.14) 
 
2.6.3.3 Digoxin use and the risk of prostate cancer 
Several epidemiological studies on cardiac glycosides and prostate cancer risk have 
been published. A study, including 9,271 digitoxin users and one control for each 
drug user, reported increased prostate cancer risk among the drug users compared 
to non-users (OR 1.25, 95% CI 1.08-1.45) (Haux et al. 2001b). In a large prospective 
cohort study of 47,884 men, there was a significant association between current 
digoxin use during the follow-up and a reduced prostate cancer risk (RR 0.78, 95% 
CI 0.67-0.90). The association was strongest for long-term (over 10 years) use (RR 
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0.54, 95% CI 0.37-0.79) (Platz et al. 2011). An U.S. case-control study had slightly 
incoherent results; digoxin use was not statistically significantly associated with the 
prostate cancer incidence (OR 0.58, 95% CI 0.30-1.10) and long-term users had a 
higher prostate cancer risk than short-term users. However, prostate cancer risk was 
decreased among digoxin users with 3 or more PSA-tests during the past five years 
(OR 0.44, 95% CI 0.20-0.98) (Wright, Hansten, Stanford 2014). There was no 
association between digoxin use and the  prostate cancer risk (HR 0.89, 95% CI 0.67-
1.18) in a Taiwanese cohort study (L. T. Kao et al. 2018). 
A meta-analysis containing the studies mentioned above along with the two 
studies included in this doctoral thesis observed no association between digoxin use 
and the prostate cancer risk (RR 1.02, 95% CI 0.87-1.19), but there was a significant 
heterogeneity in the results; in contrast to others, the case-control study published 
by Haux et al  2001 observed increased prostate cancer risk among digoxin users. 
This is probably due to lack of adjustments for confounders.  There was some 
suggestion that long-term use (5 years or longer) of digoxin might lower prostate 
cancer risk (RR 0.89, 95% CI 0.79-1.02) and the risk of cancer with Gleason score 7 
or more was diminished (RR 0.80, 95% CI 0.68-0.96) (Osman et al. 2017).   
2.6.3.4 Digoxin use and prostate cancer prognosis 
Two studies considering digoxin use and prostate cancer prognosis have been 
published. The first followed 5,732 men with prostate cancer for a median follow-
up of 4.3 years. Men with digoxin exposure prior to prostate cancer diagnosis had a 
statistically significant increase in all-cause mortality, but not in prostate cancer-
specific mortality (HR 1.24, 95% CI 1.07-1.43 and HR 1.13, 95% CI 0.91-1.42, 
respectively) (Flahavan et al. 2014). 
The second study identified 13,134 prostate cancer cases with a mean follow-up 
of 5.0 years. Digoxin use after prostate cancer diagnosis was not associated with 
prostate cancer-specific survival (HR 1.13, 95% CI 0.93-1.37) but all-cause mortality 
was increased among digoxin users compared to non-users (HR 1.39, 95% CI 1.23-
1.56), mainly due to cardiovascular deaths (HR 1.85, 95% CI 1.49-2.31) (Karasneh 
et al. 2016). 
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2.7 Other antiarrhythmic drugs 
2.7.1 Antiarrhythmic drugs classification 
Antiarrhythmic agents are divided into four separate groups by mechanism of action. 
Class I includes Na+-channel blockers and there are three subclasses Ia (lengthens 
repolarization), Ib (shortens repolarization) and Ic (slows electrical conduction). 
Agents belonging to class Ia are quinidine and disopyramide, to class Ib lidocaine 
and mexiletine and to class Ic flecainide and propafenone. 
Class II drugs are beta-blockers (BBs). We did not include pure BBs in the cohort 
studies, as they are studied together with antihypertensive agents (Siltari et al. 2018). 
Agents blocking K+-channel form class III. The agents prolong duration of 
action potential, repolarization and refractory period. Class III includes amiodarone, 
dronedarone, sotalol, ibutilide and dofetilide. 
Slow Ca2+-channel blockers belong to class IV. The only drugs in clinical use 
from this group are verapamil and diltiazem. Ca2+-channel blockers are commonly 
used as antihypertensive agents and we did not include them into the study. 
In addition, there are drugs with antiarrhythmic properties not fitting any 
traditional antiarrhythmic agent class. Therefore, class V has been developed. It 
contains digoxin (discussed previously), adenosine (activates K+-channels in the 
atrium and in the sinus node and thus shortens the duration of action potential) and 
novel agents such as vernakalant and ivabradine. 
2.7.2 Antiarrhythmic drugs and cancer 
2.7.2.1 Beta-blockers and cancer 
Beta-adrenergic activation is vital to several hallmarks of cancer and therefore, BBs 
have been hypothesized to have potential to prevent cancer progression (Cole and 
Sood 2012). Many observational studies have been published on risk of cancer death 
among BB users, summarized in meta-analyses. 
A review covering 24 epidemiological studies found that pre-diagnostic BB use 
had no influence on either all-cause mortality or cancer-specific mortality (HR 1.04, 
95% CI 0.95-1.13 and HR 0.91, 95% CI 0.84-1.00, respectively). In addition, pre-
diagnostic BB use was not statistically significantly associated with prostate cancer-
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specific death (HR 0.87, 95% CI 0.71-1.07). However, compared to non-users, post-
diagnostic BB users had a reduced all-cause mortality (HR 0.89, 95% CI 0.81-0.98) 
and cancer-specific mortality (HR 0.89, 95% CI 0.79-0.99). The association was not 
statistically significant for prostate cancer-specific death only (HR 0.84, 95% CI 0.70-
1.01) (Zhong et al. 2016). 
Choi et al. 2014 included 12 epidemiological studies and BB use was associated 
with improved overall survival (HR 0.79, 95% CI 0.67-0.93) and prolonged disease-
free survival (HR 0.69, 95% CI 0.53-0.91). There was no association between beta 
blocker use and prostate cancer death (HR 0.61, 95% CI 0.23-1.60) (Choi et al. 2014). 
Interestingly, immortal time bias, which is discussed more in chapter 6, might 
explain the observed beneficial risk associations in observational studies. A meta-
analysis of 30 studies showed a reduced risk of death among BB users compared to 
non-users (HR 0.88, 95% CI 0.79-0.97). Nevertheless, after excluding 11 studies 
potentially prone to immortal time bias, there was no association between BB use 
and overall survival (HR 1.00, 95% CI 0.93-1.07). A similar phenomenon was seen 
with cancer-specific survival (Weberpals et al. 2016). 
A review, including 8 epidemiological studies (2 cohort studies and 6 case-control 
studies), summarized possible association between BB use and prostate cancer risk. 
According to the review, BB use had no statistically significant association with the 
risk of prostate cancer (HR 0.91, 95% CI 0.81-1.02) but there was significant 
heterogeneity between the studies; one of the case-control studies reported 
significantly increased prostate cancer risk, which might be due to systematic 
difference between BB users and non-users, more frequent PSA measurement 
interval or immortal time bias, for example (Cao et al. 2018b). 
2.7.2.2 Other antiarrhythmic drugs and cancer 
Studies about cancer and antiarrhythmic agents besides digoxin and BBs are sparse. 
Amiodarone might increase cancer risk. A Taiwanese cohort study found an 
increased overall cancer risk among high-dose (Defined Daily Dose (DDD) > 180) 
amiodarone users compared with the general population (SIR 1.28, 95% CI 1.00-
1.61). However, there was no clear association between overall amiodarone use and 
cancer risk (SIR 1.12, 95% CI 0.99-1.26) (Su et al. 2013). 
Another Taiwanese study, a case-control study of 9,944 cases and 19,497 matched 
controls, observed an increased liver and intrahepatic bile duct cancer incidence 
among amiodarone users compared to non-users (OR 1.60, 95% CI 1.45-1.77). 
Compared to non-uses, the risk increase was even larger among patients with high-
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dose (DDD > 145) amiodarone use (OR 1.79, 95% CI 1.50-2.15). Other 
antiarrhythmic agents (mexiletine, propafenone, quinidine and procainamide) had no 
impact on the risk of liver and intrahepatic bile duct cancer (Lim et al. 2015). 
A third Taiwanese study investigated antiarrhythmic drug use and prostate cancer 
risk. None of the observed drug groups associated with prostate cancer risk; HRs 
for Na+-channel blockers, K+-channel blocker and Ca2+-channel blockers were 1.12 
(95% CI 0.84-1.50), 0.89 (95% CI 0.59-1.34) and 1.14 (95% CI 0.95-1.36), 
respectively (Kao et al. 2017). 
A U.S. cohort study of 93,265 patients assessed Na+-channel inhibitors and 
cancer survival. There was some suggestion that users of Class I antiarrhythmic drugs 
had more favorable overall survival compared to non-users (HR 1.11, 95% CI 0.98-
1.24) (Fairhurst et al. 2015). 
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3 AIMS OF THE STUDY 
Previous epidemiological studies considering digoxin and prostate cancer have 
provided slightly inconsistent results with diverse study population and methods. We 
wanted to study the possible association between digoxin and other antiarrhythmic 
drug use and cancer among large population-based study population with robust 
information on medication use. The objective of our study is to explore whether use 
of digoxin or other antiarrhythmic drugs associates with prostate cancer risk, 
prostate cancer survival or overall cancer mortality at population level. The specific 
aims are: 
 
1. To evaluate the association between antiarrhythmic drug use and prostate 
cancer risk. 
a. Moreover, to evaluate the impact of cumulative dose, length and 
intensity of antiarrhythmic drug use. 
b. To evaluate prostate cancer risk separately by grade and stage. 
c. To evaluate the role of screening in the risk association. 
 
2. To estimate the association between prostate cancer survival and 
antiarrhythmic drug use before and after prostate cancer diagnosis in a cohort 
study. 
a. Additionally, to evaluate survival trends by amount, duration and 
intensity of post-diagnostic digoxin and sotalol use. 
b. To evaluate effect modification by age, tumor characteristics, 
screening trial arm, usage of other drug groups and primary 
treatment. 
 
3. To evaluate the association between antiarrhythmic drug use and overall 
cancer mortality in a cohort study. 
a. To further evaluate the risk of death from most frequent cancer types 
(lung, colorectal, pancreatic, gastric, liver, renal, non-Hodgkin 
lymphoma, bladder and central nervous system cancer). 
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b. To evaluate the effect of cumulative amount, duration and intensity 
of antiarrhythmic drug use. 
c. To evaluate effect modification by age, baseline cancer and use of 
other drug groups. 
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4 SUBJECTS AND METHODS 
4.1 Data sources 
4.1.1 Finnish Cancer Registry 
The Finnish Cancer Registry, established in 1953, is a population-based institute 
maintained by the Cancer Society of Finland.  All physicians are required by a sub-
law to inform the national Cancer Registry about the primary site of cancer, cancer 
stage, method of diagnosis and primary treatment. In addition, pathological 
laboratories have a similar obligation; information on tumor histology must be 
transferred to the Cancer Registry also. Cause-of-death information from the 
Statistics Finland and the data from The Care Register for Health Care are updated 
annually to the Cancer Registry. Based on information from different sources, each 
cancer case is summarized, and the data can be used for research. Information on 
practically all cancer cases diagnosed in Finland is transferred to the Cancer Registry, 
the coverage for solid tumors was estimated to be 96%, and for non-solid tumors 
86% (Leinonen et al. 2017; Pukkala et al. 2018). 
 
4.1.2 Population Register Center 
The Population Register Center maintains the Population Information System, 
which is a large data repository containing basic information about all Finnish 
citizens and foreign citizens residing permanently in Finland. The data include 
information on name, national identification number, address, citizenship, native 
language, family relations and date of birth and, if occurred, death. In addition to 
research, the information from the Population Information System is used for 
taxation, elections, and judicial administration, for example (Population Register 
Center ). 
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4.1.3 Social Insurance Institution of Finland Prescription Register 
The Social Insurance Institution (SII) is a government agency, providing social 
security for Finnish residents. Benefits provided by SII include reimbursement for 
the cost of prescribed medicines when purchased from the pharmacy. The 
Pharmaceuticals Pricing Board, operating under the Ministry of Social Affairs and 
Health, controls which drugs can be reimbursed. Currently, there are three different 
reimbursement categories after the annual deductible of 50 euros (the deductible was 
introduced 1.1.2016. There was a deductible of 10 euros for each purchase until 
2005); basic rate of reimbursement is 40%, lower special rate of reimbursement is 
65% and higher special rate of reimbursement is 100%. The reimbursement category 
depends on the indication of medication use and thus, the same agent might have 
different reimbursement rate depending on the indication. Digoxin and other 
antiarrhythmic drugs have the lower special rate of reimbursement.  
To be justified in special rate of reimbursement, patient must apply for 
entitlement to higher than regular reimbursement which requires a medical certificate 
issued by a doctor on form B. In addition, drug producers are not obligated to apply 
for reimbursement status and therefore all purchases of antiarrhythmic drugs are not 
included in our study material. For example, digoxin was removed from the 
reimbursement system at the beginning of 2013 but afterwards it was returned to the 
system. 
The reimbursement system provides an opportunity to maintain a comprehensive 
prescription database, which includes information on reimbursed drug and its 
Anatomical Therapeutic Chemical code, date for each reimbursed purchase, number 
of packages acquired and the number and strength of pills (Klaukka 2009). All 
Nordic prescription databases are in active research use and provide accurate 
information for pharmacoepidemiologic studies (Wettermark et al. 2013). 
4.1.4 Finnish Randomized Study of Screening for Prostate Cancer 
The FinRSPC started over 20 years ago and still provides useful data for researchers. 
The overall study population was 80,458 (but 312 were excluded because of death, 
prevalent prostate cancer or emigration) Finnish men, aged 55-67 years at entry. The 
men were identified from the Population Register Center and each year in 1996-1999 
8,000 men were randomized to the screening arm and the remaining roughly 12,000 
men formed the control arm. All men in the trial were followed up for cancer 
incidence through the national Finnish Cancer Registry. Men in the screening arm 
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were invited to PSA determination with a four-year interval (1996-1999, 2000-2003 
and 2004-2007), except for men aged 67 years at the first screening, who were invited 
only to two screening rounds. If the PSA concentration was ≥ 4.0 ug/l (or 3.0-3.99 
ug/l if free to total PSA ratio was ≤ 16%), men were referred to a local urology clinic 
for DRE, TRUS and biopsy. During the first three years of the study, DRE was used 
instead of free to total PSA ratio since it was not on clinical use. (Kilpelainen et al. 
2013). Detected cancers were treated according to existing guidelines, similarly to 
cancers in the control arm. 
A total of 2,702 men were excluded from the screening arm due to prostate 
cancer diagnosis before randomization or during the first year after the last screening 
round, emigration or death. A total of 4,847 men participated once, 6,958 men 
participated twice and 9,886 men participated three times to the screening, and there 
were 7,607 (26.0%) nonparticipants in the screening arm (Pakarainen et al. 2016). A 
total number of 2,416 (10.2%) prostate cancers were diagnosed from men attending 
screening (23,771 men) whereas 467 (5.8%) and 3,337 (6.9%) prostate cancers were 
diagnosed among never-participants of the screening arm (8,095 men) and in the 
control arm (48,278 men), respectively, during the median follow-up of 12 years 
(Time from the first of January in the year of randomization ending at death, 
emigration, or at the common closing date, December 31st, 2010). A total of 149 
(0.5%) men in the control arm and 266 (0.6%) men in the screening arm died due to 
prostate cancer (Kilpelainen et al. 2013). 
4.1.5 Statistics Finland 
Statistics Finland is the national statistical institution. It collects and maintains data 
on different aspects of the society. For example, Statistics Finland produces annual 
statistics on causes of death. The statistics are based on information from the 
compulsory death certificates, which are coded and complemented with data on 
deaths from the Population Register. The 10th revision of the International 
Classification of Diseases (ICD-10) has been used since 1996. 
Information on cause of death from Statistics Finland has been found to be 
reliable (Lahti and Penttila 2001; Lahti and Penttila 2003). A cause-of-death 
committee evaluated all deaths among FinRSPC participants with prostate cancer 
between 1996-2003. The decision by the committee based on patient files was 
compared with the official causes of death from Statistics Finland and concordance 
was high (97.7%, kappa  = 0.95) (Mäkinen et al. 2008). Similar results were observed 
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in a more recent study; concordance was high with the registry both in the screening 
arm and in the control arm (94.6%, kappa = 0.88 and 95.4%, kappa = 0.91, 
respectively) (Kilpelainen et al. 2016). 
4.1.6 Care Register for Health Care 
The Care Register for Health Care is a register maintained by the National Institute 
for Health and Welfare. It contains information from 1969 to the present. At first, 
the register contained information only on inpatient care. In 1998, the register started 
to collect data on outpatient care from specialized health care and the gathering was 
expanded to primary health care at the beginning of 2011. The subject of the register 
is to accumulate information on the actions of healthcare departments for research 
and statistic. The Care Register collects data on all service periods both at public and 
private hospitals, the statistical unit being a visit. In addition, the register involves 
information on patients discharged from inpatient care, number of patients in 
inpatient care at the end of the year, day surgeries and outpatient care in all public 
and private hospitals. The basic data include information on patients’ national 
identification number, place of residence, date, type and route of admission, 
diagnoses, external cause, type of accident and date of discharge, for example. 
4.2 Study settings 
Study details are presented in Table 9. 
4.2.1 Case-control study (I) 
Every Finnish man with prostate cancer diagnosed for the first time in 1995-2002 
was identified from the Finnish Cancer Registry, altogether 25,029 prostate cancer 
cases. A total number of 24,723 matched controls without prostate cancer were 
individually selected from the Population Register Center using incidence density 
sampling, which means that the selection of controls is determined by the diagnoses 
of cases. When a case is diagnosed, a control is selected from other members of 
the cohort having not the diagnosis but being at risk to have it (Greenland and 
Thomas 1982). The matching was based on the same age (±1 year) and area of 
residence at the time of the diagnosis. However, no matched control in the same 
 64 
 
residence area was found for 121 cases in the oldest age group and hence, they were 
excluded from the analyses. A total of 963 men in the control group developed 
prostate cancer during the study period. Therefore, they were included in the analysis 
twice; first as a control and afterwards as a prostate cancer case. A total of 24,657 
case-control pairs were included in the final analyses. 
Information on the primary site of cancer, date, method of diagnosis and tumor 
histology were obtained from the Cancer Registry. Diagnosis was based on histology 
from the primary tumor in 99.3% of cases. Other methods of diagnosis were clinical 
diagnosis (0.4%), radiological finding (0.3%) and specific laboratory finding (0.02%). 
Information on diagnosis method was missing from 185 prostate cancer cases and 
they were excluded from the analyses. Stage (local, locally advanced, advanced) of 
prostate cancer was available for 13,616 patients (55% of cases) and 73% of these 
were localized. There was no information on PSA concentration or Gleason score 
in the Cancer Registry. 
We used the Finnish Prescription Register of SII to gather information on 
medication use. Prescribed antiarrhythmic agent purchases between 1995 and 2002 
were obtained from the database. We were able to link the data from the prescription 
database to study participants via unique national identification number issued for 
all Finnish residents. Antiarrhythmic drugs included were quinidine, disopyramide, 
mexiletine, tocainide, propafenone and flecainide (Na+‐channel inhibitors), 
amiodarone and sotalol (K+‐channel inhibitors), pindolol, propranolol, timolol, 
carvedilol, labetalol, oxprenolol, alprenolol and sotalol (non‐selective BBs), 
acebutolol, atenolol, betaxolol, bisoprolol, metoprolol and celiprolol (β1‐selective 
BBs). BBs were also categorized as hydrophilic (sotalol, atenolol and celiprolol) and 
hydrophobic (rest of analyzed BBs) agents. In addition, digoxin and etilefrine were 
included. Use of other medication (NSAID, aspirin, antidiabetic medication, statin, 
antihypertensive, 5-ARI and alpha-blocker) was gathered to evaluate possible effect 
of comorbidities. 
4.2.2 Cohort studies (II-IV) 
Men in the FinRSPC screening trial formed the study population in our cohort 
studies. In studies II and IV, all men who we were able to link with SII prescription 
database (78,615 men) were used. Of them, 30,194 belonged to the screening arm 
and 48,421 to the control arm. Each man was followed until the date of prostate 
cancer diagnosis, emigration, death or common closing date in the study II and until 
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the date of death, emigration or common closing date in the study IV. In the prostate 
cancer survival study (III), the study population consisted of 6,537 prostate cancer 
cases diagnosed in 1996-2009 (3,668 from the screening arm and 2,869 from the 
control arm). Each man was followed until the date of death, emigration or common 
closing date in the study III. 
There were 6,639 prostate cancer diagnoses before 2010. Of them, 2,584 (42.5%) 
were detected through screening and 1,938 (31.9%) between the screening rounds. 
A total of 327 (5.4%) of the cases were among men invited to screening but not 
participating.  The detection method was known for 6,527 cases (98.3%). Majority 
of the cases was histologically confirmed (97.9%). Other diagnostic methods were 
clinical diagnosis (0.3%), autopsy (1.6%), radiological finding (0.1%) and cytological 
finding (0.1%). 
Information on the Gleason grade at diagnosis, TNM stage, primary treatment, 
the date and method of diagnosis and the serum PSA concentration was included in 
the FinRSPC study. We used the criteria of the European Association of Urology to 
categorized prostate cancer cases to low/medium risk or high risk. Medication 
besides antiarrhythmic agents was used to evaluate comorbidities. We had data on 
NSAID, aspirin, antidiabetic medication, statin, antihypertensive, 5-ARI and alpha-
blocker use. In addition, data on socioeconomic and demographic factors such as 
marriage and level of education was gathered from the Statistics Finland. 
Furthermore, information on the tumor characteristics (such as the Gleason grade 
and TNM stage) was collected individually from hospitals’ patient records for the 
control arm.  
We obtained causes of death in the study population during 1996–2015 from the 
Statistics Finland. In the survival study (III), cases were recorded as a prostate cancer 
death if prostate cancer (ICD-10 code C61) was recorded as the primary cause of 
death. Deaths with ICD-10 code C61 as the intermediate or contributory cause of 
death were analyzed separately for PCa-related mortality. In the mortality study (IV), 
cases with prostate (C61), lung (C34), colorectal (C18), pancreatic (C25), gastric 
(C16), liver (C22), renal (C64), non-Hodgkin lymphoma (C81), bladder (C67) or 
central nervous system cancer (C71 and C72) recorded as the primary cause of death 
were considered as cancer deaths. Overall cancer mortality included deaths with any 
C-code in ICD-10 (C00-C99) as the primary cause of death.  
We collected information on diagnoses recorded for in- and outpatient hospital 
contacts during 1996–2012 from the Care Register for Health Care. The data was 
used to calculate a modified CCI for the study population (Quan et al. 2011). 
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Furthermore, we gathered information on antiarrhythmic drug use indications: heart 
failure (ICD-10 code I50) and cardiac arrhythmias (I47 and I49). 
Data on medication use was gathered from the prescription database of the SII. 
All antiarrhythmic agents purchased during 1995–2015 were obtained and linked to 
the study population by the national identification number. Agents categorized as 
antiarrhythmic drugs included amiodarone, digoxin, disopyramide, etilefrine, 
flecainide, quinidine, mexiletine, procainamide, propafenone and sotalol.  
4.3 Statistical methods 
4.3.1 Case-control study (I) 
We collected information on medication use of prostate cancer cases from the 
beginning of 1995 to prostate cancer diagnosis. Similarly, medication use was 
followed from 1995 to the date of diagnosis of the matched case among the controls. 
To equalize the dose information of antiarrhythmic medication use between 
different drug groups, we divided the purchased milligram amount of a drug by its 
DDD set by the World Health Organization (WHO) (WHO Collaborating Centre 
for Drug Statistics Methodology ). DDDs contained in each purchase for a drug 
were summed up to obtain a total sum of DDDs of every antiarrhythmic agent used 
by each study participant. 
Conditional logistic regression models were used to estimate OR and 95% 
confidence intervals (CI) for ORs. Overall prostate cancer rate and advanced 
prostate cancer rate related to antiarrhythmic medication were calculated. We 
performed both age-adjusted analyses (age at diagnosis, treated as a continuous 
variable) and analyses further adjusted for use of other medications. Non-users of 
antiarrhythmic drugs were the reference group in all analyses. Initially, we also 
included place of residence in the regression model. However, it was not statistically 
non-significant predictor of prostate cancer risk due to matching of case-control 
pairs and was therefore left out of the study analyses.  
In addition to evaluation of association between ever-use of antiarrhythmic 
medication and prostate cancer risk, we performed analyses stratified by quartiles of 
the amount, duration and intensity of medication use. Annual amount of medication 
use was estimated by calculating the cumulative milligram amount from every 
purchase during each year separately for all antiarrhythmic agents. The cumulative 
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amount was standardized by dividing the milligram amount of each drug with the 
drug-specific standard DDD. Duration of antiarrhythmic drug use was calculated by 
adding together the number of years with medication purchases. Finally, the average 
intensity of use (DDDs/year) was calculated by dividing the annual DDD amount 
with the duration of usage. Men discontinuing use before the end of follow-up 
retained the level reached and continued from that level if purchases reoccurred. 
 Trends in association between prostate cancer risk and antiarrhythmic drug use 
were analyzed by adding cumulative number of DDDs or years of drug use into the 
logistic regression model as a continuous variable. We analyzed all antiarrhythmic 
drugs separately and in broader groups (all antiarrhythmic drugs, Na+‐channel 
inhibitors, K+‐channel inhibitors, β1‐selective and non-selective BBs). 
Several sensitivity analyses were performed. We included 5alpha‐reductase 
inhibitor and alpha-blocker users only in the analysis to estimate the effect of 
previous PSA‐testing. Furthermore, we gathered data on use of other drug groups 
during the follow-up from the prescription database of the SII to evaluate possible 
effect modification. The analysis was stratified by use of cholesterol-lowering 
medication, NSAIDs, antidiabetic drugs and antihypertensive drugs. Statistical 
significance of interaction between digoxin and each drug mentioned above was 
evaluated by including an interaction term (e.g. antiarrhythmic drug use*statin use) 
in the logistic regression model and p-values less than 0.05 were considered 
statistically significant. 
The data were analyzed using Stata 8.2 software (College Station, Texas). 
4.3.2 Cohort studies (II-IV) 
We considered antiarrhythmic drug use as a time-dependent variable. Medication use 
status was updated annually throughout the follow-up based on medication 
purchases obtained from the prescription database. All participants were categorized 
as non-users until the first medication purchase and after the first purchase, the 
exposure status changed to user. If a user had no antiarrhythmic drug purchases 
during a calendar year, the status was updated into previous user. However, it was 
possible to change the status back to a user if a further drug purchase occurred at a 
later point of the follow-up. We used non-users as the reference group in studies II 
and IV, except in the study III, where users of other antiarrhythmic drugs other than 
digoxin and sotalol were the reference group. 
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The survival study (III) differed from the other two analyses. Use of 
antiarrhythmic medication before prostate cancer diagnosis was analyzed as a time-
independent variable fixed at baseline. Men with antiarrhythmic drug use within the 
year preceding the diagnosis were classified as active users. If a man used 
antiarrhythmic medication before but not during the calendar year of diagnosis, he 
was classified as a previous user. In addition, we combined active users and previous 
users into any use category. Use of antiarrhythmic drugs after the prostate cancer 
diagnosis was analyzed as a time-dependent variable with the principles mentioned 
above. 
Cox regression method was used in all studies. Various model adjustments were 
used. All studies included age-adjusted analyses (age as a continuous variable). In 
addition, the multivariable model in the study estimating prostate cancer risk (II) 
included adjustments for age, screening trial arm and use of NSAIDs, aspirin, 
antidiabetic medication, cholesterol-lowering medication, antihypertensives, 5alpha-
reductase inhibitors and alpha-blockers. Information on use of other medication 
during the follow-up was gathered from the prescription database of the SII. In the 
survival study (III), we used a regression model adjusted for age and EAU tumor 
risk group and a multivariable-adjusted model similar to the model mentioned above. 
The study on overall cancer mortality included analyses with adjustment for baseline 
cancer diagnosis, trial arm (when prostate cancers were considered) and use of other 
drug groups. 
Amount, duration and intensity of medication use were calculated similarly as 
described in the chapter 4.3.1. Trends in prostate cancer risk, prostate cancer survival 
and cancer mortality by amount, duration and intensity of used medication were 
estimated by generating a new exposure variable in which the cohort was stratified 
by the median (in the study III) or tertiles (in the studies II and IV) of the cumulative 
amount, duration and intensity. 
In the incidence study (II), we analyzed prostate cancer risk overall and by 
Gleason grade and cancer stage. Subgroup analyses were conducted by stratifying 
the population by age, antiarrhythmic medication use before randomization and by 
use of other drug groups. Effect modification on prostate cancer risk among 
antiarrhythmic drug users was evaluated by adding an interaction term with 
medication use into the Cox regression model. 
In the study on prostate cancer survival (III), we evaluated risk of prostate cancer 
death among men using digoxin or sotalol compared to the users of other 
antiarrhythmic drugs. Analyses were conducted separately for pre- and post-
diagnostic antiarrhythmic drug use. We stratified the study population according to 
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age, tumor characteristics, screening trial arm, use of other drug groups and primary 
treatment and performed subgroup analyses to evaluate effect modification. In the 
subgroup analyses, non-users were the reference group. In the sensitivity analyses, 
we estimated delayed effects of drug use by conducting a lag time analysis by relating 
the drug use to outcomes occurring 1-3 years later. Furthermore, a competing risk 
analysis with deaths from other causes than cancer as the competing events was 
performed using the method described by Fine and Gray (Fine and Gray 1999). 
In the overall cancer mortality study (IV), we estimated the association of 
antiarrhythmic drug use with both risk of cancer death overall and deaths due to 
specific types of cancer. Mortality was evaluated among users of any antiarrhythmic 
drugs and separately among digoxin and sotalol users. In subgroup analyses, effect 
modification by age, baseline cancer, use of other drug groups and socioeconomic 
factors was estimated by stratifying men according to the variables mentioned above. 
In addition, we conducted similar exposure lagging and competing risk regression 
analyses with non-cancer deaths as the competing risk as in the prostate cancer 
survival study (III). 
All statistical tests are two-sided. No adjustment for multiple testing was 
employed. P values 0.05 or less were considered statistically significant. IBM SPSS 
Statistics 22 (Chicago, IL, USA) software was used in the studies II and III and IBM 
SPSS Statistics 23 (Chicago, IL, USA) in the study IV for data analyses.
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4.4 Ethical considerations 
Ethical considerations in prostate cancer screening are related to PSA testing and its 
poor sensitivity and specificity. Even though prostate cancer screening might 
improve survival, a great number of men need to be screened and prostate cancers 
to be detected to avoid one prostate cancer death. Prostate biopsy might cause 
adverse effects and side effects can be related to prostate cancer treatment methods. 
It is possible that harmless asymptomatic prostate cancer is diagnosed by PSA 
screening and the patient suffers a permanent adverse effect from the cancer 
treatment. 
The ethics committee of the Pirkanmaa health care district reviewed the protocol 
of the case-control study (tracking number ETL R03290). According to the Finnish 
regulations, it was not necessary to obtain informed consent from the study 
population, as the analysis was based on data routinely gathered to national registries 
and on already gathered FinRSPC data, and as part of the study cohort was deceased 
or emigrated. 
The ethical committees of Helsinki University Hospital and Tampere University 
Hospital had evaluated the FinRSPC trial protocol (tracking number R10167). 
Informed consent was received from the participants in the screening arm. Men in 
the control arm were not contacted and were followed via national registries. 
Privacy and data protection; all personal identifiers were deleted from the data 
used in the analyses and results reported in such form that no individuals can be 
identified, as all health-related information is regarded as sensitive and confidential. 
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5 RESULTS 
5.1 Antiarrhythmic drug use and risk of prostate cancer 
5.1.1 Case-control study (I) 
The number of antiarrhythmic drug users was similar among cases and control; 3,408 
men (13.8%) among the cases and 3,316 men (13.4%) among the controls. 
Prevalence of use for NSAIDs (53.8% vs 46.5%), cholesterol-lowering medication 
(10.6% vs 9.9%), antihypertensives (51.6% vs 47.6%) and BPH medication (18.7% 
vs 12.5%), was higher among the cases than controls. However, there were fewer 
antidiabetic medication users (9.0% vs 9.7%). 
Compared to non-users, overall antiarrhythmic drug use was associated neither 
with the overall prostate cancer risk (OR 0.96, 95% CI 0.91-1.01) nor advanced 
prostate cancer risk (OR 0.90, 95% CI 0.77-1.04) (Table 10). There were no 
significant association between prostate cancer risk and antiarrhythmic drug use 
within any quartile of cumulative amount and duration of drug use. However, some 
suggestion of a decreasing trend in overall prostate cancer risk by duration of usage 
was observed (p for trend = 0.058). 
There was no association between digoxin use and overall prostate cancer risk 
(OR 0.96, 95% CI 0.90-1.02). Similarly, risk of advanced prostate cancer risk did not 
differ by digoxin use (OR 0.89, 95% CI 0.76-1.05) (Table 10). Digoxin use was not 
associated with prostate cancer risk in analysis stratified by quartiles of digoxin usage. 
There was no statistically significant trend in prostate cancer risk by cumulative 
duration of digoxin use. 
Neither use of Na+-channel blockers nor K+-channel blockers as a group was 
associated with prostate cancer risk (OR 0.98, 95% CI 0.84-1.13 and OR 0.94, 95% 
CI 0.85-1.03, respectively). A similar observation was made for advanced prostate 
cancer risk (Table 10). There was no association between use of any individual Na+-
channel blocker and prostate cancer risk. However, sotalol users had a statistically 
significant risk decrease for advanced prostate cancer compared to non-users (OR 
0.73, 95% CI 0.56-0.96) (Table 10). Even though the overall prostate cancer risk did 
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not differ from non-users (OR 0.94, 95% CI 0.85-1.04), it was diminished among 
long-term (5 years or longer) sotalol users (OR 0.68, 95% CI 0.55-0.85). There was 
a significant decreasing trend in overall prostate cancer risk by duration of sotalol 
use (p for trend = 0.038). 
Neither β1-selective nor non-selective BBs associated with prostate cancer risk. 
(OR 1.00, 95% CI 0.96-1.05 and OR 0.99, 95% CI 0.93-1.06, respectively). However, 
there was an association between hydrophilic BBs and advanced prostate cancer (OR 
0.80, 95% CI 0.68-0.96). After exclusion of sotalol, the association between 
hydrophilic BBs and the risk of advanced prostate cancer disappeared (OR 0.95, 95% 
CI 0.78-1.16) (Table 10). 
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5.1.2 Cohort study (II) 
There were 8,064 (10.3%) antiarrhythmic drug users, 5,668 (7.2%) digoxin users and 
2,540 (3.2%) sotalol users. Baseline PSA levels did not differ by antiarrhythmic drug 
use. A total of 6,639 prostate cancer cases were diagnosed during the median follow-
up of 12 years. Prevalence of use for NSAIDs (82.0% vs 78.9%), aspirin (18.4% vs 
15.4%), 5-ARIs (14.2% vs 12.1%), alpha-blockers (31.8% vs 26.6%), 
antihypertensive drugs (96.1% vs 64.0%), antidiabetic drugs (30.3% vs 19.1%) and 
cholesterol-lowering medication (53.7% vs 40.4%) was higher among the 
antiarrhythmic drug users compared to the non-users. 
Compared to non-users, antiarrhythmic drug users had a slightly elevated overall 
prostate cancer risk in the age-adjusted analysis (HR 1.13, 95% CI 1.01-1.27). 
However, the association was reduced in the multivariable-adjusted analysis (HR 
1.05, 95% CI 0.94-1.18) (Table 11). The risks of high-grade and metastatic prostate 
cancer were analyzed separately, and no significant risk difference was observed (HR 
0.90, 95% CI 0.74-1.08 and HR 1.21, 95% CI 0.80-1.83, respectively). There were 
no significant trends in prostate cancer risk by cumulative amount, duration or 
intensity of antiarrhythmic drug use. 
Ever use of digoxin was not associated with prostate cancer risk (HR 1.01, 95% 
CI 0.87-1.16). A similar observation was made for high-grade cancer and metastatic 
disease (Table 11). No statistically significant trends in prostate cancer were observed 
by amount, duration or intensity of digoxin use, even though risk estimates for high-
grade and advanced disease tended to decrease with increasing amount and duration. 
Among men using digoxin for ≥6 years, the HR of high-grade prostate cancer was 
0.71 (95% CI 0.49-1.03). In the subgroup analysis, men in the screening arm had a 
decreased risk for high-grade prostate cancer if they had used digoxin for longer than 
5 years (HR 0.31, 95% CI 0.12-0.84). 
There was no association between sotalol use and prostate cancer (HR 0.97, 95% 
CI 0.76-1.24). Sotalol had no influence on risk of high-grade or advanced prostate 
cancer, either (Table 11). Prostate cancer risk did not differ by amount, duration or 
intensity of sotalol use. 
The association between antiarrhythmic drugs and prostate cancer risk was 
modified by age at randomization. A non-significantly lowered risk estimate by 
antiarrhythmic drug use was observed among men aged 55-59 years at baseline (HR 
0.84, 95% CI 0.68-1.04), while no risk difference was observed among men aged 63-
67 (HR 1.09, 95% CI 0.95-1.25) (p for interaction = 0.001). Sotalol use was 
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associated with a decreased overall prostate cancer risk among men aged 55-59 years 
at entry (HR 0.54, 95% CI 0.30-0.97 and p for interaction = 0.006). There was no 
effect modification by use of other medications.
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5.2 Antiarrhythmic drug use and prostate cancer survival (III) 
Among 6,537 prostate cancer cases, 730 men (11.2%) had used antiarrhythmic drugs, 
485 (7.4%) digoxin and 241 (3.7%) sotalol after the randomization. In total 1,861 
men died during the median follow-up of 7.5 years after PCa diagnosis. There were 
617 deaths (9.4%) with prostate cancer as the underlying cause of death. Prevalence 
of use for aspirin (15.8% vs 13.3%), 5-ARIs (14.2% vs 13.8%), alpha-blockers 
(49.7% vs 46.0%), antihypertensive drugs (97.8% vs 69.5%), antidiabetic drugs 
(27.7% vs 18.5%) and cholesterol-lowering medication (57.3% vs 45.5%) was higher 
among the antiarrhythmic drug users compared to the non-users. 
Pre-diagnostic digoxin use had no effect on prostate cancer survival compared to 
users of other antiarrhythmic drugs (HR 1.00, 95% CI 0.56-1.80 and HR 1.21, 95% 
CI 0.71-2.05 for current use and any use, respectively) (Table 12). Stratifying the 
analysis over the median of cumulative amount, duration or intensity of pre-
diagnostic digoxin use increased HR of prostate cancer death compared to users of 
other antiarrhythmic drugs but the associations were statistically non-significant (HR 
1.56, 95% CI 0.84-2.91, HR 1.54, 95% CI 0.77-3.05 and HR 1.32, 95% CI 0.71-2.47, 
respectively). 
There was no obvious association between post-diagnostic digoxin use and 
prostate cancer survival (HR 0.81, 95% CI 0.43-1.51 and HR 1.00, 95% CI 0.59-1.71 
for current use and any use, respectively) (Table 12). The risk of prostate cancer 
death was decreased statistically non-significantly if the cumulative amount (HR 
0.59, 95% CI 0.24-1.43) or duration (HR 0.31, 95% CI 0.08-1.17) of post-diagnostic 
digoxin use was above the median. 
Pre-diagnostic sotalol use was not associated with prostate cancer survival (HR 
0.82, 95% CI 0.34-1.97) (Table 12). Similarly, post-diagnostic use of sotalol was not 
associated with the risk of prostate cancer death (HR 0.80, 95% CI 0.25-2.26), but 
men who had discontinued sotalol use had an increased risk of prostate cancer death 
(HR 2.73, 95% CI 1.28-5.84) compared to the users of other antiarrhythmic drugs. 
Risk estimates tended to decrease with cumulative sotalol amount and duration of 
use, but the CIs remained wide. 
Compared to non-users, overall antiarrhythmic drug use before prostate cancer 
diagnosis did not associate with prostate cancer survival (HR 1.16, 95% CI 0.82-
1.65). An analogous observation was made for men with any antiarrhythmic drug 
use after the diagnosis (HR 0.94, 95% CI 0.61-1.44). Furthermore, we compared 
 84 
 
digoxin users to non-users of antiarrhythmic drugs. There was no association 
between digoxin use before (HR 1.22, 95% CI 0.87-1.72) or after (HR 1.09, 95% CI 
0.72-1.65) the diagnosis and prostate cancer survival. Digoxin users had an increased 
all-cause mortality (HR 1.43, 95% CI 1.08-1.88 and HR 1.46, 95% CI 1.11-1.92, for 
pre- and post-diagnostic use, respectively).
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5.3 Antiarrhythmic drug use and cancer mortality (IV) 
In the study cohort of 78,615 men, there were 9,023 (11.5%) antiarrhythmic drug 
users, 6,329 (8.1%) digoxin users and 2,304 (2.9%) sotalol users. A total of 28,936 
men died, 8,889 (%) of them from cancer during the median follow-up of 17.0 years. 
The most frequent cancers were lung cancer (2,384 deaths), colorectal cancer (861 
deaths) and pancreatic cancer (782 deaths). Prevalence for use of NSAIDs (82.5% 
vs 78.8%), aspirin (18.3% vs 15.4%), alpha-blockers (32.2% vs 26.5%), 
antihypertensive drugs (93.7% vs 63.9%), antidiabetic drugs (28.5% vs 19.1%) and 
cholesterol-lowering medication (53.6% vs 40.3%) was higher and the CCI was 
higher (CCI 2 or greater 41.1% vs 23.1%) among antiarrhythmic drug users 
compared to non-users. 
Ever-users of antiarrhythmic drug had an increased risk of cancer death 
compared to the non-users (HR 1.43, 95% CI 1.34-1.53). A comparable observation 
was made for users of digoxin and sotalol (HR 1.59, 95% CI 1.47-1.72 and HR 1.16, 
95% CI 1.03-1.31, respectively) (Table 13). The risk of death decreased with 
increasing amount, duration and intensity of any antiarrhythmic drug use and the 
risk association disappeared among men with largest cumulative amount and 
duration of medication use. A comparable observation was made for digoxin use. In 
addition, risk estimates attenuated in the lag-time analysis (Table 13). 
Overall antiarrhythmic drug use and digoxin use were both associated with 
increased risk of lung cancer death compared to the non-users (HR 1.72, 95% CI 
1.52-1.95 and HR 2.10, 95% CI 1.82-2.41, respectively). However, there was no 
association between sotalol use and lung cancer mortality (HR 1.10, 95% CI 0.85-
1.41) (Table 13). Analogous trends in risk difference by amount, duration and 
intensity as with overall cancer mortality were observed. 
Both users of antiarrhythmic drugs in general and users of digoxin had an 
increased colorectal cancer mortality compared to non-users (HR 1.38, 95% CI 1.11-
1.73 and HR 1.59, 95% CI 1.24-2.05, respectively). Sotalol use was not associated 
with the risk for colorectal cancer death (HR 0.70, 95% CI 0.42-1.17) (Table 13). 
Antiarrhythmic drug use had no effect on pancreatic cancer mortality (HR 1.02, 
95% CI 0.79-1.31). Neither use of digoxin nor sotalol associated with the risk of 
pancreatic cancer death (HR 1.06, 95% CI 0.79-1.43 and HR 0.99, 95 % CI 0.63-
1.54, respectively) (Table 13). 
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Use of antihypertensives and use of antidiabetic medication modified the 
association between antiarrhythmic drugs and cancer mortality. Among non-users 
of antihypertensives, men with overall antiarrhythmic drug use or with digoxin use 
had more substantial increase in the risk of cancer death than among men using 
antihypertensives (p for interaction 0.01 and 0.002, respectively). A similar 
phenomenon was also seen for antidiabetic medication usage (p for interaction 0.01). 
CCI was used to stratify the study population by comorbidities. Among men 
without major comorbidities, antiarrhythmic drug users had an increased cancer 
mortality (CCI 0: HR 1.37, 95% CI 1.19-1.56). Similarly, antiarrhythmic drug use was 
associated with non-significant increase in cancer mortality among men with 
intermediate comorbidities (CCI 1: HR 1.22, 95% CI 0.87-1.71), but the result was 
statistically non-significant. However, there was no association between 
antiarrhythmic drug use and the risk of cancer death among men with most 
comorbidities (CCI 2 or greater: 0.98, 95% CI 0.91-1.06). CCI was a statistically 
significant effect modifier (p for interaction < 0.001). 
Antiarrhythmic drug use was not associated with cancer mortality in competing 
risk analyses (HR 1.04, 95% CI 0.97–1.12). Similar results were obtained for use of 
digoxin and sotalol (HR 1.01, 95% CI 0.93–1.10 and HR 1.03, 95% CI 0.91–1.17, 
respectively). 
The risk association between the indications for antiarrhythmic drug use and 
cancer mortality were used to evaluate possible confounding by indication. In the 
Care Register for Health Care database, 4,199 men had a diagnosis of cardiac 
insufficiency and 1,507 men had a diagnosis of arrhythmia. Men with a diagnosis of 
cardiac insufficiency had increased cancer mortality compared to the men without 
the diagnosis (HR 1.19, 95% CI 1.08-1.31). The risk increase was comparable to the 
result in our main analysis. However, having a recorded diagnosis of arrhythmia was 
associated with a lowered risk of cancer death (HR 0.76, 95% CI 0.64-0.90).
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6 DISCUSSION 
6.1 Antiarrhythmic drugs and risk of prostate cancer 
In the case-control study, antiarrhythmic medication use did not have an influence 
on prostate cancer risk at population level. Nevertheless, sotalol use was associated 
with a decreased risk of advanced prostate cancer. Furthermore, men with five or 
more years with sotalol use had a lower overall prostate cancer risk compared to 
non-users. 
In the cohort study, there was no association between prostate cancer risk and 
use of antiarrhythmic medication, digoxin or sotalol, but there was a decreasing trend 
for Gleason 7-10 cancer risk with increasing duration of digoxin use. However, users 
of any antiarrhythmic drug had a comparable decreasing trend in high-grade cancer 
risk by duration of use, and digoxin did not have the protective association with 
high-grade prostate cancer risk when compared to other antiarrhythmic drug users. 
Therefore, our observation might be due to systematic differences between users 
and non-users of antiarrhythmic drugs rather than due to pharmacological properties 
of digoxin. Nonetheless, we observed a borderline non-significant risk reduction 
among digoxin users in the screening arm. The risk reduction was statistically 
significant for Gleason 7-10 cancers among long-term users of digoxin in the 
screening arm. However, screening of prostate cancer did not modify risk association 
between digoxin use and Gleason 7-10 cancer statistically significantly (p for 
interaction = 0.33). 
Our results are partly coherent with previously published studies. In The Health 
Professionals Follow-up study of 47,884 men, digoxin users had a decreased risk of 
overall prostate cancer (RR 0.78, 95% CI 0.67-0.90) compared to the non-users. The 
association was strongest for men with 10 or more years of digoxin use (RR 0.54, 
95% CI 0.37-0.79) (Platz et al. 2011). Since PSA testing is rather common in the US, 
the study population of the Health Professionals Follow-up study was probably in 
regular PSA surveillance. In the Europe, PSA testing has been more infrequent 
compared to the US, but men in the screening study were under regular PSA testing 
making the screening arm more comparable to the US population. Thus, there is no 
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inconsistency between our results and those from The Health Professionals Follow-
up study. 
A previous case-control study with 1,943 men observed decreased risk of prostate 
cancer among digoxin users but association was statistically non-significant 
association (OR 0.58, 95% CI 0.30-1.10). Contrary to our studies, long-term users 
had a more prominent increase in the risk estimates than short-term users. However, 
digoxin users with 3 or more PSA-tests during the past five years had a decreased 
prostate cancer risk (OR 0.44, 95% CI 0.20-0.98) (Wright et al. 2014). This finding 
is coherent with our result of digoxin users under regular PSA-surveillance having 
lower prostate cancer risk than men in the control arm. 
In conclusion, PSA surveillance is a modifying factor for digoxin users’ prostate 
cancer risk and the results suggest that digoxin users attending regular PSA-
surveillance have a slightly lowered prostate cancer risk compared to the non-users. 
It has been suggested that digoxin might decrease PSA-concentration which could 
explain the observed finding (Lin et al. 2014). Especially long-term use of digoxin 
might be beneficial as antineoplastic effects likely require long-term exposure to 
occur. A protective association between sotalol use and prostate cancer risk was 
observed in the case-control but not in the cohort study. 
6.2 Antiarrhythmic drugs and prostate cancer survival 
In the prostate cancer survival study, prostate cancer survival among digoxin or 
sotalol users did not differ from men using other antiarrhythmic drugs. The results 
were similar for both pre- and postdiagnostic use. Stratifying analyses by cumulative 
amount, duration or intensity of medication use did not change the results although 
long-term users of digoxin had lower risk estimates than short-term users. The trial 
arm (screening vs control), tumor characteristics, screening, use of other drug groups 
and primary treatment did not modify the results. 
Our study is in concordance with two previous studies on digoxin use and 
prostate cancer survival. Flavahan et al. followed 5,732 prostate cancer cases for a 
median follow-up of 4.3 years. The full study cohort had 391 men with digoxin 
exposure before the prostate cancer diagnosis. Propensity score matched sensitivity 
analysis with 387 digoxin-exposed and 387 non-exposed men was performed. In the 
full cohort, digoxin users had an increased all-cause mortality (HR 1.24, 95% CI 1.07-
1.43), but there was no statistically significant increase in prostate cancer-specific 
mortality (HR 1.13, 95% CI 0.91-1.42). The results were comparable in the 
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propensity score matched population (HR 1.20, 95% CI 1.00-1.49 for all-cause 
mortality and HR 1.17, 95% CI 0.88-1.57 for prostate cancer-specific mortality). The 
influence of the cumulative duration of digoxin use was not analyzed. (Flahavan et 
al. 2014). 
Karesneh et al. evaluated prostate cancer survival among 13,134 prostate cancer 
cases for the mean follow-up of 5.0 years. Of them, 701 (5.3%) had used digoxin 
after prostate cancer diagnosis. In the adjusted analysis (adjusted for year of 
diagnosis, age at diagnosis, cancer treatment within 6 months, comorbidities prior to 
diagnosis and other medication use), digoxin use was not associated with prostate 
cancer-specific survival (HR 1.13, 95% CI 0.93-1.37). However, digoxin users had 
increased all-cause mortality compared to the non-users (HR 1.39, 95% CI 1.23-
1.56). Stratifying the analysis by cumulative amount did not affect to the risk 
estimates and the influence of the duration of digoxin use was not evaluated 
(Karasneh et al. 2016). Analyses are comparable to our survival study; we had a 
parallel percentage of digoxin users within the cohort (7.4%) and the adjustments 
were coherent. 
Especially long-term use of digoxin has been reported to have anticancer effects, 
and since we were able to stratify the study population by duration of digoxin use, 
our study provides additional information to the prior studies. Furthermore, we 
evaluated the effect of both pre- and post-diagnostic digoxin use, contributing novel 
information on the effect of the timing of medication use. 
In conclusion, we did not observe statistically significant risk reductions among 
digoxin or sotalol users. Our results and previously published studies suggest that 
digoxin use does not improve prostate cancer survival. 
6.3 Antiarrhythmic drugs and cancer mortality 
In study IV, antiarrhythmic drug users had a statistically significantly increased 
overall cancer mortality and lung cancer mortality compared to non-users. 
Furthermore, digoxin use was associated with a statistically significantly increased 
risk of death from all cancers combined, lung cancer, colorectal cancer, bladder 
cancer and non-Hodgkin lymphoma. There was no statistically significant 
association between sotalol use and risk of cancer death in the age-adjusted analysis. 
However, in the multivariable analysis sotalol users had an increased cancer mortality 
similar to digoxin users indicating sotalol users had less risk factors for cancer death. 
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 The observed elevation in risk of cancer death among antiarrhythmic drug users 
is likely due to differences between users and non-users. We observed a similar risk 
association between indication of digoxin use (cardiac insufficiency) and cancer 
mortality. In addition, the association tended to decrease with increasing cumulative 
amount and duration of antiarrhythmic medication. An opposite trend would 
probably be observed if antiarrhythmic medication increased the risk directly. 
Therefore, the association between drug use and cancer mortality is unlikely to be 
due to pharmacological properties of antiarrhythmic medication, but more probably 
due to confounding by systematic background differences, such as smoking, alcohol 
consumption and high-fat diet, between antiarrhythmic drug users and non-users. 
Digoxin users have more co-morbidities, such as coronary artery disease, congestive 
heart failure and diabetes mellitus, than non-users, which might result in a non-causal 
risk association in our study. A subgroup analysis stratified by the CCI supports this. 
Among men with no major co-morbidity burden (CCI = 0), digoxin users had a 
statistically significant increase in cancer mortality. However, among men with more 
co-morbidities (CCI = 1 and CCI ≥ 2 or more), the risk association was no observed 
indicating that the association is modified by co-morbidities. Furthermore, the CCI 
was found to be an independent risk factor for cancer death and in the competing 
risk analysis, where non-cancer deaths were the competing risk, antiarrhythmic drug 
use was not associated with risk of cancer death. Antiarrhythmic drug use could not 
be considered as a time-dependent variable, and thus is possible that immortal time 
bias is not as robust controlled as in Cox regression analysis leading to disappearance 
of risk increase. 
Our results are coherent with previous studies on digoxin but there are no 
previous publications on other antiarrhythmic drug use and an overall cancer 
mortality. There are a few published studies on use of digoxin and cancer mortality 
in separate cancer types and a meta-analysis based on the studies. Digoxin use was 
associated with a statistically significantly increased all-cause mortality (HR 1.35, 95% 
CI 1.25-1.46), but cancer-specific mortality did not differ between digoxin users and 
non-users (HR 1.08, 95% CI 0.97-1.19) in the meta-analysis of six cohort studies 
(Osman et al. 2017). 
In conclusion, antiarrhythmic drug use did not decrease cancer mortality in our 
retrospective study. In contrast, antiarrhythmic drug users had an increased cancer 
mortality compared to non-users, but the risk association was probably non-causal, 
since it was found mainly in short-term use and vanished in long-term use. Possible 
antineoplastic effects of digoxin or any other antiarrhythmic drug did not translate 
to a diminished cancer mortality. 
 95 
 
6.4 Methodological considerations 
We used two study populations; the case-control study containing all prostate cancer 
cases diagnosed in Finland during 1995-2002 and the study population from the 
FinRSPC. Both study settings had different strengths and limitations allowing a 
thorough evaluation of the research question. 
Both studies were population-based with a solid representation of the entire 
Finland. The case-control study had a population of 49,314 men and cohort studies 
78,615 men and the prostate cancer survival analysis covered 6,537 prostate cancer 
cases from the FinRSPC population. The Finnish Cancer Registry is a robust source 
of information since the coverage of cancer diagnosed in Finland is comprehensive. 
Therefore, misclassification of outcome and related information bias are likely to be 
minimal. Large study populations enabled statistical power to analyze rather seldom 
used drugs. Nevertheless, CIs for especially subgroup analyses were wide in the 
survival study. One possible limitation is potential indolent prostate cancers 
diagnosed in men the FinRSPC screening arm. However, since there were both 
antiarrhythmic drug users and non-users in the screening arm, confounding is 
unlikely and furthermore, we were able to analyze separately high-grade cancer risk 
and prostate cancer-specific survival. 
Since we obtained information on drug purchases from the prescription database, 
surveys on medication exposure were not required and recall bias does not affect the 
results. Furthermore, data on cancer treatment and clinical characteristics was 
gathered from medical records allowing us to adjust analysis by cancer grade and 
stage or by given treatment. In the case-control study, the controls were individually 
matched to the cases for age and residential area at the time of diagnosis to avoid 
confounding by the above-mentioned variables. 
We updated medication usage status annually and use of antiarrhythmic drugs 
was treated as a time-dependent variable in order to avoid immortal time bias. Men 
were classified as non-users before the first antiarrhythmic purchase occurred. 
Failing to consider unexposed time period correctly in the regression analysis will 
result in immortal time bias. Immortal time refers to a time interval during the 
follow-up where it would be impossible for the outcome to occur. Immortal time 
bias often occurs if a time period prior to initiating an exposure of interest 
(antiarrhythmic drug use in this study) is not assessed properly. Since outcome 
cannot occur during the time span, it is inevitable that the subject remains free of 
outcome until the exposure has truly initiated if classified as exposed (Suissa 2008).  
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We used different sensitivity analyses to evaluate influence of biases and 
confounding and to evaluate possible causality. The total propensity score for use of 
antiarrhythmic medication was calculated and the analysis for prostate cancer risk 
was stratified by quartiles or median of the total propensity score in order to estimate 
the risk in subgroups homogenous in possible background confounding factors. The 
delayed effects of medication use were estimated by conducting a lag time analysis 
in which we related the drug use to outcomes occurring 1-5 years later.  
When the event of interest is cancer death, competing risks might modify the 
chance that the outcome happens. In order to evaluate the cumulative incidence 
function, which indicates the probability of outcome occurring before a given time, 
we performed competing risk regression analyses with non-cancer deaths as the 
competing risk using the method described by Fine and Gray (Fine and Gray 1999). 
We performed the competing risk regression, where non-cancer deaths were 
competing risk, since antiarrhythmic drug users might die due to vascular diseases 
which would bias down risk estimates for cancer mortality. Surprisingly, risk of 
cancer death was lower in the competing risk regression compared to the Cox 
regression suggesting that deaths due to non-cancer causes did not bias down the 
risk estimates. CCI was used to stratify the study population by comorbidities and to 
estimate risk of outcomes among men with different range of comorbid conditions. 
Confounding by indication means that observed association between an exposure 
(antiarrhythmic medication) and an outcome (prostate cancer risk or death) is not 
due to the exposure but an indication or a factor related to the indication for which 
the exposure was used (Salas, Hofman, Stricker 1999). Smoking is a risk factor for 
both heart diseases and cancer. Therefore, especially in the overall cancer mortality 
study confounding by indication is likely to exist. To evaluate the influence of 
confounding by indication, users of other antiarrhythmic drugs were used as the 
reference group for digoxin and sotalol users, thus performing analysis in a group 
where we assumed everyone had the identical indication for antiarrhythmic drug use.  
These results were compared to analyses where non-users of antiarrhythmic drugs 
were the reference group. In addition, we used antihypertensive drug users as the 
reference group, since they are frequently used in the management of cardiac 
insufficiency, a common indication also for digoxin use. Furthermore, 
antiarrhythmic drug users’ risk of death due to any cause was calculated since digoxin 
is used in management of atrial fibrillation and cardiac insufficiency, which are 
associated with cardiovascular diseases. The risk association between the indication 
for digoxin use (cardiac insufficiency or arrhythmias) and cancer mortality was 
observed. 
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Several limitations need to be considered. We gathered the information on 
medication use from the national prescription database, which records the 
reimbursed drug purchases. There is no certainty whether men have used the 
medication they bought, which might have caused exposure misclassification. Since 
exposure status might be equally misclassified among men developing and not 
developing the outcome, misclassification is non-differential. Non-differential 
misclassification biases the results towards the null if the exposure variable is 
dichotomous (Dosemeci, Wacholder, Lubin 1990; Wacholder et al. 1995). In 
addition, we have no information on medication used during inpatient stays. Data 
on antiarrhythmic drug use before 1995 was not available which may lead to 
underestimation of cumulative amount and duration of drug use among men with 
history of antiarrhythmic drug use prior to 1995 resulting, probably in bias towards 
the null, assuming information bias is non-differential. We had no information on 
use of over-the-counter drugs but since purchase of any antiarrhythmic agent 
requires a prescription in Finland, this limitation does not cause bias in our study. 
We gathered information on drug use during 1995-2015 so current deductible did 
not affect our study. However, deductible prior to 2005 might have caused some 
bias since all digoxin purchases were not necessarily reimbursed; if a patient bought 
only digoxin, the total cost might have remained under 10 euros and the purchase 
was not recorded into the prescription database. The limitations mentioned above 
might fade the potential protective effect of digoxin use. In the study III we 
compared digoxin users to users of other antiarrhythmic drugs which increases 
possibility of immortal time bias. Nevertheless, digoxin users were compared to non-
users in sensitivity analyses and comparable results were obtained indicating 
immortal time bias is unlikely. 
There was no information on behavioral factors such as smoking, diet, ejaculation 
frequency or family history which might have caused confounding. Smoking is a 
strong risk factor for cardiac diseases, and it worsens cancer patients’ prognosis and 
thus it might have caused confounding increasing observed risk estimates among 
medication users. Men using antiarrhythmic medication might be sexually less active, 
and thus ejaculate less frequently. This might bias results away from the null since it 
has been observed that high ejaculation frequency is associated with a decreased 
prostate cancer risk. Furthermore, we did not have data on the number of health 
care contacts which might have been greater among men with antiarrhythmic 
medication. This might result in earlier detection of tumor, more active treatment 
and lower cancer mortality creating so called healthy user bias. We performed a 
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variety of subgroup analyses and therefore, multiple comparison bias might exist 
resulting in an erroneous statistically significant finding. 
Users and non-users of antiarrhythmic drugs are not necessarily comparable, 
since medication users have often more comorbidity compared to non-users. This 
might result in non-causal risk differences in epidemiological studies and provides a 
likely explanation for the observed increase in cancer mortality among 
antiarrhythmic drug users. CCI was an independent risk factor for cancer death and 
in subgroup analyses stratified by CCI, we observed an increased cancer mortality 
among digoxin users without major comorbidity (CCI 0), but there was no risk 
difference between digoxin users and non-users among men with comorbidity 
(CCI>0). In addition, use of antiarrhythmic medication was not associated with risk 
of cancer death in the competing risk analyses providing additional evidence for the 
hypothesis that use of antiarrhythmic drugs is not associated with cancer mortality 
when the effect of non-cancer deaths as competing causes are taken into 
consideration. 
 
6.5 Future considerations 
Even though digoxin has been a promising antineoplastic agent in in vitro 
experiments and there are several plausible pharmacological mechanisms to suggest 
cancer protective effects, digoxin use has not been consistently associated with a 
diminished cancer incidence or an improved cancer-specific survival. However, 
long-term digoxin use of more than 10 years might be beneficial especially against 
prostate cancer. Very long-term benefits might exist. In future, it might be justifiable 
to evaluate effects of digoxin at population level with extended follow-up (20 years 
for example). The ideal study population should have comparable comorbidities and 
baseline characteristics, since it is inadequate to compare men using digoxin to 
healthy men. In addition, information on antiarrhythmic drug use should be as 
accurate as possible. Clinical trials comparing digoxin to other antiarrhythmic drugs 
in order to test cancer protective effects are not indicated currently, since short-term 
impact of digoxin has not been observed on epidemiological studies.  
Sotalol users had a reduced risk of advanced prostate cancer in our case-control 
study. However, use of sotalol did not associate with risk of prostate cancer, prostate 
cancer survival or overall cancer mortality in the FinRSPC cohort. As 
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epidemiological evidence of effects of sotalol is uncertain, the priority of future 
studies is to define mechanism of possible beneficial effect of sotalol in in vitro studies 
in order to find out which target group would be most likely to benefit. 
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7 CONCLUSION 
This study shows that use of digoxin does not increase prostate cancer incidence, 
worsen prostate cancer prognosis or increase overall mortality. The main limitation 
of our study was possible differences in baseline characteristics and comorbidities, 
and therefore users and non-users of antiarrhythmic drugs were not necessarily 
comparable. Very long-term use of digoxin might be beneficial due to antineoplastic 
effects of digoxin, but the effect is probably minor, since it was not clearly observed 
in our large study population during the relatively long follow-up of over 10 years. 
Use of other antiarrhythmic medication is neither advantageous nor harmful when 
considering prostate cancer. 
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Abstract 
 
Purpose: Long-term usage of the antiarrhythmic drug digoxin has been connected to lowered risk of 
prostate cancer. A recent study has suggested that beta-blockers might also have similar risk decreasing 
effects. We evaluated the association between use of digoxin, beta-blocker sotalol and other 
antiarrhythmic drugs and prostate cancer risk in a retrospective cohort study. 
Methods: Our study population consisted of men in the Finnish Prostate Cancer Screening Trial during 1996 
– 2012 (n=78,615). During median follow-up of 12 years, 6,639 prostate cancer cases were diagnosed. The 
national prescription database was the source of the information of antiarrhythmic drug purchases. Data 
was analyzed using Cox regression method with medication use as a time-dependent variable.  
Results: No association was found for overall prostate cancer risk with antiarrhythmic drug use (HR 1.05 
95% CI 0.94-1.18). Neither sotalol (HR 0.97 95% CI 0.76-1.24) nor digoxin (HR 1.01 95% CI 0.87-1.16) users 
had a decreased risk of prostate cancer. Similar results were obtained for high-grade (Gleason 7-10) and 
metastatic prostate cancer. Nevertheless, the risk estimates for Gleason 7-10 prostate cancer tended to 
decrease by duration of digoxin use (p for trend = 0.052), suggesting that the drug may reduce the risk in 
long-term usage (HR 0.71, 95% CI 0.49-1.03). In analysis stratified by screening trial arm the protective 
association against Gleason 7-10 disease was observed only in the screening arm (HR 0.31, 95% CI 0.12-0.84 
for men who had used digoxin for five years or longer). 
Conclusion: Digoxin or other antiarrhythmic drugs are not associated with any clear decrease in prostate 
cancer risk. However, digoxin might have a benefit in long-term use by reducing risk of high-grade disease. 
Further research will be needed to evaluate possible effects on prostate cancer survival.  
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INTRODUCTION 
 
Despite being the most common cancer among men, prostate cancer etiology remains poorly understood. 
Even minor preventive effects would have major benefits to both public health and economics. The 
American Cancer Society estimates that in 2011, 240,890 men were diagnosed with prostate cancer and 
33,720 men died because of the disease in the U.S.1 As little as one percent reduction in population risk of 
prostate cancer would mean that thousands of cancers did not occur2. 
The antiarrhythmic drug digoxin has been suggested to have prostate cancer preventive effects both by in 
vitro and epidemiological studies3,4. In vitro digoxin inhibits plasma membrane Na+/K+ -ATPase and 
disarrays intracellular K+ and Ca2+ concentrations4. An increased Ca2+ concentration in the cell increases 
apoptosis5. In support of digoxin’s beneficial effects, a large cohort study (47,884 men) recently showed 
decreased prostate cancer incidence among men who had used digoxin constantly for over ten years4 and a 
case-control (1,001 cases and 942 controls) study reported the prostate cancer risk was decreased in 
digoxin users especially among men with 3 or more PSA-tests during the past five years.3 
Beta-blockers are usually used for management of hypertension but sotalol, which is both a beta- and a K+-
channel blocker, is a common antiarrhythmic drug. It has been suggested that regular use of beta-blockers 
is associated with decreased risk of cancer6. We have previously shown that sotalol users may have lowered 
prostate cancer risk7. 
We analyzed how use of digoxin, sotalol or other antiarrhythmic drugs is linked with overall prostate cancer 
risk and with tumor characteristics at diagnosis in a cohort of men participating in the Finnish Prostate 
Cancer Screening Trial. 
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MATERIALS & METHODS 
 
Study Population 
The study cohort consisted of men randomized to the Finnish Prostate Cancer Screening Trial (FinRSPC) 
during 1996-1999 and followed up until the end of 2012. The FinRSPC protocol has been previously 
described in detail8. In brief, 80,456 men aged 55-67 years and living in the metropolitan areas of Tampere 
and Helsinki, Finland, were identified from the Population Register Center and randomized either to be 
screened for prostate cancer with PSA test at four-year intervals (31,866 men, the screening arm) or to be 
followed through the national Finnish Cancer Registry (48,278 men, the control arm).   
Information on prostate cancers cases diagnosed in the study population included information on tumor 
Gleason grade at diagnosis, TNM stage, serum PSA value (for the screening arm) and the date and method 
of diagnosis.  
Prostate cancer was diagnosed in 6,639 men of the study population before 2010. The method of detection 
was known for 6,082 cases (91.6%). Of these, 2,584 (42.5%) were detected through screening, 1,938 
(31.9%) between the screening rounds, 327 (5.4%) in men invited to screening but not participating and 29 
(0.5%) in autopsy. Most cases were histologically confirmed (98.1%). Other methods of diagnostic 
verification included clinical (0.3%) and at autopsy (1.6%). One case was only radiologically and one 
cytologically confirmed. The method of diagnosis was unknown in three cases. 
The study was approved by the Ethics committee of the Pirkanmaa health care district, Finland (tracking 
number ETL 95077). 
Information on medication use 
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Data of refunded physician-prescribed medication purchases for the entire cohort during 1995 – 2009 was 
collected from the nationwide prescription database of the Social Insurance Institution (SII) of Finland. SII 
provides reimbursements for the costs of medicine prescribed by a physician for all Finnish residents9. 
Every reimbursed purchase of a prescribed drug is registered in the database. The information in the 
registry includes date for each purchase, number of packages obtained, as well as the number and dosage 
of pills. 
Information on drugs categorized as antiarrhythmic in Pharmaca Fennica, the Finnish national 
pharmaceutical guide was collected: amiodarone, digoxin, disopyramide, etilefrine, flecainide, quinidine, 
mexiletine, procainamide, propafenone and sotalol. All drugs were available for every year of the study 
follow-up except etilefrine (1995 – 2008) and procainamide (only 1995). The purchases of most drugs 
reduced significantly over time. For example, 6,110 men bought digoxin in 1997 but only 1,815 in 2009. 
Only purchases of flecainide increased from 92 (in 1995) to 473 (in 2009) during the study. Purchases of 
amiodarone and propafenone remained constant. Information on medication use was available for 78,615 
men (98.1% of the entire screening trial population). 
Statistical Analysis 
We used Cox regression method to analyze prostate cancer risk overall, as well as by stage and Gleason 
grade. We performed age-adjusted and multivariable analyses (further adjustment for use of other drug 
groups: NSAIDs, aspirin, antidiabetic medication, statins, antihypertensives, 5alpha-reductase inhibitors and 
alpha-blockers). Multivariable adjusted risk estimates are reported unless otherwise stated. We analyzed 
class effect of antiarrhythmic drugs by comparing users of any antiarrhythmic drugs to non-users. Drug-
specific effects were separately analyzed for digoxin and sotalol. Men who had used both drug groups were 
included in both analyses. Sensitivity analyses with further adjustment for digoxin or sotalol usage were 
performed to adjust for simultaneous usage. 
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Medication use status was updated prospectively each year of follow-up based on yearly medication 
purchases. Men with recorded purchases at any given year were regarded as users for that year. Users with 
a full year without purchases changed status into previous users. The status was allowed to change back to 
users if drug purchases were resumed at later point of follow-up. Never-users and all users before the first 
purchase were classified as non-users. Non-users were used as the reference group in all analyses. 
The amount of antiarrhythmic drug use was standardized by dividing the yearly mg amount of each drug 
with the standard Defined Daily Dose (DDD) published in public WHO website10. Duration of usage was 
calculated as number of years with medication purchases. Intensity of use (DDDs/year) was calculated by 
dividing the yearly cumulative amount with the number of years of usage. In men who stopped previous 
usage before the end of follow-up, the cumulative amount, duration and intensity of use remained at the 
level reached before discontinuation 
Cumulative amount (DDDs), duration (years) and intensity (DDDs/year) of medication use were also 
updated prospectively according to the yearly purchases. Men discontinuing previous use retained the level 
reached before the discontinuation. Trends in prostate cancer risk by amount, duration and intensity of the 
medication use were evaluated by stratifying the cohort by tertiles and repeating the analysis for each 
stratum. Additionally, we analyzed the trends by adding the cumulative amount/duration/intensity of use 
as a continuous variable into the Cox regression model. These analyses were necessary to estimate the 
association between prostate cancer risk and long-term drug usage, which was linked with reduced risk in 
the previous study3.  
Subgroup analyses were performed by stratifying the population by baseline characteristics, screening trial 
arm and by usage of other drug groups. We estimated effect modification by these variables on prostate 
cancer risk among antiarrhythmic medication users by adding interaction term with medication use into the 
Cox regression model. Furthermore, we estimated the effect of confounding by indication comparing 
digoxin users to men using other types of antiarrhythmic drugs or antihypertensive drugs. 
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We used X2-test to estimate the statistical significance of differences in population characteristics by 
antiarrhythmic drug use.  
All statistical tests are two-sided. P values 0.05 or less were considered statistically significant. IBM SPSS 
Statistics 22 (Chicago, IL, USA) software was used for data analyses.  
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RESULTS 
 
Population Characteristics 
The overall prevalence of antiarrhythmic drug use was 10.3% (8,064 men). The prevalence of digoxin use 
was 7.2% (5,668 men) and for sotalol 3.2% (2,540 men). Median age at baseline among never-users of 
antiarrhythmic drugs was 59 years. Among users the median age was slightly greater, 63 years. A similar 
difference was observed between ever vs. never users of digoxin and sotalol. No differences were observed 
in baseline PSA levels by antiarrhythmic drug use (Table 1). 
During the median follow-up of 12 years 6,639 prostate cancer cases were diagnosed within the cohort. 
Compared to non-users of antiarrhythmic drugs, the users had lower cumulative incidence of high-grade 
(Gleason 7-10) tumors (42.2% vs 39.2) and metastatic disease at diagnosis (6.29% vs 5.89%, respectively) 
(Table 1). The incidence of high-grade disease was also slightly lower among users of digoxin (40.8% vs. 
39.2% in non-users and users, respectively) and sotalol (41.9% vs. 40.2%). 
The usage of other drug groups (NSAIDs, aspirin, 5alfa-reductase inhibitors, alpha-blockers, 
antihypertensive drugs, antidiabetic drugs and statins) was more frequent among antiarrhythmic drug 
users compared to the non-users (Table 1). 
 
Antiarrhythmic drugs in general and prostate cancer 
Overall prostate cancer risk was slightly elevated among current antiarrhythmic drug users compared to 
non-users in the age-adjusted analysis, but not in the multivariable-adjusted analysis (Table 2). No 
significant association was observed either for risk of high-grade or metastatic prostate cancer. 
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The overall prostate cancer risk increased slightly by cumulative amount and intensity of antiarrhythmic 
drug use, although the trend was not significant (Table 3). This trend, however, was not observed for high-
grade cancer. For metastatic cancer, the risk was elevated at the beginning of usage, i.e. men whose 
cumulative amount was lowest, but not with continued use. 
 
Digoxin use and prostate cancer 
Overall, digoxin use was not associated with prostate cancer risk or with tumor grade or stage (Table 2). 
However, the association between digoxin use and prostate cancer was modified by prostate cancer 
screening; digoxin users had a borderline significantly decreased prostate cancer risk in the screening arm 
(HR 0.82, 95% CI 0.64-1.04) but not in the control arm (p for interaction = 0.052) (Table 2).  
Risk estimates for high-grade and metastatic prostate cancer tended to decrease with increasing amount 
and duration of digoxin use (Table 3), but remained statistically non-significant. A borderline significant 
decrease in the risk of high-grade prostate cancer was observed among men who used digoxin for six years 
or longer (HR 0.71, 95% CI 0.49-1.03). A similar decrease in the risk estimate was also observed for 
metastatic disease in long-term users (HR 0.80, 95% CI 0.30-2.16). No clear trends in risk estimates were 
observed for intensity of digoxin use. 
Among men in the screening arm a significant risk reduction for Gleason 7-10 prostate cancer was observed 
for men that have used digoxin for longer than 5 years (HR 0.31, 95% CI 0.12-0.84). Antiarrhythmic drug use 
in general among the same sub-cohort (screening arm, longer than 5 years of drug usage) was not 
associated with significant risk reduction (HR 0.64, 95% CI 0.40-1.02). 
Sotalol use and prostate cancer 
No risk association was observed with sotalol use for overall, high-grade and metastasized prostate cancer 
risks (Table 2). 
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The amount of sotalol usage was not associated with overall or high-grade prostate cancer risk. No 
significant risk difference was observed for metastatic disease, either (Table 3). 
 
Subgroup analyses 
Age at randomization modified the association between antiarrhythmic drugs and prostate cancer risk; the 
risk was lower in men aged 55-59 years at baseline (p for interaction = 0.001). The overall prostate cancer 
risk was decreased among 55-59 years old current sotalol user compared to non-users; HR 0.54, 95% CI 
0.30-0.97. This difference was not seen in the older age group (p for interaction = 0.006) (Table 4). 
Prostate cancer risk in digoxin users did not differ from men using other types of antiarrhythmic drugs in a 
sensitivity analysis limited to drug users only (HR 0.96, 95% CI 0.81-1.15). No risk difference was observed 
for high-grade or metastatic disease, either. Further, digoxin use was not associated with prostate cancer 
risk in analysis with antihypertensive drug users as the comparison group (HR 1.00, 95% CI 0.86-1.16). 
Use of other medications did not modify the effect of antiarrhythmic drugs (Table 4). The sensitivity 
analyses to estimate the effect of simultaneous usage of digoxin and sotalol did not show any differences in 
prostate cancer risk estimates.  
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DISCUSSION 
 
We did not find a clear association between antiarrhythmic drug usage and prostate cancer risk. Similarly, 
neither usage of digoxin nor sotalol had an influence on the risk. Nonetheless, the risk estimates for high-
grade and metastatic prostate cancer tended to decrease by increasing cumulative amount and duration of 
digoxin use. However, a similar decreasing trend was observed also for antiarrhythmic drugs in general, and 
could thus be due to systematic differences between users and non-users of this drug group rather than 
due to digoxin usage. However, the risk reduction for Gleason 7-10 cancer in the screening arm was 
observed only for long-term users of digoxin. Thus our results lend some support for oncological benefits of 
long-term digoxin use, as previously reported by Platz et al in a case-control study3. 
We must consider the possibility that the observed risk associations result from confounding by indication. 
When digoxin users were compared to other antiarrhythmic drug users, i.e. within the group supposedly 
having similar indications for drug usage, no protective risk differences were observed.  
Besides being used in treatment of atrial fibrillation, digoxin is also used in management of congestive 
heart failure. Antihypertensive drugs are also commonly used in heart failure patients. However, no risk 
association was found when digoxin users were compared to these antihypertensive drug users.  
The Health Professionals Follow-up study demonstrated that long-term digoxin users (>10 years) had a 
lowered prostate cancer risk (RR 0.54 95 % CI 0.37-0.79, P-trend < 0.001)4. Our study cohort was larger 
(78,615 vs. 47,884) with more prostate cancer diagnoses (6,639 vs. 5,002) and more digoxin-users (485 vs. 
243). In the previous study, only 28 men had used digoxin over ten years. We categorized the use of 6 years 
or more as long-term usage. Our study population consisted of 305 long-term users and 175 men that have 
used digoxin for over 10 years. Therefore our study had greater statistical power to study the long-term 
effects of these drugs. It should be noted that we observed a protective risk association for long-term 
digoxin use only among men under prostate cancer screening, not in the control arm. Due to widespread 
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PSA testing in the US, participants of the Health Professionals Follow-up study were likely in regular PSA 
surveillance. Thus our results are in concordance with this previous study. 
Our study cohort also has some similarities to the Health Professionals study. At the beginning of the 
follow-up, participants were 40 – 75 years old in the US study, whereas the age of our study population was 
55-67 at the start of the follow-up. Both cohorts consisted mostly of Caucasians, so ethnicity is unlikely to 
be a confounding factor. 
Our study has some strengths. Our information on medication use was comprehensive with minimal 
misclassification; a possible recall bias is excluded in our study as medication purchases are recorded by the 
database regardless of cancer status. Another important strength of our study is the large study population 
consisting of men living in two metropolitan areas in Finland. The study cohort was large enough to analyze 
the influence of an uncommonly used drug, such as digoxin, on the risk of prostate cancer, even by disease 
grade and stage. In comparison to the previous US study, our information on medication use was not 
collected from surveys but from objectively recorded national registry data.  
Some limitations should be considered. First, from the nationwide prescription database of the SII of 
Finland we were able to obtain the purchase information of any reimbursed drugs. Conversely, the exact 
indication for the purchases of the antiarrhythmic drugs was not available and thus we were not able to 
control for indication of drug usage in our analysis. However, evidence linking cardiac arrhythmias to 
prostate cancer risk is sparse. We were able control for underlying diseases indirectly by adjusting for the 
usage of other drug groups.  
Second, we had no information on lifestyle factors. Previous studies have showed that factors such as 
exercise, BMI, smoking and diet might have an impact on the risk of prostate cancer11. These could have 
caused confounding in either direction depending on their distribution between the users and non-users of 
the antiarrhythmic drugs.  
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Third, we did not have information about whether the received drugs were actually used. This might have 
caused exposure misclassification and bias towards the null. 
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Conclusion 
 
In conclusion, neither antiarrhythmic drug usage in general, nor digoxin or sotalol usage impacted the 
overall risk of prostate cancer. Nonetheless, our study does lend some support for the protective effect of 
long-term usage of digoxin, as the risk estimates for high-grade (Gleason score 7-10) cancer tended to 
decrease as the cumulative years of digoxin use increase. This effect was more distinct among men in the 
screening arm. Further studies should address whether or not digoxin use affects prostate cancer mortality.  
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Table 2. Prostate cancer risk, overall and by grade and stage in antiarrhythmic drug users 
  All FinPCST participants Screening arm Control arm 
 N Age-adjusted 
analysis 
Multivariable-
adjusted analysisa 
Multivariable-
adjusted 
analysisa,b 
Multivariable-
adjusted 
analysisa,b 
Overall risk  HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) 
All antiarrhythmic 
drugs 
     
Users 319 1.13 (1.01-1.27) 1.05 (0.94-1.18) 0.97 (0.81-1.16) 1.09 (0.94-1.26) 
Previous users 197 1.08 (0.93-1.26) 1.00 (0.86-1.17) 1.00 (0.78-1.28) 0.99 (0.81-1.21) 
Digoxin      
Users 191 1.06 (0.92-1.23) 1.01 (0.87-1.16) 0.82 (0.64-1.04) 1.13 (0.94-1.35) 
Previous users 135 1.09 (0.90-1.31) 1.03 (0.85-1.24) 1.08 (0.81-1.43) 0.97 (0.76-1.25) 
Sotalol      
Users 63 1.05 (0.82-1.34) 0.97 (0.76-1.24) 0.88 (0.60-1.30) 1.05 (0.76-1.45) 
Previous users 129 1.16 (0.96-1.41) 1.07 (0.88-1.29) 1.13 (0.84-1.54) 1.02 (0.80-1.30) 
Gleason 7-10 prostate 
cancer risk 
    
All antiarrhythmic 
drugs 
     
Users 118 0.99 (0.82-1.19) 0.90 (0.74-1.08) 0.92 (0.67-1.25) 0.88 (0.70-1.11) 
Previous users 100 1.17 (0.95-1.44) 1.06 (0.86-1.31) 1.23 (0.87-1.74) 0.97 (0.74-1.26) 
Digoxin      
Users 73 0.94 (0.75-1.19) 0.87 (0.69-1.10) 0.67 (0.43-1.04) 0.97 (0.73-1.27) 
Previous users 66 1.12 (0.86-1.46) 1.04 (0.80-1.35) 1.28 (0.85-1.93) 0.91 (0.64-1.29) 
Sotalol      
Users 25 1.11 (0.75-1.65) 1.03 (0.69-1.52) 1.25 (0.69-2.26) 0.91 (0.54-1.54) 
Previous users 57 1.10 (0.83-1.46) 1.00 (0.75-1.33) 1.40 (0.90-2.16) 0.81 (0.56-1.18) 
      
Metastatic prostate cancer  
riskc 
    
20 
 
All antiarrhythmic 
drugs 
     
Users 24 1.33 (0.88-2.01) 1.21 (0.80-1.83) 1.48 (0.71-3.07) 1.10 (0.66-1.84) 
Previous users 12 1.03 (0.55-1.93) 0.94 (0.50-1.77) 0.74 (0.18-3.02) 1.00 (0.49-2.03) 
Digoxin      
Users 15 1.29 (0.77-2.16) 1.14 (0.68-1.92) 1.06 (0.39-2.90) 1.18 (0.64-2.16) 
Previous users 11 1.39 (0.72-2.70) 1.25 (0.64-2.44) 1.02 (0.25-4.18) 1.34 (0.63-2.85) 
Sotalol      
Users 6 1.55 (0.69-3.46) 1.49 (0.67-3.35) 1.83 (0.45-7.43) 1.36 (0.50-3.65) 
Previous users 5 0.87 (0.36-2.11) 0.83 (0.34-2.01) 2.23 (0.70-7.10) 0.42 (0.10-1.68) 
a From Cox regression model adjusted for age, screening trial arm and use of cholesterol-lowering, 
antidiabetic and antihypertensive drugs, aspirin and other NSAIDs, and 5alpha-reductase inhibitors and 
alpha-blockers 
b p for interaction in risk of prostate cancer among digoxin users by FinPCST study arm = 0.052 
c Stage M1 at diagnosis 
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Table 4. Prostate cancer risk by antiarrhythmic drug usage in subgroups stratified by baseline variables 
 All Antiarrhythmic drugs Digoxin Sotalol 
 HR (95% CI)multivariable-
adjusted
a 
HR (95% CI)multivariable-
adjusted
a 
HR (95% CI)multivariable-
adjusted
a 
Age at randomization  
55 – 59 0.84 (0.68 – 1.04) 0.90 (0.68 – 1.18) 0.54 (0.30 – 0.97) 
63 – 67 1.09 (0.95 – 1.25) 0.99 (0.84 – 1.18) 1.08 (0.82 – 1.41) 
P for interaction 0.001 0.143 0.006 
Antiarrhythmic drug use before randomization  
No 0.96 (0.81-1.13) 0.93 (0.75-1.15) 0.99 (0.70-1.40) 
Yes 1.11 (0.79-1.55) 0.96 (0.73-1.25) 0.87 (0.59-1.28) 
P for interaction 0.42 0.72 0.65 
NSAID usage 
Non-users 1.26 (0.95 – 1.68) 1.19 (0.84 – 1.69) 1.40 (0.75 – 2.62) 
Users 1.02 (0.90 – 1.15) 0.97 (0.83 – 1.14) 0.92 (0.70 – 1.21) 
P for interaction 0.843 0.474 0.401 
ASA usage 
Non-users 1.08 (0.96 – 1.22) 1.04 (0.89 – 1.21) 0.92 (0.69 – 1.22) 
Users 0.91 (0.66 – 1.24) 0.83 (0.54 – 1.27) 1.26 (0.74 – 2.13) 
P for interaction 0.820 0.468 0.222 
Antidiabetic drug usage 
Non-users 1.06 (0.93 – 1.22) 1.00 (0.83 – 1.20) 1.00 (0.75 – 1.32) 
Users 1.02 (0.82 – 1.25) 1.02 (0.80 – 1.30) 0.89 ( 0.54 – 1.48) 
P for interaction 0.155 0.446 0.434 
Statin usage 
Non-users 1.13 (0.95 – 1.33) 1.11 (0.90 – 1.36) 0.95 (0.67 – 1.43) 
Users 1.00 (0.86 – 1.17) 0.93 (0.76 – 1.14) 0.98 (0.71 – 1.34) 
P for interaction 0.687 0.555 0.880 
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a From Cox regression model adjusted for age, screening trial arm and use of cholesterol-lowering, 
antidiabetic and antihypertensive drugs, aspirin and other NSAIDs, and 5alpha-reductase inhibitors and 
alpha-blockers 
 
 
Antihypertensive drug usage 
Non-users 1.13 (0.61 – 2.11) 1.34 (0.50 – 3.58) 0.51 (0.13 – 2.03) 
Users 1.05 (0.94 – 1.18) 1.00 (0.86 – 1.16) 1.00 (0.78 – 1.29) 
P for interaction 0.222 0.883 0.528 
5alpha-reductase inhibitor usage 
Non-users 1.04 (0.92 – 1.18) 1.00 (0.85 – 1.17) 0.96 (0.74 – 1.26) 
Users 1.07 (0.80 – 1.43) 1.05 (0.71 – 1.54) 0.97 (0.50 – 1.87) 
P for interaction 0.958 0.878 0.584 
Alpha-blocker usage 
Non-users 1.05 (0.90 – 1.24) 0.95 (0.77 – 1.17) 1.04 (0.74 – 1.45) 
Users 1.03 (0.88 – 1.20) 1.04 (0.85 – 1.27) 0.91 (0.63 – 1.31) 
P for interaction 0.750 0.765 0.275 
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Background: Protective effects have been suggested for digoxin against prostate cancer risk. However, few studies have evaluated the
possible effects on prostate cancer-specific survival. We studied the association between use of digoxin or beta-blocker sotalol and
prostate cancer-specific survival as compared with users of other antiarrhythmic drugs in a retrospective cohort study.
Methods: Our study population consisted of 6537 prostate cancer cases from the Finnish Randomized Study of Screening for
Prostate Cancer diagnosed during 1996–2009 (485 digoxin users). The median exposure for digoxin was 480 DDDs (interquartile
range 100–1400 DDDs). During a median follow-up of 7.5 years after diagnosis, 617 men (48 digoxin users) died of prostate cancer.
We collected information on antiarrhythmic drug purchases from the national prescription database. Both prediagnostic and
postdiagnostic drug usages were analysed using the Cox regression method.
Results: No association was found for prostate cancer death with digoxin usage before (HR 1.00, 95% CI 0.56–1.80) or after
(HR 0.81, 95% CI 0.43–1.51) prostate cancer diagnosis. The results were also comparable for sotalol and antiarrhythmic drugs in
general. Among men not receiving hormonal therapy, prediagnostic digoxin usage was associated with prolonged prostate
cancer survival (HR 0.20, 95% CI 0.05–0.86).
Conclusions: No general protective effects against prostate cancer were observed for digoxin or sotalol usage.
Previous epidemiological studies have suggested that the antiar-
rhythmic drug digoxin may have prostate cancer (PCa)-protective
effects especially in long-term usage (Platz et al, 2011; Wright et al,
2014; Kaapu et al, 2015). The proposed mechanism at the cellular
level is digoxin-induced inhibition of the plasma membrane
Naþ /Kþ -ATPase, which elevates the intracellular Ca2þ con-
centration, enhancing apoptosis of cancer cells (McConkey et al,
2000; Prevarskaya et al, 2014). Furthermore, HIF-1a has been
reported to be overexpressed in PCa cells. This overexpression
might stimulate tumour growth and metastasis. Digoxin has been
proposed to inhibit HIF-1a protein synthesis and the expression
of HIF-1a target genes in prostate tumours (Zhang et al, 2008).
A previous cohort study has linked use of digoxin and other
HIF-1a-inhibitory drugs with delayed occurrence of castration
resistance and distant metastases in PCa patients treated with
androgen-deprivation therapy (Ranasinghe et al, 2014).
Usage of beta-blockers may be associated with decreased
cancer incidence (Monami et al, 2013) and cancer mortality
(Choi et al, 2014). We have previously shown in a case–control
study that use of the antiarrhythmic drug sotalol, with both beta-
blocker and Kþ -channel inhibitor properties, decreased the risk
of advanced PCa (Kaapu et al, 2016). Some studies also suggest
that other beta-blockers may be associated with prolonged
survival of PCa patients (Grytli et al, 2014; Lu et al, 2015),
although conflicting results have been presented as well (Assayag
et al, 2014; Cardwell et al, 2014).
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Currently, there is little knowledge about the effect of digoxin or
sotalol use on PCa mortality; two published studies suggest no
connection with digoxin use (Flahavan et al, 2014; Lip et al, 2015).
However, digoxin use may prolong the doubling time of prostate-
specific antigen (PSA) level in PCa patients (Lin et al, 2014). No
studies have evaluated the association between other antiarrhyth-
mic drugs and PCa mortality.
We evaluated whether the use of digoxin, sotalol or other
antiarrhythmic drugs is related to PCa survival in the Finnish
Randomized Study of Screening for Prostate Cancer (FinRSPC).
MATERIALS AND METHODS
Study cohort. Our study population consisted of men within
FinRSPC, the largest component of the European Randomized
Study of Screening for Prostate Cancer. The detailed trial protocol
has been described previously (Kilpela¨inen et al, 2013). In brief, a
total of 80 458 men aged 55–67 years were identified in the years
1996–1999 and randomised to either PCa screening with a PSA test
at 4-year intervals (31 866 men, the screening arm) or no
intervention (48 278 men, the control arm). Prostate cancer cases
diagnosed among the study population were identified from the
Finnish Cancer Registry. During 1996–2009, 6537 new cases of
PCa were diagnosed. Available information on cancer cases
included the Gleason grade, TNM stage, primary treatment
(surgery, radiation therapy, endocrine treatment or surveillance)
and the serum PSA concentration. Each case was categorised as
either low/medium risk or high risk according to the criteria of the
European Association of Urology.
Causes of death among the study population in 1996–2012 were
obtained from Statistics Finland, which has been found to be a
reliable source of information by the FinRSPC cause-of-death
committee (Ma¨kinen et al, 2008). In this study, deaths where PCa
(ICD-10 code C61) was recorded as the primary cause of death
were considered as PCa deaths. Cases with ICD-code C61 as the
intermediate or contributory cause of death were analysed
separately for PCa-related mortality.
The study was approved by the Ethics committee of the
Pirkanmaa health-care district, Finland (tracking number R10167).
Information on medication use. The information on antiar-
rhythmic drug purchases was collected from the reimbursement
database of the Social Insurance Institution of Finland (SII). The
database includes the information on physician-prescribed medication
purchases during 1995–2009. This linkage was based on the unique
personal identification number assigned for all Finnish residents. The
database contains records of the date, the number of packages
acquired and the number and dosage of the pills for each purchase.
All Finnish residents are entitled to a reimbursement provided by
the SII for every physician-prescribed drug purchase in the outpatient
setting (Hemminki and Bomann-Larsen, 1981). The database covers
all antiarrhythmic drugs, including amiodarone, digoxin, disopyr-
amide, etilefrine, flecainide, quinidine, mexiletine, procainamide,
propafenone and sotalol. Additional information was obtained
concerning use of statins, antidiabetic medication (oral drugs and
insulins), antihypertensive medication (beta-blockers, ACE inhibitors/
ATII receptor blockers, calcium-channel blockers, diuretics and other
types of drugs, such as methyldopa and clonidine), aspirin and other
NSAIDs, 5-alpha-reductase inhibitors and alpha-blockers. The
database does not cover over-the-counter medication purchases or
the drugs used by hospital inpatients.
Statistical analysis. Differences in the baseline characteristics of
ever- vs never-users of digoxin and sotalol were compared
separately using the chi-square test (categorical variables) and
the Mann–Whitney U-test (continuous variables).
The analysis was limited to include only men who have used
some antiarrhythmic drug during the study period to minimise the
effects of confounding by indication. The association between
usage of digoxin and sotalol and risk of PCa-specific death was
estimated using the Cox regression model. Follow-up started at
PCa diagnosis. The analysis was conducted separately for
prediagnostic and postdiagnostic use of medication.
Antiarrhythmic drug usage before PCa diagnosis was analysed
as a time-independent variable fixed at baseline. Participants using
medication at the time of diagnosis were classified as active users.
If the medication had been used previously but not during the year
of diagnosis, the participant was classified as a previous user.
Active users and previous users were also combined into one
category called ‘any users’.
Antiarrhythmic drug usage after PCa was analysed as a time-
dependent variable. The medication use status was updated each
year, based on yearly medication purchases during the follow-up.
All participants were categorised as non-users until the first
medication purchase. At the first purchase, the exposure status
changed to user. Men who discontinued previous drug purchases
remained in the category of any users to minimise bias owing to
selective discontinuation of drug usage during the terminal phases
of cancer.
We used three differently adjusted regression models: (1) age-
adjusted (2) additionally adjusted for tumour risk group and
(3) multivariable-adjusted (further adjustment for FinRSPC trial
arm and use of other drugs during the study period: drugs used for
benign prostatic hyperplasia, diabetes, hypercholesterolemia or
hypertension and aspirin and other NSAIDs). To avoid over-
adjustment of the analysis, we did not adjust for PCa treatment, as
the treatment depends on patient age, tumour characteristics and
co-morbidities, all of which were adjusted for, and the effect of
drug use may occur through tumour characteristics.
The annual amount of medication use was estimated by adding
together the milligram amount of all purchases of a given drug
(dosage multiplied by the number of pills) during the year. We
standardised the amount of usage between different antiarrhythmic
drugs by dividing the yearly milligram amount with the drug-specific
average defined daily dose (DDD) published by WHO (2015).
Intensity of drug use (DDDs per year) was calculated by dividing the
yearly cumulative amount with the number of years of usage.
The amount (DDDs), duration (years) and intensity (DDDs per
years) of postdiagnostic antiarrhythmic drug use were also time-
dependent variables, which were updated by recorded medication
purchases during each year of follow-up. At discontinuation,
cumulative medication use remained at the reached level.
We evaluated survival trends by amount, duration and intensity
of either digoxin or sotalol use by dividing the cohort into two
subgroups according to the median of cumulative amount/
duration/intensity of drug use. The over-median and under-
median subgroups were compared with the users of other
antiarrhythmic drugs.
Effect modification by age, tumour characteristics, screening
trial arm, usage of other drug groups and primary treatment was
evaluated in subgroup analyses stratified according to these
variables. In the subgroup analyses, non-users were used as a
reference. Prediagnostic and postdiagnostic antiarrhythmic drug
usages among these subgroups were analysed separately. The
statistical significance of effect modification was evaluated by
adding an interaction term to the Cox regression model between
the variable of interest and medication use.
Several sensitivity analyses were performed to characterise
the association between digoxin use and PCa-specific survival. The
impact of medication use during the final years of life was
evaluated in a lag time analysis, where exposure was lagged to
occur 1–3 years later than the actual purchases. Possible
confounding owing to background variables was controlled by
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calculating a propensity score, as described previously (Rosenbaum
and Rubin, 1984), and stratifying the analysis according to the
median of the propensity score. In short, antiarrhythmic drug use
was analysed as the dependent variable using the logistic regression
method. The explanatory variables were age at diagnosis, use of
other drugs and the tumour risk group. Propensities from each
background variable were summed together to form a total
propensity score, which was then used to stratify the population.
Competing risk regression analyses with non-cancer deaths as the
competing risk were carried out according to the method described
by Fine and Gray (1999) in order to compare the risks of prostate
cancer death among users of digoxin and users of sotalol to men
using other types of antiarrhythmic drugs.
All the statistical tests mentioned above are two-sided. P-values
of p0.05 were considered statistically significant. IBM SPSS
Statistics 22 (Chicago, IL, USA) software was used for data
analyses.
RESULTS
Population characteristics. In the study population of 6537 PCa
cases, the median age at diagnosis was 63 years among prediagnostic
ever- and never-users of antiarrhythmic drugs, as well as among
digoxin and sotalol users. In total, 730 men (11.2%) had used
antiarrhythmic drugs during the follow-up, 485 (7.4%) had used
digoxin and 241 (3.7%) sotalol. The median exposures to digoxin and
sotalol were 480 and 380 DDDs (ranges 100–1400 and 50–1500
DDDs), respectively. During the median follow-up of 7.5 years after
PCa diagnosis, 1861 (28.5%) subjects died, 617 (9.4%) with PCa as the
underlying cause of death, including 70 men with any antiarrhythmic
drug use, 48 men with digoxin use and 26 with sotalol use.
Among ever-users of antiarrhythmic drugs, the proportion of men
with Gleason 7–10 cancer was slightly lower compared with never-
users (39.4% vs 42.2%). Also the prevalence of Gleason 8–10 PCa was
lower among the users (12.2% vs 14.1%). The same trend was
observed between ever- and never-users of digoxin or sotalol (39.2%
vs 42.0% and 40.6% vs 42.0%, respectively). The proportion of
metastatic cases did not vary by antiarrhythmic drug usage (Table 1).
The usage of other drug groups (NSAIDs, aspirin, 5-alpha-
reductase inhibitors, alpha-blockers, antihypertensive drugs, anti-
diabetic drugs and statins) was generally more frequent among the
antiarrhythmic drug users compared with the non-users (Table 1).
Antiarrhythmic drug use before prostate cancer diagnosis.
Digoxin use was not significantly associated with the risk of PCa
death (age-adjusted HR 1.33, 95% CI 0.99–1.77 and HR 1.53, 95%
CI 0.88–2.65 for any use and current use, respectively; Table 2).
Further adjustment for tumour risk group and use of other
medications did not change the result (Figure 1). Non-significantly
increased hazard ratios were observed among cases where the
cumulative amount, duration or intensity of digoxin usage was
above the median (Table 2).
Prediagnostic sotalol usage did not affect the risk of PCa death
and no clear risk trends were observed by cumulative usage
(Table 2).
Antiarrhythmic drug use after prostate cancer diagnosis. Post-
diagnostic digoxin usage was not significantly associated with PCa
survival (age-adjusted HR 1.19, 95% CI 0.72–1.97 and HR 1.02,
95% CI 0.60–1.87 for any and current use, respectively; Table 3).
Again, further model adjustment did not change the result. No
consistent survival differences were observed by cumulative
amount and duration of postdiagnostic digoxin use (Table 3).
Postdiagnostic usage of sotalol was generally not significantly
associated with the risk of PCa death (multivariable-adjusted HR
1.53, 95% CI 0.78–2.98 for any use; Table 3). Only men who
had discontinued sotalol usage had an elevated risk of PCa death
(HR 2.73, 95% CI 1.28–5.84). Risk increases were observed only in
short-term use at low cumulative doses and low intensity and were
no longer significant after adjustment for other prognostic factors.
Subgroup analyses. Use of ADT as primary treatment of PCa
did not modify the effect of digoxin (P for interaction 0.60),
although a significant risk decrease was observed among men not
receiving ADT and using digoxin before diagnosis (HR 0.20, 95%
CI 0.048–0.86).
The risk of PCa death was neither lowered nor elevated in the
other analysed subgroups for digoxin use before diagnosis
(Figure 2) or postdiagnosis (Figure 3).
Sensitivity analyses. The risk of PCa death was compared between
all antiarrhythmic drug users and non-users to see whether there is
general risk variance associated with the usage. When men with
any antiarrhythmic drug usage before PCa diagnosis were
compared with never-users, no risk difference was observed
(HR 1.16, 95% CI 0.82–1.65). The results were similar for men
with any antiarrhythmic drug usage after the diagnosis (HR 0.94,
95% CI 0.61–1.44). Furthermore, digoxin users were compared
with non-users of antiarrhythmic drugs. We found no material
survival association for digoxin use before (HR 1.22, 95% CI 0.87–
1.72) or after (HR 1.09, 95% CI 0.72–1.65) the diagnosis. Further
adjustment for primary and secondary PCa treatment did not
modify the main results.
In a separate analysis, we used antihypertensive drug users as the
reference group, because these drugs are often used in the manage-
ment of cardiac insufficiency, which is also a common indication for
digoxin use. There was no risk association observed in this analysis,
neither for prediagnostic (HR 1.11, 95% CI 0.70–1.74) nor for
postdiagnostic drug usage (HR 0.95, 95% CI 0.55–1.62).
No risk association was seen for PCa-related deaths (HR 0.92,
95% CI 0.54–1.56 for prediagnostic and HR 1.00, 95% CI 0.60–1.68
for postdiagnostic digoxin usage).
Digoxin usage was not associated with PCa death in lag-time
analyses either: the risk estimate in the analysis with a 1-year lag
was 1.40, 95% CI 0.86–2.28 and in the 3-year lag time analysis 1.34,
95% CI 0.83–2.19.
In an analysis stratified by the median of the propensity scores,
the effects of digoxin use were comparable among men with low
and high propensity for antiarrhythmic drug use (usage before
diagnosis HR 1.72 95% CI 0.85–3.46 and 1.45 95% CI 0.81–2.59;
usage after diagnosis HR 0.79 95% CI 0.30–2.12 and 1.26 95% CI
0.67–2.39, respectively). The findings for sotalol were similar.
Further, digoxin or sotalol uses were not associated with the risk of
PCa death in an analysis adjusted for the propensity score.
Digoxin use, both before and after PCa diagnosis, was not
associated with risk of PCa death when non-cancer deaths were
analysed as a competing cause of death (HR 1.03, 95% CI 0.72–1.07
and HR 0.85, 95% CI 0.60–1.22, respectively).
Overall risk of death and death owing to causes other than
prostate cancer by digoxin and sotalol use are reported in
Supplementary Table S1. Digoxin users were at greater risk of
dying from non-PCa causes compared with other antiarrhythmic
drug users, whereas the risk was lowered among sotalol users.
Furthermore, we performed a Cox regression that included only
those variables that showed a significant association with the risk
of PCa death in crude analyses. Results were comparable to the
main analysis (Supplementary Table S2).
DISCUSSION
Our study found no significant association between PCa survival
and digoxin or sotalol usage. The timing of the drug usage did not
affect the results, as no difference was observed between survival
estimates of prediagnostic and postdiagnostic digoxin usage. No
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dose–response was found in the risk by the cumulative amount,
duration or intensity of digoxin use. Furthermore, the results did
not differ between men in the screening and control arms. Thus
our results do not support the PCa-protective effects of this
antiarrhythmic agent.
A previous cohort study including 5732 PCa patients reported
that digoxin usage at PCa diagnosis did not associate with PCa
survival (Flahavan et al, 2014). Our findings are in concordance
with the results reported previously, and some new aspects are
considered. We analysed prediagnostic and postdiagnostic drug
Table 1. Population characteristics
Use of antiarrhytmic drugs Use of digoxin Use of sotalol
Never Ever P-value Never Ever P-value Never Ever P-value
No. of cases 5807 730 6052 485 6296 241
Gleason grade 0.23 0.35 0.56
p6 3205 (55.2%) 419 (57.5%) 3345 (55.3%) 279 (57.6%) 3490 (55.4%) 134 (55.6%)
7 1632 (28.1%) 198 (27.2%) 1703 (28.1%) 127 (26.2%) 1760 (28.0%) 70 (29.0%)
X8 818 (14.1%) 89 (12.2%) 844 (13.9%) 63 (13.0%) 879 (14.0%) 28 (11.6%)
Information unknown 152 (2.6%) 22 (3.2%) 160 (2.6%) 14 (3.1%) 167 (2.6%) 9 (3.7%)
Tumour stage at diagnosis 0.26 0.55 0.76
Localised 5300 (91.3%) 676 (92.6%) 5531 (91.4%) 445 (91.8%) 5755 (91.4%) 221 (91.7%)
Metastatic cases 365 (6.3%) 43 (5.9%) 376 (6.2%) 32 (6.6%) 392 (6.2%) 16 (6.6%)
The last observed PSA value (7.00) 7.30 (7.00) 7.40 0.91 (7.00) 7.30 (7.15) 7.75 0.50 (7.00) 7.30 (7.00) 7.50 0.90
Use of other drugs
NSAIDs 5009 (86.3%) 627 (85.9%) 0.79 5226 (86.4%) 410 (84.5%) 0.26 5432 (86.3%) 204 (84.6%) 0.47
Aspirin 773 (13.3%) 115 (15.8%) 0.070 822 (13.6%) 66 (13.6%) 0.99 842 (13.4%) 46 (19.1%) 0.011
Statins 2641 (45.5%) 418 (57.3%) o0.001 2797 (46.2%) 262 (54.0%) 0.001 2903 (46.1%) 156 (64.7%) o0.001
Antidiabetic drugs 1072 (18.5%) 202 (27.7%) o0.001 1120 (18.5%) 154 (31.8%) o0.001 1214 (19.3%) 60 (24.9%) 0.031
Antihypertensives 4034 (69.5%) 714 (97.8%) o0.001 4269 (70.5%) 479 (98.8%) o0.001 4511 (71.6%) 237 (98.3%) o0.001
5-alpha-reductase inhibitors 804 (13.8%) 104 (14.2%) 0.77 844 (13.9%) 64 (13.2%) 0.65 873 (13.9%) 35 (14.5%) 0.77
Alpha-blockers 2669 (46.0%) 363 (49.7%) 0.055 2794 (46.2%) 238 (49.1%) 0.22 2908 (46.2%) 124 (51.5%) 0.11
Primary treatment
Radical prostatectomy 1535 (26.4%) 117 (16.0%) o0.001 1589 (26.3%) 63 (13.0%) o0.001 1614 (25.6%) 38 (15.8%) 0.001
Radiation therapy 2069 (35.6%) 306 (41.9%) 0.002 2170 (35.9%) 205 (42.3%) 0.009 2266 (36.0%) 109 (45.2%) 0.013
Hormonal therapy 2328 (40.1%) 341 (46.7%) 0.001 2428 (40.1%) 241 (49.7%) o0.001 2559 (40.6%) 110 (45.6%) 0.12
Active surveillance 1016 (17.5%) 136 (18.6%) 0.44 1061 (17.5%) 91 (18.8%) 0.48 1111 (17.7%) 41 (17.0%) 0.80
Abbreviations: NSAID¼ non-steroidal anti-inflammatory drug; PSA¼prostate-specific antigen.
Table 2. Prostate cancer-specific survival among men using digoxin and sotalol before prostate cancer diagnosis as compared
with other antiarrhythmic drug users in the cohort of 6537 prostate cancer cases diagnosed in the Finnish Randomized Study of
Prostate Cancer Screening
Digoxin Sotalol
N
Age-adjusted
HR (95% CI)
Multivariable-
adjusted1a
HR (95% CI)
Multivariable-
adjusted2b
HR (95% CI) N
Age-adjusted
HR (95% CI)
Multivariable-
adjusted1a
HR (95% CI)
Multivariable-
adjusted2b
HR (95% CI)
Prediagnostic usage
None 396 Ref. Ref. Ref. 525 Ref. Ref. Ref.
Any 334 1.33 (0.99–1.77) 1.38 (0.86–2.22) 1.21 (0.71–2.05) 205 1.07 (0.80–1.43) 1.04 (0.62–1.75) 1.12 (0.63–1.98)
Current user 191 1.53 (0.88–2.65) 1.33 (0.76–2.31) 1.00 (0.56–1.80) 63 0.93 (0.40–2.16) 0.80 (0.34–1.87) 0.82 (0.34–1.97)
Previous user 143 1.69 (0.92–3.11) 1.46 (0.79–2.69) 1.57 (0.84–2.95) 142 1.17 (0.64–2.11) 1.12 (0.66–2.17) 1.16 (0.63–2.15)
Cumulative DDD amountc
Under median 168 1.52 (0.85–2.72) 1.31 (0.73–2.35) 0.99 (0.52–1.88) 105 1.04 (0.52–2.04) 0.98 (0.50–1.94) 0.98 (0.47–2.03)
Over median 166 1.67 (0.94–2.95) 1.45 (0.81–2.58) 1.56 (0.84–2.91) 100 1.13 (0.57–2.23) 1.10 (0.55–2.16) 1.38 (0.64–2.97)
Cumulative years of usaged
Under median 176 1.62 (0.93–2.81) 1.35 (0.78–2.35) 1.05 (0.58–1.90) 121 1.12 (0.61–2.06) 1.05 (0.57–1.93) 1.08 (0.57–2.03)
Over median 158 1.55 (0.84–2.86) 1.42 (0.76–2.65) 1.54 (0.77–3.05) 84 1.01 (0.46–2.24) 1.02 (0.46–2.26) 1.17 (0.53–2.59)
Intensity of use (DDDs per year)e
Under median 174 1.60 (0.90–2.83) 1.46 (0.82–2.60) 1.10 (0.57–2.11) 103 0.86 (0.41–1.81) 0.85 (0.40–1.80) 0.84 (0.39–1.82)
Over median 160 1.59 (0.89–2.84) 1.30 (0.72–2.34) 1.32 (0.71–2.47) 102 1.31 (0.70–2.46) 1.21 (0.65–2.28) 1.18 (0.58–2.42)
Abbreviations: CI¼ confidence interval; DDD¼defined daily dose; HR¼ hazard ratio.
aFrom Cox regression model adjusted for age and the tumour risk group.
bFrom Cox regression model adjusted for age, screening trial arm and use of cholesterol-lowering, antidiabetic and antihypertensive drugs, aspirin and other NSAIDs and 5-alpha-reductase
inhibitors and alpha-blockers and additionally for the tumour risk group.
cMedian for cumulative amount of medication use: Digoxin: 550 DDD; Sotalol 550 DDD.
dMedian for cumulative duration of medication use: Digoxin: 3 years; Sotalol 3 years.
eMedian for intensity of medication use: Digoxin: 175 DDDs per year; Sotalol 192 DDDs per year.
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usage separately, providing new information on the possible
importance of the timing of drug usage. The median follow-up
time in our study was 7.5 years, while in the previous study it was
4.3 years (Flahavan et al, 2014). This increase in the median follow-
up time is important when studying PCa death as an end point, as
PCa often has a good long-term survival.
The association between digoxin usage and PCa risk has been
more comprehensively studied than PCa survival. Nevertheless,
incongruous results have been reported. Platz et al (2011) reported
digoxin users having a lowered PCa risk compared with non-users
in the Health Professionals Follow-up Study. The risk decrease was
more distinct among men who had used digoxin for 410 years.
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Figure 1. Kaplan–Meier plot for prostate cancer-specific survival by digoxin use before diagnosis among men using any antiarrhythmic drugs
between 1995 and 2009. Cohort of 6537 prostate cancer cases diagnosed in FinRSPC.
Table 3. Prostate cancer-specific survival among men using digoxin and sotalol after prostate cancer diagnosis as compared with
other antiarrhythmic drug users in the cohort of 6537 prostate cancer cases diagnosed in the Finnish Randomized Study of
Prostate Cancer Screening
Digoxin Sotalol
Age-adjusted HR
(95% CI)
Multivariable-
adjusted1a
HR (95% CI)
Multivariable-
adjusted2b
HR (95% CI)
Age-adjusted HR
(95% CI)
Multivariable-
adjusted1a
HR (95% CI)
Multivariable-
adjusted2b
HR (95% CI)
Postdiagnostic usage
None Ref. Ref. Ref. Ref. Ref. Ref.
Any 1.19 (0.72–1.97) 1.14 (0.69–1.88) 1.00 (0.59–1.71) 1.56 (0.83–2.92) 1.35 (0.72–2.53) 1.53 (0.78–2.98)
Current user 1.02 (0.60–1.87) 0.95 (0.52–1.74) 0.81 (0.43–1.51) 0.73 (0.23–2.34) 0.67 (0.21–2.15) 0.80 (0.25–2.64)
Previous user 1.62 (0.78–3.36) 1.62 (0.79–3.36) 1.42 (0.64–3.18) 2.56 (1.24–5.29) 2.08 (1.00–4.32) 2.73 (1.28–5.84)
Cumulative DDD amountc
Under median 1.46 (0.82–2.59) 1.42 (0.80–2.52) 1.23 (0.67–2.23) 2.37 (1.20–4.64) 1.88 (0.96–3.71) 2.04 (0.99–4.23)
Over median 0.82 (0.37–1.83) 0.76 (0.34–1.71) 0.59 (0.24–1.43) 0.57 (0.14–2.35) 0.55 (0.13–2.29) 0.69 (0.16–2.91)
Cumulative years of usaged
Under median 1.43 (0.84–2.44) 1.40 (0.82–2.39) 1.22 (0.70–2.15) 2.06 (1.01–4.16) 1.67 (0.82–3.40) 1.88 (0.89–3.94)
Over median 0.55 (0.17–1.79) 0.48 (0.15–1.59) 0.31 (0.081–1.17) 0.90 (0.28–2.90) 0.85 (0.26–2.74) 0.96 (0.29–3.21)
Intensity of use (DDDs per year)e
Under median 1.39 (0.75–2.57) 1.35 (0.73–2.51) 1.24 (0.66–2.34) 2.29 (1.09–4.81) 1.80 (0.85–3.80) 1.84 (0.84–4.06)
Over median 0.99 (0.50–1.97) 0.93 (0.47–1.84) 0.71 (0.33–1.50) 0.95 (0.34–2.63) 0.90 (0.32–2.49) 1.15 (0.40–3.28)
Abbreviations: CI¼ confidence interval; DDD¼defined daily dose; HR¼ hazard ratio.
aFrom Cox regression model adjusted for age and the tumour risk group.
bFrom Cox regression model adjusted for age, screening trial arm and use of cholesterol-lowering, antidiabetic and antihypertensive drugs, aspirin and other NSAIDs and 5-alpha-reductase
inhibitors and alpha-blockers.
cMedian for cumulative amount of medication use: Digoxin: 450 DDD; Sotalol 600 DDD.
dMedian for cumulative duration of medication use: Digoxin: 3 years; Sotalol 2 years.
eMedian for intensity of medication use: Digoxin: 150 DDDs per year; Sotalol 215 DDDs per year.
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We have previously demonstrated in this study population that
digoxin use may be linked with a lower risk of Gleason 7–10 PCa,
specifically in men under systematic PCa screening (Kaapu et al,
2015). The current study shows that this possible benefit in PCa
risk does not translate into improved disease-specific survival.
The only subgroup in the present study where a possible protective
effect of digoxin was observed was the men who did not receive ADT
as the primary treatment choice. Although the interaction term was
non-significant, this suggests that ADT may modify the effects of
digoxin in PCa patients. Our results do not support the previous study
reporting digoxin and other HIF-1a inhibitors to enhance the efficacy
of ADT (Ranasinghe et al, 2014). On the other hand, digoxin is a
phytoestrogen affecting the estrogen receptor (Rifka et al, 1978). Thus
the protective effects could be diluted in men managed with ADT but
observed in men managed otherwise.
The decreased risk of advanced PCa observed among sotalol
users in our previous study (Kaapu et al, 2015) did not translate
into a survival benefit in the present study. Additionally, our recent
cohort study (Kaapu et al, 2016) lacked this association and
therefore we must consider the possible protective effects of sotalol
usage in relation to prostate cancer death as uncertain.
Several strengths can be identified in our study. Men living in two
different metropolitan areas in Finland comprised a comprehensive
and representative study population. The study cohort enabled us to
assess reliably the effects of relatively infrequent antiarrhythmic
agents. Furthermore, information on medication use was collected
from a national prescription database, thus allowing us to evaluate
both prediagnostic and postdiagnostic drug usage. Recall bias was
avoided, as the information on medication use was not self-reported;
the database records medication purchases regardless of cancer status.
In addition, information on the treatment and characteristics of the
cancer was available from medical records.
Analyses on the risk of death among digoxin users are easily
influenced by competing causes of death as the drug is used in the
management of atrial fibrillation and cardiac insufficiency, both of
which are strongly associated with cardiovascular diseases. This was
demonstrated by the increased risk of non-PCa death among digoxin
users. To minimise the possibility of confounding by indication, users
of other antiarrhythmic drugs were used as a reference group. In the
multivariable-adjusted analyses, the influence of tumour risk group
and usage of other medication were considered. Furthermore, we were
able to evaluate the role of screening in the survival association, as
men in the screening arm and in the control arm were analysed
separately. Additionally, performing the analysis with competing risk
regression did not change the result.
A few limitations should be considered. The indications for
antiarrhythmic drugs prescribed to men in the study were not
available. Most other diseases among the men could be adjusted for in
the multivariable analyses as described above, but no information on
untreated chronic conditions was available. Furthermore, only 48
digoxin users died of PCa. Thus our analysis was probably
underpowered to detect small differences in PCa survival.
CONCLUSION
We found no clear association between digoxin or sotalol usage
and PCa-specific survival.
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Figure 2. Subgroup analyses for men using digoxin before PCa diagnosis.
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Figure 3. Subgroup analyses for men using digoxin after PCa diagnosis.
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Kalle J. Kaapuͷ, Lauri Rantaniemiͷ, Kirsi Talala͸, Kimmo Taari͹, Teuvo L. J. Tammelaͷǡͺ, 
Anssi Auvinenͻ & Teemu J. Murtolaͷǡͺ
In-vitro studies have suggested that the antiarrhythmic drug digoxin might restrain the growth of 
cancer cells by inhibiting Na+/K+-ATPase. We evaluated the association between cancer mortality 
and digoxin, sotalol and general antiarrhythmic drug use in a retrospective cohort study. The study 
ͽ;ǡͼͷͻƤ	
for Prostate Cancer. Information on antiarrhythmic drug purchases was collected from the national 
Ǥ
ǤǦͷͽǤͶ
͸;ǡͿ͹ͼȋ͹ͼǤ;άȌǡ;ǡ;;ͿǤͿǡͶ͸͹ȋͷͷǤͻάȌ
had used antiarrhythmic drugs. Overall cancer mortality was elevated among antiarrhythmic drug 
ǦȋͷǤͺ͹ǡͿͻάͷǤ͹ͺȂͷǤͻ͹ȌǤ
ǤǡǦƤ
ǦǤǡ
users. This association is probably non-causal as it was related to short-term use and disappeared in 
ǦǤơ
drug.
Various preclinical studies have suggested that the antiarrhythmic drug digoxin may have antineoplastic effects1–3. 
Digoxin may be able to inhibit growth of lung4–6, prostate7,8 and pancreatic9 tumor cell lines and suppress cancer 
progression. The anticancer effects have been suggested to be due to inhibition of the plasma membrane Na+/
K+-ATPase which increases intracellular concentration of Ca2+, eventually causing apoptosis7,10. Another pro-
posed mechanism is inhibition of HIF-1alpha, an important regulator of cell growth8,11.
Digoxin use might be associated with a decreased risk of prostate cancer12, especially among patients under 
regular PSA-surveillance13,14, but is not associated with prostate cancer-specific survival15–17. In a British cohort 
study there was no association between digoxin use and cancer-specific survival from prostate, breast, respira-
tory or gastrointestinal cancer18. Further, digoxin use was not associated with survival among ovarian cancer 
patients19.
Digoxin has estrogenic effects20 and has been associated with an increased risk of breast21 and uterine can-
cer but digoxin users may have a better prognosis and a decreased risk of metastases22–24. Digoxin use has also 
been linked to a higher risk of colorectal cancer25 but no difference in cancer-specific survival after diagnosis of 
colorectal cancer was found in a population-based cohort study26.
Studies concerning other antiarrhythmic drugs and cancer survival are sparse. The beta-blocker sotalol is both 
a K+-channel blocker and used clinically as an antiarrhythmic drug. Adrenergic activation is essential for cancer 
and therefore the use of beta-blockers might be beneficial27. We have previously shown in a population-based 
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case-control study that sotalol is associated with a lowered prostate cancer risk28 but does not associate with sur-
vival17. Beta-blockers as a group have been linked with prolonged cancer survival29.
We estimated the association between use of digoxin, sotalol or other antiarrhythmic drugs and overall 
cancer mortality and separately lung, colorectal, pancreatic, liver, bladder, renal and CNS cancer mortality in a 
population-based cohort of Finnish men.
Results
Population characteristics. A total of 78,615 men with data from the SII prescription database were 
included in the study. Of these 9,023 (11.5%) had used at least one antiarrhythmic drug during the follow-up; 
6,329 (8.1%) had used digoxin and 2,304 (2.9%) had used sotalol. The median age at baseline was 59 years among 
the never-users of antiarrhythmic drugs and 63 years among men with any antiarrhythmic drug use during the 
follow-up.
During the median follow-up of 17.0 years after baseline, 28,936 (36.8%) men died. There were 8,889 cancer 
deaths altogether, and the most frequent individual cancers were lung cancer (2,384 deaths), colorectal cancer 
(861 deaths) and pancreatic cancer (782 deaths) (Table 1).
In general, the use of other drugs (NSAIDs, aspirin, statins, antidiabetic drugs, antihypertensive drugs, 
alpha-blockers and 5-alpha-reductase inhibitors) was more common and the Charlson comorbidity index (CCI) 
was higher among antiarrhythmic drug users compared to non-users (Table 1).
Antiarrhythmic drug use and overall cancer mortality. Antiarrhythmic drug use in general 
was associated with increased cancer mortality in both age-adjusted and multivariable-adjusted analyses 
(multivariable-adjusted HR 1.43, 95% CI 1.34–1.53,). A similar risk increase was observed for men with digoxin 
use (HR 1.59, 95% CI 1.47–1.72) and sotalol use (HR 1.16, 95% CI 1.03–1.31) (Table 2). The risk increase attenu-
ated with increasing amount, duration and intensity of drug use but there was no risk decrease even in long-term 
use (Table 3). Furthermore, the risk elevation tended to decrease also in lagged analysis estimating long-term 
effects of antiarrhythmic drug use (Table 2).
Antiarrhythmic drug use Digoxin use Sotalol use
Never Ever P-value Never Ever P-value Never Ever P-value
Characteristics of Participants
Number of participants 69,592 9,023 72,286 6,329 76,311 2,304
Median Age (IQR) 59 (55–63) 63 (59–67) 0.00 59 (55–63) 63 (59–67) 0.00 59 (55–63) 63 (59–67) 0.00
Median BMI (IQR) 26.3 (24.2–28.7) 27.2 (24.8–30.3) 0.00 26.3 (24.2–28.7) 27.4 (25.1–30.9) 0.00 26.3 (24.2–29.0) 27.2 (25.0–30.2) 0.00
Baseline cancer diagnosis 
(any) 2,822 (4.1%) 457 (5.1%) 0.00 2,956 (4.1%) 323 (5.1%) 0.00 3,165 (4.1%) 114 (4.9%) 0.06
Charlson comorbidity index 0.00 0.00 0.00
0 50,305 (72.3%) 4,703 (52.1%) 52,097 (72.1%) 2,911 (46.0%) 53,653 (70.3%) 1,355 (58.8%)
1 3,192 (4.6%) 614 (6.8%) 3,322 (4.6%) 484 (7.6%) 3,683 (4.8%) 123 (5.3%)
2 or greater 16,095 (23.1%) 3,706 (41.1%) 16,867 (23.3%) 2,934 (46.4%) 18,975 (24.9%) 826 (35.9%)
Cancer death
Overall cancer death 7,873 (11.3%) 1,016 (11.3%) 8,143 (11.3%) 746 (11.8%) 8,622 (11.3%) 267 (11.6%)
Lung cancer death 2,090 (3.0%) 294 (3.3%) 2,152 (3.0%) 232 (3.7%) 2,320 (3.0%) 64 (2.8%)
Colorectal cancer death 770 (1.1%) 91 (1.0%) 792 (1.1%) 69 (1.1%) 846 (1.1%) 15 (0.7%)
Pancreatic cancer death 714 (1.0%) 68 (0.8%) 734 (1.0%) 48 (0.8%) 762 (1.0%) 20 (0.9%)
Gastric cancer death 316 (0.5%) 27 (0.3%) 321 (0.4%) 22 (0.3%) 336 (0.4%) 7 (0.3%)
Hepatic cancer 425 (0.6%) 48 (0.5%) 436 (0.6%) 37 (0.6%) 454 (0.6%) 19 (0.8%)
Renal cancer 251 (0.4%) 35 (0.4%) 259 (0.4%) 27 (0.4%) 277 (0.4%) 9 (0.4%)
Non-Hodgkin lymphoma 256 (0.4%) 46 (0.5%) 267 (0.4%) 35 (0.6%) 295 (0.4%) 7 (0.3%)
Bladder cancer 190 (0.3%) 29 (0.3%) 198 (0.3%) 21 (0.3%) 215 (0.3%) 4 (0.2%)
Central nervous system 
cancer 191 (0.3%) 17 (0.2%) 198 (0.3%) 10 (0.2%) 203 (0.3%) 5 (0.2%)
Prevalence of medication use
NSAIDs 54,837 (78.8%) 7,436 (82.5%) 0.00 57,145 (79.1%) 5,128 (81.0%) 0.00 60,311 (79.0%) 1,962 (85.2%) 0.00
Aspirin 10,732 (15.4%) 1,647 (18.3%) 0.00 11,287 (15.6%) 1092 (17.3%) 0.00 11,894 (15.6%) 485 (21.1%) 0.00
Statins 28,014 (40.3%) 4,840 (53.6%) 0.00 29,540 (40.9%) 3,314 (52.4%) 0.00 31,489 (41.3%) 1,374 (59.6%) 0.00
Antidiabetic drugs 13,321 (19.1%) 2,572 (28.5%) 0.00 13,871 (19.2%) 2,022 (31.9%) 0.00 15,274 (20.0%) 619 (26.8%) 0.00
Antihypertensives 44,472 (63.9%) 8,459 (93.7%) 0.00 46,878 (64.9%) 6,053 (95.6%) 0.00 50,731 (66.5%) 2,200 (95.5%) 0.00
Alpha-blockers 18,442 (26.5%) 2,901 (32.2%) 0.00 19,399 (26.8%) 1,944 (30.7%) 0.00 20,554 (26.9%) 789 (34.2%) 0.00
Table 1. Population characteristics in the Finnish Randomized Study of Screening for Prostate Cancer.
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Antiarrhythmic drug use and individual cancers. Both usage of antiarrhythmic drugs in general and 
usage of digoxin were associated with increased lung cancer mortality (HR 1.72, 95% CI 1.52–1.95 and HR 2.10, 
95% CI 1.82–2.41, respectively). This association was not observed for sotalol use (HR 1.10, 95% CI 0.85–1.41) 
(Table 2). There were similar trends by amount, duration and intensity as with overall cancer mortality (Table 3).
The results for colorectal cancer mortality were rather similar to those for lung cancer mortality; 
Antiarrhythmic drug use in general and digoxin use both elevated risk of death (HR 1.38, 95% CI 1.11–1.73 and 
HR 1.59, 95% CI 1.24–2.05). Usage of sotalol was not associated with the risk for colorectal cancer death (HR 
0.70, 95% CI 0.42–1.17) (Table 2).
Pancreatic cancer differed from other cancer types since antiarrhythmic drug use had no influence on pan-
creatic cancer mortality (HR 1.02, 95% CI 0.79–1.31). Identical findings were observed for digoxin use (HR 1.06, 
95% CI 0.79–1.43) and for sotalol use (HR 0.99, 95% CI 0.63–1.54).
Furthermore, antiarrhythmic drug use and digoxin use were associated with elevated risk of death due to 
non-Hodgkin lymphoma and bladder cancer (Table S1).
Ǥ The overall cancer mortality of antiarrhythmic drug users was increased in all sub-
groups that we analyzed (Fig. 1). The risk estimates for overall cancer death were most increased among non-users 
of antihypertensive drugs (p for interaction 0.01). There was a similar risk difference between users and non-users 
of antihypertensive drugs among digoxin users (p for interaction 0.002). Furthermore, there was an interaction by 
antidiabetic drug use, the risk being higher among men who were not using antidiabetic drugs (p for interaction 
0.01) (Fig. 1).
We used the CCI to stratify the study population by comorbidities. Antiarrhythmic drug use associated 
with increased cancer mortality among the men with least comorbidities (Charlson index 0: HR 1.37, 95% CI 
1.19–1.56). A similar result was observed among men with intermediate comorbidities (Charlson index 1: HR 
1.22, 95% CI 0.87–1.71) but the CIs are wider since there were less men in this cohort. There was no association 
between cancer mortality and antiarrhythmic drug use among men with the most comorbidities (Charlson index 
2 or greater: 0.98, 95% CI 0.91–1.06). There was a statistically significant effect modification by CCI (p for inter-
action < 0.001).
Ǥ To evaluate confounding by indication we estimated the risk association between the 
indications for antiarrhythmic drug and digoxin use (cardiac insufficiency and arrhythmias) and cancer mor-
tality. 4,199 men had recorded diagnosis of cardiac insufficiency (ICD-10 codes I50) in the HILMO database, 
while 1,507 men had a diagnosis of arrhythmia (I47 and I49). The increase in overall cancer mortality risk that 
we observed for cardiac insufficiency (HR 1.19, 95% CI 1.08–1.31) was similar to the risk for antiarrhythmic drug 
use in general that we observed in our main analysis. However, having a recorded diagnosis of arrhythmia was 
associated with a lowered risk of cancer death (HR 0.76, 95% CI 0.64–0.90). There was no association between 
antiarrhythmic drug use and cancer mortality in competing risk analyses. The HR for overall antiarrhythmic drug 
Antiarrhythmic 
drug use
Overall cancer deatha
Lung cancer 
death
Colorectal cancer 
death
Pancreatic cancer 
death
Age-adjusted 
model
Multivarible-
adjusted modelb
Multivarible-
adjusted modelc
Multivarible-
adjusted modelc
Multivarible-
adjusted modelc
HR (95%CI) HR (95%CI) HR (95%CI) HR (95%CI) HR (95%CI)
No use Ref Ref Ref Ref Ref
Any use 1.40 (1.31–1.50) 1.43 (1.34–1.53) 1.72 (1.52–1.95) 1.38 (1.11–1.73) 1.02 (0.79–1.31)
Lag 3 v 1.24 (1.15–1.34) 1.26 (1.17–1.36) 1.39 (1.20–1.61) 1.36 (1.07–1.74) 0.98 (0.74–1.30)
Lag 5 v 1.21 (1.12–1.31) 1.23 (1.13–1.33) 1.29 (1.10–1.51) 1.42 (1.10–1.82) 0.99 (0.74–1.33)
Digoxin use
No use Ref Ref Ref Ref Ref
Any use 1.60 (1.48–1.73) 1.59 (1.47–1.72) 2.10 (1.82–2.41) 1.59 (1.24–2.05) 1.06 (0.79–1.43)
Lag 3 v 1.35 (1.23–1.47) 1.33 (1.21–1.45) 1.59 (1.34–1.88) 1.53 (1.15–2.02) 1.00 (0.72–1.40)
Lag 5 v 1.30 (1.18–1.44) 1.28 (1.16–1.41) 1.49 (1.23–1.79) 1.59 (1.19–2.14) 0.97 (0.67–1.39)
Sotalol use
No use Ref Ref Ref Ref Ref
Any use 1.11 (0.98–1.25) 1.16 (1.03–1.31) 1.10 (0.85–1.41) 0.70 (0.42–1.17) 0.99 (0.63–1.54)
Lag 3 v 1.11 (0.98–1.26) 1.16 (1.02–1.32) 1.07 (0.82–1.39) 0.83 (0.51–1.37) 0.98 (0.61–1.57)
Lag 5 v 1.08 (0.95–1.24) 1.14 (0.99–1.30) 0.98 (0.74–1.31) 0.89 (0.54–1.47) 1.06 (0.66–1.69)
Table 2. Antiarrhythmic drug use and cancer mortality in Finnish Randomized Study of Screening for Prostate 
Cancer. aIncluding lung, prostate, colorectal, pancreatic, gastric, liver, renal, non-Hodgkin lymphoma, bladder 
and central nervous system cancer. bFrom Cox regression model adjusted for age, screening trial arm and use 
of cholesterol-lowering, antidiabetic and antihypertensive drugs, aspirin and other NSAIDs, 5alpha-reductase 
inhibitors, alpha-blockers and cancer diagnose at baseline. cFrom Cox regression model adjusted for age and use 
of cholesterol-lowering, antidiabetic and antihypertensive drugs, aspirin and other NSAIDs, 5alpha-reductase 
inhibitors, alpha-blockers and cancer diagnose at baseline.
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use was 1.04 (95% CI 0.97–1.12). For digoxin and sotalol users the HRs were 1.01 (95% CI 0.93–1.10) and 1.03 
(95% CI 0.91–1.17), respectively.
Both overall antiarrhythmic drug use (HR 1.13, 95% CI 1.05–1.21) and digoxin use (HR 1.13, 95% CI 1.05–
1.23) were associated with increased cancer mortality in a sensitivity analysis adjusted by the CCI. However, the 
risk estimates were lower compared to the main analyses. In this analysis, sotalol use had no effect on cancer 
mortality (HR 0.98, 95% CI 0.86–1.10). In addition, the CCI was independently associated with an increased risk 
of cancer death; HR 1.51, 95% CI 1.50–1.52 per increase of one point.
All-cause mortality among antiarrhythmic drug users was increased compared to non-users (HR 2.14, 95% 
CI 2.07–2.21). Digoxin users had an even greater risk of death (HR 2.52, 95% CI 2.43–2.61), whereas sotalol 
users had a minor, but nevertheless statistically significant, increase in mortality (HR 1.35, 95% CI 1.27–1.44). 
Excluding prevalent cancers at baseline from analysis did not modify results (Table S2).
Compared to the users of other antiarrhythmic drugs, digoxin users had an increased risk of cancer death (HR 
3.06, 95% CI 2.64–3.54). Sotalol use was not associated with cancer mortality (HR 1.12, 95% CI 0.99–1.32 in a 
similar sensitivity analysis.
Discussion
The usage of antiarrhythmic drugs was associated with elevated overall cancer mortality and with increased lung 
cancer mortality in this retrospective cohort study. Digoxin users had a more prominent increase in risk estimates 
for cancer death, compared to overall antiarrhythmic drug users. The individual cancer types with increased mor-
tality by digoxin use were lung cancer, colorectal cancer, bladder cancer and non-Hodgkin lymphoma. Usage of 
sotalol and cancer mortality had no association in the age-adjusted analysis but in the multivariable analysis users 
had a statistically significant increase in the risk of cancer-specific death.
Digoxin’s mechanism of action differs from other classic antiarrhythmic drugs. Vaughan Williams classifi-
cation is used to categorize antiarrhythmic agents by mechanism of action. Class I is divided to subclasses Ia, Ib 
and Ic, all of which are Na+-channel blockers. Class II includes beta-blockers (excluding sotalol) and Class III 
K+-channel blockers. Finally, Ca2+-channel blockers form class IV and agents with unknown or other mecha-
nisms form class V. Digoxin belongs to the Class V and is a Na+/K+-ATPase inhibitor. This increases intracel-
lular Na+-concentration leading to decreased activity of Na+/Ca2+-exchanger. Eventually, this cascade results in 
increased concentration of calcium-ions, which might induce apoptosis7,10.
All antiarrhythmic drugs Digoxin Sotalol
Overall cancer 
mortality
Lung cancer 
mortality
Pancreatic 
cancer mortality
Overall cancer 
mortality
Lung cancer 
mortality
Pancreatic 
cancer mortality
Overall cancer 
mortality
Lung cancer 
mortality
Pancreatic 
cancer 
mortality
HR (95% CI)a HR (95% CI)a HR (95% CI)a HR (95% CI)a HR (95% CI)a HR (95% CI)a HR (95% CI)a HR (95% CI)a HR (95% CI)a
Cumulative quantity of medication useb
DDD tertiles
1st tertile 1.85 (1.67–2.05) 2.22 (1.84–2.67) 1.30 (0.87–1.92) 1.97 (1.76–2.21) 2.47 (2.00–3.04) 1.31 (0.83–2.07) 1.18 (0.97–1.44) 1.29 (0.88–1.88) 0.84 (0.38–1.88)
2nd tertile 1.39 (1.25–1.55) 1.88 (1.56–2.28) 0.95 (0.62–1.45) 1.59 (1.39–1.81) 2.03 (1.59–2.58) 1.14 (0.69–1.88) 1.15 (0.93–1.43) 1.17 (0.77–1.76) 1.07 (0.51–2.25)
3rd tertile 1.10 (0.97–1.25) 1.07 (0.83–1.38) 0.84 (0.54–1.32) 1.22 (1.06–1.41) 1.77 (1.39–2.27) 0.78 (0.45–1.35) 1.14 (0.92–1.42) 0.79 (0.47–1.34) 1.07 (0.51–2.26)
Duration of medication usec
Year tertiles
1st tertile 1.72 (1.56–1.89) 2.14 (1.80–2.55) 1.14 (0.78–1.67) 1.84 (1.66–2.05) 2.46 (2.04–2.96) 1.35 (0.90–2.02) 1.32 (1.09–1.60) 1.53 (1.07–2.18) 0.72 (0.30–1.74)
2nd tertile 1.36 (1.22–1.51) 1.72 (1.41–2.09) 0.77 (0.49–1.23) 1.61 (1.41–1.84) 2.18 (1.72–2.76) 0.86 (0.48–1.52) 1.00 (0.81–1.22) 0.88 (0.57–1.35) 0.74 (0.33–1.65)
3rd tertile 1.13 (0.98–1.30) 1.06 (0.79–1.43) 1.17 (0.75–1.82) 1.17 (0.99–1.38) 1.37 (0.99–1.88) 0.86 (0.47–1.56) 1.21 (0.95–1.53) 0.84 (0.48–1.49) 1.75 (0.90–3.38)
Intensity of medication use (DDDs/year)d
Intensity tertiles
1st tertile 1.91 (1.72–2.11) 2.26 (1.87–2.74) 1.25 (0.83–1.89) 2.13 (1.91–2.38) 2.71 (2.22–3.30) 1.30 (0.82–2.05) 1.19 (0.97–1.46) 1.25 (0.85–1.86) 1.18 (0.59–2.36)
2nd tertile 1.42 (1.26–1.59) 1.75 (1.41–2.16) 1.08 (0.71–1.66) 1.49 (1.28–1.74) 1.93 (1.46–2.56) 0.91 (0.49–1.71) 1.22 (0.99–1.50) 1.04 (0.67–1.61) 1.10 (0.52–2.32)
3rd tertile 1.10 (0.98–1.24) 1.30 (1.05–1.61) 0.80 (0.52–1.23) 1.20 (1.06–1.37) 1.68 (1.33–2.11) 0.97 (0.61–1.53) 1.08 (0.87–1.34) 0.99 (0.63–1.56) 0.71 (0.29–1.71)
Table 3. Cancer mortality by amount, duration and intensity of antiarrhythmic drug use in the the Finnish 
Randomized Study of Screening for Prostate Cancer. aFrom Cox regression model adjusted for age, screening 
trial arm (only for overall cancer mortality) and use of cholesterol-lowering, antidiabetic and antihypertensive 
drugs, aspirin and other NSAIDs, and 5alpha-reductase inhibitors and alpha-blockers. bTertile cut-points for 
cumulative amount of medication use: All antiarrhythmic drugs combined 1st tertile: 1–280 DDD, 2nd tertile: 
281–1,400 DDD, 3rd tertile: more than 1,400 DDD; Digoxin 1st tertile: 1–200 DDD, 2nd tertile: 201–960 DDD, 
3rd tertile: more than 960 DDD; Sotalol 1st tertile: 1–200 DDD, 2nd tertile: 201–1,230 DDD, 3rd tertile: more than 
1,230 DDD. cTertile cut-points for cumulative duration of medication use: All antiarrhythmic drugs combined 
1st tertile: 1–2 years, 2nd tertile: 3–7 years, 3rd tertile: longer than 7 years; Digoxin 1st tertile: 1–2 years, 2nd tertile: 
3–6 years, 3rd tertile: longer than 6 years; Sotalol 1st tertile: 1 year, 2nd tertile: 2–5 years, 3rd tertile: longer than 5 
years. dTertile cut-points for intensity of medication use: All antiarrhythmic drugs combined 1st tertile: 1–116 
DDDs/year, 2nd tertile: 117–228 DDDs/year, 3rd tertile: more than 229 DDDs/year; Digoxin 1st tertile: 1–100 
DDDs/year, 2nd tertile: 101–170 DDDs/year, 3rd tertile: more than 170 DDDs/year; Sotalol 1st tertile: 1–120 
DDDs/year, 2nd tertile: 121–285 DDDs/year, 3rd tertile: more than 285 DDDs/year.
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Divergences between users and non-users (confounding by indication) provide a likely explanation for the 
observed increase in cancer mortality. When we analyzed the association between cardiac insufficiency (the indi-
cation) and cancer mortality, a comparable risk elevation was observed. Furthermore, the risk increase tended 
to disappear with increasing amount, duration and intensity of antiarrhythmic drug use, suggesting that the 
increased mortality is unlikely to be caused by antiarrhythmic drug use but rather by residual confounding by 
unmeasured background differences between antiarrhythmic drug uses and non-users. If the drugs did indeed 
increase the risk, an opposite trend would be presumed.
Digoxin users are likely more fragile than non-users, which may cause non-causal risk differences in epide-
miological studies. This explanation was supported by subgroup analyses stratified by the CCI; among men with 
a low co-morbidity burden, digoxin use was associated with an increased risk of cancer death. However, among 
men with a high co-morbidity burden, the risk difference disappeared. This confirms that the risk association is 
modified by background co-morbidities. Further, the CCI was an independent risk factor for cancer death. In the 
competing risk analyses antiarrhythmic drug use was not associated with cancer mortality, further supporting the 
notion that use of digoxin or other antiarrhythmic drugs does not affect cancer mortality when non-cancer deaths 
are taken into account. When compared to users of other antiarrhythmic drugs, digoxin users had an increased 
cancer mortality. Therefore, the co-morbidity burden may differ even between users of different antiarrhythmic 
drugs.
Our main results are slightly inconsistent with previously published ones. There are no studies concerning 
overall cancer mortality and few studies about individual cancer types. In vitro studies have suggested that digoxin 
might have a suppressive effect on lung neoplasms via multiple mechanisms; it has been shown that digoxin hin-
ders tumor progression by inhibiting the activation of an important oncogene Src4. Moreover, digoxin decreases 
the expression of VEGF and NDRG1 through inhibition of HIF-1alpha synthesis5 and induces autophagy through 
the regulation of mTOR and ERK1/2 signaling pathways in non-small cell lung cancer cells6. A Swedish study 
observed that digoxin users had a diminished risk of lung neoplasms (HR 0.55, 95% CI 0.39–0.79) compared to 
users of organic nitrates30. Nonetheless, these chemopreventive features of digoxin did not translate into dimin-
ished lung cancer mortality in our large population-based study.
One population-based cohort study regarding colorectal cancer survival has previously been published26. 
The study included 10,357 patients with a colorectal cancer diagnosis and during the median follow-up of 4.8 
years 2,724 colorectal cancer–specific deaths occurred. Before model adjustments digoxin use was associated 
with elevated colorectal cancer–specific mortality (HR 1.25, 95% CI 1.07–1.46), but the association disappeared 
after adjustment for confounders (HR 1.10, 95% CI 0.91–1.34). In our study, digoxin users had slightly elevated 
colorectal cancer mortality in the multivariable adjusted analysis. This inconsistency is probably due to differences 
Figure 1. Overall cancer mortality by overall antiarrhythmic drug use and by digoxin use versus non-use 
stratified by patient characteristics in the the Finnish Randomized Study of Screening for Prostate Cancer.
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in adjustment-models. Karasneh et al.26 were able to adjust the analysis for received radiotherapy, chemotherapy 
or surgery within 6 months and for comorbidities more comprehensively compared to us.
Interestingly, pancreatic cancer differed from other cancer types. There was no association between pancreatic 
cancer mortality and digoxin use, whereas there was a statistically significant risk increase for other major cancer 
types. It has been observed that there is an elevated level of HIF-1alpha expression in pancreatic cancer31 and a 
previous study observed that intraperitoneal digoxin injections significantly reduced pancreatic tumor volume 
compared to placebo-injections9. Furthermore, the same study noticed that digoxin injections decreased the 
expression of stem cell factor (SCF), a cytokine commonly involved in tumor progression. However, these path-
ways should be relevant also for other cancer types besides pancreatic cancer. Thus, the differing risk association 
between digoxin use and pancreatic cancer could be due to other causes.
In contrast to other cancer types, there was no association between sotalol use and death due to lung and 
colorectal cancer. Sotalol is both a beta-blocker and K+-channel blocker and it is possible that these properties 
may overcome the otherwise increased cancer mortality among antiarrhythmic drug users in these cancer types. 
Another possibility is that sotalol users had a different distribution of co-morbidities and therefore confound-
ing by indication could have less of an effect. Furthermore, the number of sotalol users was lower compared to 
digoxin users, resulting in wider confidence intervals and less robust results.
Our study had several strengths. First, we had a large population-based cohort that comprehensively repre-
sents the Finnish male population. Additionally, detailed information on antiarrhythmic drug purchases was 
available, allowing us to calculate the individual amounts and durations of drug use. Consequently, we were able 
to perform time-dependent regression analyses in order to control for the immortal time bias. We were able to 
adjust for comorbidities and drugs regularly used along with antiarrhythmic drugs since the information was 
available from the national registries.
On the other hand, a few limitations should be discussed. There was no information on exact indications of 
antiarrhythmic drug use even though we were able to separately evaluate the most common indications. We also 
lacked data on lifestyle habits such as diet, alcohol consumption, smoking and physical activity, all of which may 
be risk factors for cancer death. Furthermore, there was no information on tumor grade, metastases or given 
treatment. Since we were not able to adjust analyses by these factors, confounding is possible. Smoking is a risk 
factor for both cardiac diseases and cancer death thus it could be a confounding factor increasing observed cancer 
mortality among antiarrhythmic drug users. We did not have information on frequency of health care contacts. 
This might have been greater among antiarrhythmic drug users and therefore leading to earlier detection of tum-
ors, which might result in lower observed cancer mortality.
Our information on medication use is based on reimbursed drug purchases. We do not know for sure whether 
or not patients have actually used the drugs they have bought. Finally, the study population was originally 
recruited for a prostate cancer screening trial. The cohort included principally Caucasian men so there is no cer-
tainty whether the results can be generalized to women or other ethnic groups.
Conclusion
We observed that antiarrhythmic drug use has neither general cancer protective effects nor a beneficial impact 
on any particular cancer type. In contrast, cancer mortality was increased among antiarrhythmic drug users 
compared to non-users, but the risk increase was likely non-causal as it was related to short-term use only and 
disappeared in long-term use. Our results do not support the hypothesis of digoxin’s anticancer effects or those of 
any other antiarrhythmic drug.
Material and Methods
Ǥ We used the population of the Finnish Randomized Study of Screening for Prostate Cancer 
(FinRSPC), which is the largest component of the European Randomized Study of Screening for Prostate Cancer 
(ERSPC). The detailed trial protocol has been described previously32. In short, 80,458 men were recruited to the 
study during the years 1996–1999. Men were randomized to either the screening arm (31,866 men, prostate-spe-
cific antigen test at 4-year intervals) or control arm (48,278 men, no intervention, followed through national 
cancer registry). The follow-up continued until the end of 2015. Prevalent prostate cancer cases at baseline were 
excluded; no exclusions for other cancers were made.
The official causes of death in 1996–2015 were obtained from the death certificate registry of Statistics Finland. 
FinRSPC cause-of-death committee has previously found Statistics Finland to be a dependable source of data 
(kappa 0.95)33. The data included primary, immediate and contributory causes of death recorded as ICD-10 
codes. For this study we collected information on deaths with lung (C34), colorectal (C18), pancreatic (C25), 
gastric (C16), liver (C22), renal (C64), non-Hodgkin lymphoma (C81), bladder (C67) or central nervous system 
cancer (C71 and C72) recorded as the primary cause of death. Prostate cancer deaths were included in overall 
cancer mortality. We have previously performed a separate analysis for the risk of prostate cancer death17.
Information on diagnoses recorded during in- and outpatient hospital contacts during 1996–2012 were 
obtained from the Care Register for Health Care (HILMO) of the National Institute for Health and Welfare. The 
data was used to calculate the CCI for the study participants. Additionally, we sought information on indications 
for antiarrhythmic drug use: heart failure (ICD-10 code I50) and cardiac arrhythmias (I47 and I49).
The study was approved by the Ethics Committee of the Pirkanmaa Health Care District, Finland (tracking 
number R10167) and the Committee confirmed that all research was performed in accordance with relevant 
guidelines. Informed consent was obtained from all participants in the screening arm of the study.
Information on medication use. We collected data on antiarrhythmic drug purchases during 1995–2015 
from the reimbursement database of the Social Insurance Institution of Finland (SII). SII is a governmental 
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agency that provides reimbursements for physician-prescribed drug purchases to all Finnish citizens as part of a 
national health insurance. All reimbursed purchases are registered in the database that records the date, number 
of packages acquired, and number and dosage of the tablets for every purchase. This information allowed us to 
calculate the amount of the medication purchases for each drug on a yearly basis.
Antiarrhythmic drug purchases were identified with drug-specific ATC–codes. Drugs in clinical use during 
the study period were amiodarone, digoxin, disopyramide, etilefrine, flecainide, quinidine, mexiletine, procaina-
mide, propafenone and sotalol. Additionally, we obtained information on use of statins, antidiabetic medication 
(oral glucose-lowering drugs and insulins), antihypertensive medication (beta-blockers, ACE-inhibitors/ATII 
receptor blockers, calcium-channel blockers, diuretics and other types of drugs, such as methyldopa and cloni-
dine), aspirin and other NSAIDs, 5-alpha-reductase inhibitors and alpha-blockers.
Ǥ The baseline characteristics were compared between ever-users and never-users of anti-
arrhythmic drugs using the Chi-square test for categorical variables and the Mann-Whitney U test for continuous 
variables. The association between antiarrhythmic drug use and cancer mortality was estimated using the Cox 
proportional hazards regression. We estimated hazard ratios (HR) and their 95% confidence intervals (CIs) for 
cancer death overall and for deaths due to specific types of cancer by antiarrhythmic drug use. We analyzed 
mortality by overall antiarrhythmic drug use and separately by digoxin and sotalol use. The follow-up time was 
calculated from FinRSPC randomization to the date of death, emigration or the common closing date (December 
31th 2015), whichever occurred first.
Antiarrhythmic drug use was analyzed as a time-dependent variable to minimize immortal time bias. 
Therefore, we updated the medication use status prospectively for every year of follow-up by annual medication 
purchases. If there was a recorded purchase at any point during a year, the man was regarded as a user. If medica-
tion purchases were stopped during the follow-up, the participant remained in the user category to minimize bias 
due to selective discontinuation of medication use in the terminal phase of cancer. Men without any purchases 
during the follow-up and all users before the first purchase were classified as non-users, which was used as the ref-
erence group in the main analyses. Age-adjusted and multivariable analyses (further adjustment for baseline can-
cer diagnosis and use of other drug groups: drugs used in management of benign prostatic hyperplasia, diabetes, 
hypercholesterolemia or hypertension, and aspirin and other NSAIDs) were conducted. Besides antiarrhythmic 
drugs, use of other drugs was included in the analyses as a time-independent variable.
We standardized amounts of antiarrhythmic drugs use by dividing the cumulative annual milligram amount 
of each drug with the standard Defined Daily Dose (DDD) published on the WHO website34. By adding together 
years with antiarrhythmic drug purchases, we were able to estimate cumulative duration of drug use. Intensity 
of drug use (DDDs/year) was calculated by dividing the cumulative annual amount with duration of medication 
use. We stratified men into tertiles by the variables mentioned above to estimate whether the amount or duration 
of drug use affects mortality.
Effect modification by age, baseline cancer, use of other drug groups and socioeconomic factors was evaluated 
in subgroup analyses stratified according to these variables. The statistical significance of each effect modifier was 
evaluated by adding an interaction term between antiarrhythmic drug use and the background variable into the 
multivariable-adjusted Cox regression model.
We evaluated the long-term effects of antiarrhythmic drug use in lag-time analyses, in which the 
time-dependent status of antiarrhythmic drug use was lagged forward 3–5 years in follow-up time. These analyses 
were carried out to minimize confounding by indication, as especially digoxin is commonly used in management 
of potentially lethal congestive heart failure. In addition, we performed competing risk regression analyses with 
non-cancer deaths as the competing risk. These analyses were conducted according to the method reported by 
Fine and Gray35.
The statistical tests were two-sided. P-values of 0.05 or less were considered statistically significant. IBM SPSS 
Statistics 23 (Chicago, IL, USA) software was used for data analyses.
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